<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: GnbtS%2D1.xfr; Date: 2020%2D02%2D14T20:35:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80130002 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:GNBT="http://generex.com/20191031">
    <link:schemaRef xlink:href="gnbt-20191031.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2018-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_SeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_SeriesIPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GNBT:SeriesIPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_SeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_SeriesIPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GNBT:SeriesIPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_VenetoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:VenetoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_RegentysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_MedisourceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:MedisourceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_PantheonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PantheonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-06to2019-01-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-06</xbrli:startDate>
        <xbrli:endDate>2019-01-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-18_custom_HemaDiagnosticSystemsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GNBT:HemaDiagnosticSystemsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_CallOptionMember206716051">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeliabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeliabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeliabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_DerivativeliabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeliabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_EmpireStatePharmacyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:EmpireStatePharmacyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_GrainlandPharmacyAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:GrainlandPharmacyAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-01-18_custom_BerkmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:BerkmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_HDSMember_custom_HemaDiagnosticSystemsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:HemaDiagnosticSystemsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_RegentysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-07_custom_RegentysMember302122456">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_RegentysMember302174389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_RegentysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_PantheonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:PantheonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-29to2018-12-02_custom_AlternativeExecutionGroupMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:AlternativeExecutionGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-29</xbrli:startDate>
        <xbrli:endDate>2018-12-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-29to2018-12-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-29</xbrli:startDate>
        <xbrli:endDate>2018-12-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2017-08-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2017-08-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-01to2019-11-27_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-12-01to2011-12-31_custom_DamagesForUnpaidInvoicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GNBT:DamagesForUnpaidInvoicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-12-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-12-01to2012-11-16_custom_DamagesForUnpaidInvoicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GNBT:DamagesForUnpaidInvoicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-12-01</xbrli:startDate>
        <xbrli:endDate>2012-11-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_BreachOfContractMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GNBT:BreachOfContractMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_ComputersAndTechnologicalAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GNBT:ComputersAndTechnologicalAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_ComputersAndTechnologicalAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GNBT:ComputersAndTechnologicalAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_ComputersAndTechnologicalAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GNBT:ComputersAndTechnologicalAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_GrainlandPharmaciesHoldingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:GrainlandPharmaciesHoldingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-05-31_custom_StockPurchaseAgreementMember_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_NGDxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:NGDxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_NGDxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:NGDxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-01-07_custom_RegentysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-01-07_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_HemaDiagnosticSystemsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:HemaDiagnosticSystemsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_OlaregenSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GNBT:OlaregenSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_RegentysSeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GNBT:RegentysSeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-01_custom_BhSanfordMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:BhSanfordMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-30_custom_SalvoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:SalvoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-30_custom_MoscatoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:MoscatoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_RegentysSeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GNBT:RegentysSeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_RemainToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">GNBT:RemainToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_RemainToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">GNBT:RemainToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_OlaregenSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GNBT:OlaregenSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-27_us-gaap_SeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-18_custom_PostReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PostReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-18_custom_NetPurchasePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:NetPurchasePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-18_custom_AfterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:AfterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-18_custom_AtClosingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:AtClosingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-31_custom_MedisourceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:MedisourceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-31_custom_PantheonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PantheonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-31_custom_MedisourceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:MedisourceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-31_custom_PantheonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PantheonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_RegentysMember307928251">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-07-31_custom_NotePayableMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">GNBT:NotePayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-07-31_custom_NotePayableMember_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">GNBT:NotePayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:AccruedInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-07-31_custom_NotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">GNBT:NotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-10-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-01to2018-11-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-01-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-01to2019-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-01</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_NotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">GNBT:NotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_NotePayableMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">GNBT:NotePayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-03to2019-10-31_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-03</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_RegentysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_RegentysMember106908249">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_GenerexPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:GenerexPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_AntigenExpressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:AntigenExpressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_GenerexPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:GenerexPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_AntigenExpressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:AntigenExpressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_OlaregenMember142468271">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_SeriesHConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:SeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_SeriesIConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:SeriesIConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_ConvertibleDebtsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:ConvertibleDebtsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_custom_SeriesHConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:SeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_custom_SeriesIConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:SeriesIConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_custom_ConvertibleDebtsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:ConvertibleDebtsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GNBT:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_VendorAgreementsAndOtherIntangibleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:VendorAgreementsAndOtherIntangibleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_VendorAgreementsAndOtherIntangibleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:VendorAgreementsAndOtherIntangibleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_OtherIntangibleAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_OtherIntangibleAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2017-01-18_custom_AtClosingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:AtClosingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2017-01-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2017-01-18_custom_AfterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:AfterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2017-01-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2017-01-18_custom_PostReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PostReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2017-01-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2017-01-18_custom_NetPurchasePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:NetPurchasePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2017-01-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-29to2018-12-01_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-29</xbrli:startDate>
        <xbrli:endDate>2018-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-01_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_WarrantMember948760875">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-29to2018-12-01_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-29</xbrli:startDate>
        <xbrli:endDate>2018-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-01_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-31_custom_AllocationAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:AllocationAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-31_custom_FinalAllocationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:FinalAllocationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-03_custom_VenetoFirstClosingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:VenetoFirstClosingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-02_custom_VenetoSecondClosingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:VenetoSecondClosingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_TotalMember107864546">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:TotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_VenetoFirstClosingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:VenetoFirstClosingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_VenetoSecondClosingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:VenetoSecondClosingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_Total1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:Total1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-02_custom_MedisourceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:MedisourceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-02_custom_PantheonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PantheonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-03_custom_PreliminaryFairValueMember_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-03_custom_PreliminaryFairValueMember_custom_ReferralBaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:ReferralBaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-03_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-03_custom_PreliminaryFairValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_PreliminaryFairValueMember_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_PreliminaryFairValueMember_custom_ReferralBaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:ReferralBaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_PreliminaryFairValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-02to2019-10-03_custom_PreliminaryFairValueMember_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-02</xbrli:startDate>
        <xbrli:endDate>2019-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-02to2019-10-03_custom_PreliminaryFairValueMember_custom_ReferralBaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:ReferralBaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-02</xbrli:startDate>
        <xbrli:endDate>2019-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-02to2019-10-03_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-02</xbrli:startDate>
        <xbrli:endDate>2019-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_PreliminaryFairValueMember_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_PreliminaryFairValueMember_custom_ReferralBaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:ReferralBaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-02_custom_PreliminaryFairValueMember_custom_TradenameTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:TradenameTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-02_custom_PreliminaryFairValueMember_custom_IpTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:IpTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-02_custom_PreliminaryFairValueMember_custom_BusinessContractsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:BusinessContractsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-02_custom_PreliminaryFairValueMember_custom_CustomerBaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:CustomerBaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-02_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-02_custom_PreliminaryFairValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_custom_TradenameTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:TradenameTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-29</xbrli:startDate>
        <xbrli:endDate>2019-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_custom_IpTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:IpTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-29</xbrli:startDate>
        <xbrli:endDate>2019-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_custom_BusinessContractsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:BusinessContractsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-29</xbrli:startDate>
        <xbrli:endDate>2019-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_custom_CustomerBaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">GNBT:CustomerBaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-29</xbrli:startDate>
        <xbrli:endDate>2019-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-29</xbrli:startDate>
        <xbrli:endDate>2019-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-07_custom_AllocationAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:AllocationAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-07_custom_RevisedAllocationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RevisedAllocationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-27_custom_PreliminaryAllocationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PreliminaryAllocationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-27_custom_AllocationAdjustmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:AllocationAdjustmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-27_custom_RevisedAllocationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RevisedAllocationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-27_custom_OlaregenMember_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-27_custom_OlaregenMember_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-27_custom_RegentysMember_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-01to2019-11-27_custom_OlaregenMember_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-05-22_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-01to2018-11-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-10-03_custom_VenetoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:VenetoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-21to2019-05-22_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-21</xbrli:startDate>
        <xbrli:endDate>2019-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-01to2018-11-27_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-01to2018-11-28_custom_RegentysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-01to2017-12-28_custom_GrainlandPharmacyHoldingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GNBT:GrainlandPharmacyHoldingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-01</xbrli:startDate>
        <xbrli:endDate>2017-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-01to2017-12-28_custom_EmpireStatePharmacyHoldingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GNBT:EmpireStatePharmacyHoldingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-01</xbrli:startDate>
        <xbrli:endDate>2017-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2017-01-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2017-01-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-01_custom_BerkmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:BerkmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-02-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-29to2019-08-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-29</xbrli:startDate>
        <xbrli:endDate>2019-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_DerivativeLiabilityConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_DerivativeLiabilityConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_DerivativeLiabilityConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_DerivativeLiabilityDownsideProtectionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityDownsideProtectionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_DerivativeLiabilityDownsideProtectionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityDownsideProtectionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_DerivativeLiabilityDownsideProtectionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityDownsideProtectionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_DerivativeLiabilityConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_DerivativeLiabilityConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_DerivativeLiabilityDownsideProtectionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityDownsideProtectionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_DerivativeLiabilityDownsideProtectionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityDownsideProtectionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_custom_DerivativeLiabilityConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_custom_DerivativeLiabilityConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_custom_DerivativeLiabilityDownsideProtectionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityDownsideProtectionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_custom_DerivativeLiabilityDownsideProtectionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">GNBT:DerivativeLiabilityDownsideProtectionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_AEXGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:AEXGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_FormershareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:FormershareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2017-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2017-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_StockOptionPlan2006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_StockOptionPlan2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_StockOptionPlan2006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_StockOptionPlan2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_StockOptionPlan2006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_StockOptionPlan2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_StockOptionPlan2006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_StockOptionPlan2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GNBT:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-28to2019-09-01_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-28</xbrli:startDate>
        <xbrli:endDate>2019-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-19_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-19_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-19_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-12_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-12_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-30to2019-08-02_custom_PantheonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:PantheonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-30</xbrli:startDate>
        <xbrli:endDate>2019-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-30to2019-08-02_us-gaap_SubsequentEventMember_custom_MediSourcePartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:MediSourcePartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-30</xbrli:startDate>
        <xbrli:endDate>2019-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-13_us-gaap_SubsequentEventMember_custom_PublicSecuredFinancingFacilityAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:PublicSecuredFinancingFacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-14_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-14_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-15_us-gaap_SubsequentEventMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-16_us-gaap_SubsequentEventMember_custom_ShareExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:ShareExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-21_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-21_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-21_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-29_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-29_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-06_custom_ALTuCELLMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GNBT:ALTuCELLMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-10_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-10_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-10_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-17_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-17_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-17_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-18_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-18_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-02to2019-09-18_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-02</xbrli:startDate>
        <xbrli:endDate>2019-09-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-29to2019-10-01_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-29</xbrli:startDate>
        <xbrli:endDate>2019-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-02to2019-10-10_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-02</xbrli:startDate>
        <xbrli:endDate>2019-10-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-13_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-05_us-gaap_SubsequentEventMember_custom_EquityPurchaseAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:EquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-12_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-12_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-14_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-14_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-14_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-18_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GNBT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-21_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-21_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-21_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-21_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-21_us-gaap_SubsequentEventMember_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:AccruedInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-21_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-22_us-gaap_SubsequentEventMember_custom_ALTuCELLMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GNBT:ALTuCELLMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-24_us-gaap_SubsequentEventMember_custom_OlaregenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-25_us-gaap_SubsequentEventMember_custom_RegentysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-25_us-gaap_SubsequentEventMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GNBT:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-27_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-27_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-27_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-27_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-27_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-27_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-29_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-02to2019-11-29_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-02</xbrli:startDate>
        <xbrli:endDate>2019-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-02to2019-12-05_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-02</xbrli:startDate>
        <xbrli:endDate>2019-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-02to2019-12-05_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-02</xbrli:startDate>
        <xbrli:endDate>2019-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-02to2019-12-05_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-02</xbrli:startDate>
        <xbrli:endDate>2019-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-03to2019-12-05_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-03</xbrli:startDate>
        <xbrli:endDate>2019-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-03to2019-12-05_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-03</xbrli:startDate>
        <xbrli:endDate>2019-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-03to2019-12-05_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-03</xbrli:startDate>
        <xbrli:endDate>2019-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-12_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-12_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-03to2019-11-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-02to2019-12-12_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-02</xbrli:startDate>
        <xbrli:endDate>2019-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-02to2019-12-12_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-02</xbrli:startDate>
        <xbrli:endDate>2019-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-02to2019-12-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-02</xbrli:startDate>
        <xbrli:endDate>2019-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-03to2019-12-12_us-gaap_SubsequentEventMember_custom_PrincipalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:PrincipalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-03</xbrli:startDate>
        <xbrli:endDate>2019-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-03to2019-12-12_us-gaap_SubsequentEventMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GNBT:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-03</xbrli:startDate>
        <xbrli:endDate>2019-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-03to2019-12-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-03</xbrli:startDate>
        <xbrli:endDate>2019-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-01to2018-07-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-10-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_SubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GNBT:SubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_GoodwillMember_custom_VenetoMember310484733">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:VenetoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_GoodwillMember_custom_RegentysMember310494499">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:RegentysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2019-07-31_us-gaap_GoodwillMember_custom_OlaregenMember310502783">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001059784</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">GNBT:OlaregenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2018-07-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-07-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-10-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-07-31" unitRef="Shares" decimals="INF">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-07-31" unitRef="Shares" decimals="INF">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-10-31" unitRef="Shares" decimals="INF">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-07-31" unitRef="Shares" decimals="INF">22430121</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-07-31" unitRef="Shares" decimals="INF">62290940</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-10-31" unitRef="Shares" decimals="INF">44336023</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-10-31_custom_OlaregenMember" unitRef="Shares" decimals="INF">6236390</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityRegistrantName contextRef="From2019-08-01to2019-10-31">GENEREX BIOTECHNOLOGY CORP</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2019-08-01to2019-10-31">0001059784</dei:EntityCentralIndexKey>
    <dei:EntitySmallBusiness contextRef="From2019-08-01to2019-10-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-08-01to2019-10-31">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentType contextRef="From2019-08-01to2019-10-31">S-1</dei:DocumentType>
    <dei:AmendmentFlag contextRef="From2019-08-01to2019-10-31">false</dei:AmendmentFlag>
    <dei:EntityFilerCategory contextRef="From2019-08-01to2019-10-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-07-31_custom_SeriesIPreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2018-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="USD" decimals="0">3</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2018-07-31_custom_SeriesIPreferredStockMember" unitRef="USD" decimals="0">1</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-07-31_custom_OlaregenSeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-07-31_custom_RegentysSeriesARedeemableConvertiblePreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2017-03-27_us-gaap_SeriesHPreferredStockMember" unitRef="USD" decimals="0">3000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-07-31_custom_SeriesIPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-07-31_custom_SeriesIPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-07-31_custom_OlaregenSeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-07-31_custom_RegentysSeriesARedeemableConvertiblePreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-07-31_custom_RegentysSeriesARedeemableConvertiblePreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-07-31_custom_OlaregenSeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="Shares" decimals="INF">109000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-07-31_custom_SeriesIPreferredStockMember" unitRef="Shares" decimals="INF">6000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="Shares" decimals="INF">109000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-07-31_custom_SeriesIPreferredStockMember" unitRef="Shares" decimals="INF">6000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-07-31_custom_OlaregenSeriesAPreferredStockMember" unitRef="Shares" decimals="INF">592683</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-07-31_custom_RegentysSeriesARedeemableConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">2793192</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-07-31_custom_RegentysSeriesARedeemableConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">2793192</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-07-31_custom_OlaregenSeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-07-31_custom_SeriesIPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="Shares" decimals="INF">63000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-07-31_custom_SeriesIPreferredStockMember" unitRef="Shares" decimals="INF">16590</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-07-31_custom_OlaregenSeriesAPreferredStockMember" unitRef="Shares" decimals="INF">592683</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-07-31_custom_OlaregenSeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-03-27_us-gaap_SeriesHPreferredStockMember" unitRef="Shares" decimals="INF">63000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-07-31" unitRef="Shares" decimals="INF">22430121</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-07-31" unitRef="Shares" decimals="INF">62290940</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-10-31" unitRef="Shares" decimals="INF">44336023</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-10-26" unitRef="Shares" decimals="INF">4830000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-07-31_custom_RemainToBeIssuedMember" unitRef="Shares" decimals="INF">588658</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-07-31_custom_RemainToBeIssuedMember" unitRef="Shares" decimals="INF">302614</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-01-18_custom_PostReverseStockSplitMember" unitRef="Shares" decimals="INF">4830000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-01-18_custom_NetPurchasePriceMember" unitRef="Shares" decimals="INF">5947431</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-01-18_custom_AfterMember" unitRef="Shares" decimals="INF">420</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-01-18_custom_AtClosingMember" unitRef="Shares" decimals="INF">1117011</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-01-18" unitRef="Shares" decimals="INF">1117011</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-02-09" unitRef="Shares" decimals="INF">2179989</us-gaap:CommonStockSharesIssued>
    <GNBT:SummaryOfAcquisitionTableTextBlock contextRef="From2018-08-01to2019-07-31_custom_VenetoMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the preliminary purchase price as of the Veneto acquisition as of the First Closing&#13;and the Second Closing:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8220;First&#13;    Closing&amp;#8221; completed on&amp;#160;&lt;br /&gt; October 3, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8220;Second&#13;    Closing&amp;#8221; completed on&amp;#160;&lt;br /&gt; November 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 46%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&#13;    and cash equivalents&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,410,150&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,410,150&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    receivable, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,935,078&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,935,078&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory,&#13;    net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,068,856&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,068,856&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95,804&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95,804&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;    and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,590&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,590&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    receivables&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,014,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,014,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes&#13;    receivable - LT&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,387,763&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,387,763&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    assets, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;    assets, net&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,603&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,110,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,145,603&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,625,905&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,110,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,735,905&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    current liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,509,887&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,509,887&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes&#13;    payable&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    liabilities assumed&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,509,887&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,913,835&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    identifiable assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,116,018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,706,052&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,822,070&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,883,982&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,293,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,177,930&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    consideration transferred&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,000,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,000,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the revalued purchase price as of the Veneto acquisition as of the First Closing&#13;and the Second Closing during the year ending July 31, 2019:&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8220;First&#13;    Closing&amp;#8221; completed on&amp;#160;&lt;br /&gt; October 3, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8220;Second&#13;    Closing&amp;#8221; completed on&amp;#160;&lt;br /&gt; November 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 46%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&#13;    and cash equivalents&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,410,150&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,410,150&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    receivable, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,430,638&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,490,638&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory,&#13;    net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,068,856&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,068,856&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95,804&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95,804&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;    and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,590&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,590&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    receivables&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,014,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,014,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes&#13;    receivable - LT&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,387,763&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,387,763&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    assets, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;    assets, net&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,603&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;811,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;846,603&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,181,465&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;811,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,992,465&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    current liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,065,448&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,065,448&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes&#13;    payable&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    liabilities assumed&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,065,448&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,469,396&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    identifiable assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,116,017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,592,948&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,523,069&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,051,769&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    consideration transferred&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18,574,838&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:SummaryOfAcquisitionTableTextBlock>
    <GNBT:SummaryOfAcquisitionTableTextBlock contextRef="From2018-08-01to2019-07-31_custom_RegentysMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;The following table summarizes the allocation of the preliminary purchase price as of the Regentys acquisition:&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Preliminary Allocations as of&amp;#160;&amp;#160;&amp;#160;&amp;#160;January 7, 2019&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Allocation Adjustments&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Revised Allocation&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 46%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;61,857&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;61,857&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;13,138&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,543&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;33,591&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,181,920&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(307,495&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,488,870&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(639,009&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;29,685&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(609,324&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Loans form related parties&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(16,506&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(399,999&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(416,505&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(889,782&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;30,320&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(859,462&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;In-Process research &amp;#38; development&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,510,680&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(119,630&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,391,050&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; font-style: italic; text-align: left"&gt;Non-Controlling interest, net of proceeds:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0.1in"&gt;Note receivable from Generex&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,345,205&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,791&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,345,414&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0.1in"&gt;Redeemable non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,073,898&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,073,898&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0.1in"&gt;Non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(9,870,762&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,791&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(9,870,762&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0.1in"&gt;Cash paid prior to the time of closing&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Total Fair Value of Assets Acquired&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,259,447&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(751,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;907,833&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; font-style: italic"&gt;Consideration:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Cash paid prior to the time of closing&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Note receivable from Generex&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,345,205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,791&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,342,414&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;13,485,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;748,823&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;13,834,581&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:SummaryOfAcquisitionTableTextBlock>
    <GNBT:SummaryOfAcquisitionTableTextBlock contextRef="From2018-08-01to2019-07-31_custom_OlaregenMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the preliminary purchase price as of the Olaregen acquisition:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Preliminary Allocations as of&amp;#160;&amp;#160;&amp;#160;&amp;#160;January 7, 2019&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Allocation Adjustments&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Revised Allocation&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 46%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;608,419&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(400,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;208,419&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,488&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,488&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Inventory&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;408,501&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;408,501&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;37,950&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;37,950&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(216,670&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(216,670&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Accrued liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(216,694&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(216,694&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,040,173&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;397,513&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(642,660&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;In-Process research &amp;#38; development&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,980,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,521,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,459,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;790,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(260,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;530,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; font-style: italic; text-align: left"&gt;Non-Controlling interest, net of proceeds:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Note receivable from Generex&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11,472,663&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11,472,663&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(11,999,559&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(11,999,559&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Cash paid prior to the time of closing&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Total Fair Value of Assets Acquired&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,844,925&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,383,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,461,440&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; font-style: italic"&gt;Consideration:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Cash paid prior to the time of closing&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Note receviable from Generex&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,472,663&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,472,664&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;8,027,738&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,383,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;9,411,224&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:SummaryOfAcquisitionTableTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-08-01to2019-10-31">DE</dei:EntityIncorporationStateCountryCode>
    <us-gaap:Assets contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">6606854</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">49635991</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">52240249</us-gaap:Assets>
    <us-gaap:OtherAssets contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">7824</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">30621</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">33804</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">25745</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAssets contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">25745</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">25745</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAssets contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">25745</us-gaap:OtherAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">3211037</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">9834269</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">10802442</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">38297573</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">38901126</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2017-12-28" unitRef="USD" decimals="0">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-01-31_custom_FinalAllocationMember" unitRef="USD" decimals="0">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">8883982</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">16293948</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">25177930</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">15051769</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">471626</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">131927</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">13485758</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">748823</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">13834581</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">8027738</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">1383485</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">9411224</us-gaap:Goodwill>
    <GNBT:CallOptions contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">-2168211</GNBT:CallOptions>
    <GNBT:CallOptions contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">0</GNBT:CallOptions>
    <GNBT:CallOptions contextRef="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</GNBT:CallOptions>
    <GNBT:CallOptions contextRef="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">-2168211</GNBT:CallOptions>
    <GNBT:CallOptions contextRef="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</GNBT:CallOptions>
    <GNBT:CallOptions contextRef="AsOf2018-07-31_us-gaap_CallOptionMember206716051" unitRef="USD" decimals="0">-2168211</GNBT:CallOptions>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">31536</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">499993</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">531888</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">652590</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">652590</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">652590</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">652590</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">8992</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">67299</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">444</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">444</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">1188246</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">973535</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">1873436</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">96251</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">275731</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">451344</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">11864</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">13138</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">20543</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">33591</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">37950</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">37950</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">12075</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">363008</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">727263</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">1068856</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InventoryNet contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">1068856</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">1068856</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InventoryNet contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">1068856</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">266071</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">408501</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">408501</us-gaap:InventoryNet>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">33555</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">36311</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">154575</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">1935078</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsReceivableNet contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">1935078</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">1430638</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsReceivableNet contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">1490638</us-gaap:AccountsReceivableNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">1046365</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">298485</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-07-31" unitRef="USD" decimals="0">2879165</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">540254</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-10-31" unitRef="USD" decimals="0">2363740</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">2410150</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">2410150</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">2410150</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">2410150</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">13895</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">35410</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">61857</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">61857</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">608419</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">208419</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Liabilities contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">50191522</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">37889494</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">43296964</us-gaap:Liabilities>
    <GNBT:WarrantsToBeIssued contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">24962507</GNBT:WarrantsToBeIssued>
    <GNBT:WarrantsToBeIssued contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">0</GNBT:WarrantsToBeIssued>
    <GNBT:WarrantsToBeIssued contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">22048</GNBT:WarrantsToBeIssued>
    <GNBT:WarrantsToBeIssued contextRef="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</GNBT:WarrantsToBeIssued>
    <GNBT:WarrantsToBeIssued contextRef="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">24962507</GNBT:WarrantsToBeIssued>
    <GNBT:WarrantsToBeIssued contextRef="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</GNBT:WarrantsToBeIssued>
    <GNBT:WarrantsToBeIssued contextRef="AsOf2018-07-31_custom_WarrantsMember" unitRef="USD" decimals="0">24962507</GNBT:WarrantsToBeIssued>
    <GNBT:CommonStockPayableNoncurrent contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</GNBT:CommonStockPayableNoncurrent>
    <GNBT:CommonStockPayableNoncurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">1123188</GNBT:CommonStockPayableNoncurrent>
    <GNBT:CommonStockPayableNoncurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">215793</GNBT:CommonStockPayableNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">7820283</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">8797354</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">25229015</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">28946023</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">34261769</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">2509887</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">2509887</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">2065448</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">2065448</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxLiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">1502122</us-gaap:DeferredTaxLiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">1502122</us-gaap:DeferredTaxLiabilitiesCurrent>
    <GNBT:LoansFromRelatedParties contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">13864241</GNBT:LoansFromRelatedParties>
    <GNBT:LoansFromRelatedParties contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">19700</GNBT:LoansFromRelatedParties>
    <GNBT:LoansFromRelatedParties contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">72612</GNBT:LoansFromRelatedParties>
    <us-gaap:NotesPayable contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">320000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">8368379</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">10163610</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesPayable contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">3403948</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">3403948</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesPayable contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">3403948</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">3403948</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">639009</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-29685</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">609324</us-gaap:NotesPayable>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">11044774</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">19055822</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">22447533</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">31439</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">1181920</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">307495</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">1488870</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">4073898</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">4073898</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">-4073898</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">-4073898</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockValue contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">22430</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">62290</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">44335</us-gaap:CommonStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">6606854</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">49635991</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">52240249</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">-43584668</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">7672599</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31" unitRef="USD" decimals="0">-79876231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">4869387</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31" unitRef="USD" decimals="0">-25603074</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">4</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">4</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">22430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">22430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31_custom_CommonStockPayableMember" unitRef="USD" decimals="0">2168951</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31_custom_CommonStockPayableMember" unitRef="USD" decimals="0">2168951</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">368388265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">368388265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-445720566</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-409386468</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">783150</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">798422</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">-74357766</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">-38008396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-5518465</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-5576272</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">62290</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">408566529</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-418727875</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">797216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">-9301840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">16974439</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">4</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">28427</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31_custom_CommonStockPayableMember" unitRef="USD" decimals="0">251617</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">370402796</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-391512465</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">800048</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">-20029573</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-5573501</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">44335</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">417081503</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-427853820</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">796922</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">-9931060</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">14800447</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">-5576272</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">16974439</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">14800447</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2018-07-31_custom_NGDxMember" unitRef="USD" decimals="0">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-07-31_custom_NGDxMember" unitRef="USD" decimals="0">5576272</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">-9870762</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-2791</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">-9870762</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">-11999559</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">-11999559</us-gaap:MinorityInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">798422</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">797216</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">796922</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">368388265</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">408566529</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">417081503</us-gaap:AdditionalPaidInCapitalCommonStock>
    <GNBT:CommonStockPayable contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">2168951</GNBT:CommonStockPayable>
    <GNBT:CommonStockPayable contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">0</GNBT:CommonStockPayable>
    <GNBT:CommonStockPayable contextRef="AsOf2019-08-31" unitRef="USD" decimals="0">266793</GNBT:CommonStockPayable>
    <us-gaap:GrossProfit contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">2065308</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">703244</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">588043</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">848527</us-gaap:GrossProfit>
    <us-gaap:CostOfRevenue contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">4138453</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">133618</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">870621</us-gaap:CostOfRevenue>
    <us-gaap:Revenues contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">6203761</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">703244</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">721661</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">1719148</us-gaap:Revenues>
    <GNBT:LicensingIncome contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">0</GNBT:LicensingIncome>
    <GNBT:LicensingIncome contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">700000</GNBT:LicensingIncome>
    <us-gaap:RevenuesNetOfInterestExpense contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">6203761</us-gaap:RevenuesNetOfInterestExpense>
    <us-gaap:RevenuesNetOfInterestExpense contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">3244</us-gaap:RevenuesNetOfInterestExpense>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-24345441</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-2495609</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-4548711</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-1604181</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">26410749</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">3198853</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">5316754</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">2452708</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">21409428</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">2359706</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">4787039</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">2272641</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">1748882</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">839147</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">338734</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">180067</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-9341407</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">36334098</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-9125945</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">17874003</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-1665387</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-385400</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-186602</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-88256</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_custom_HemaDiagnosticSystemsMember" unitRef="USD" decimals="0">-122692</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-11006794</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">35948698</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-9312547</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">17785747</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-08-01to2018-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-08-01to2018-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-08-01to2018-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-08-01to2018-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-08-01to2018-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">36334098</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-08-01to2018-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">36334098</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-08-01to2018-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-385400</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-9341407</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">-9341407</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-1665387</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2018-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2018-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2018-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2018-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2018-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">17874003</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2018-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">17874003</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-08-01to2018-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-88256</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-9125945</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">-9125945</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-186602</us-gaap:NetIncomeLoss>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-31456</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-8753</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">3886</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-287587</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-16000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-403214</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-08-01to2019-10-31_custom_NotePayableMember" unitRef="USD" decimals="0">403214</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">2125449</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-1836208</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">1131157</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">66456</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">-3033820</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">-988267</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">28214</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">3085502</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2017-08-01to2018-07-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2017-08-01to2018-07-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2017-08-01to2018-07-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <GNBT:ChangesInFairValueOfContingentPurchaseConsideration contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">18587782</GNBT:ChangesInFairValueOfContingentPurchaseConsideration>
    <GNBT:ChangesInFairValueOfContingentPurchaseConsideration contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">39027901</GNBT:ChangesInFairValueOfContingentPurchaseConsideration>
    <GNBT:ChangesInFairValueOfContingentPurchaseConsideration contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">0</GNBT:ChangesInFairValueOfContingentPurchaseConsideration>
    <GNBT:ChangesInFairValueOfContingentPurchaseConsideration contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">19545098</GNBT:ChangesInFairValueOfContingentPurchaseConsideration>
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">47961</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">452</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">6660</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:InterestExpense contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">7087502</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">583594</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">2516113</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">165716</us-gaap:InterestExpense>
    <us-gaap:EarningsPerShareDiluted contextRef="From2018-08-01to2019-07-31" unitRef="USDPShares" decimals="INF">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2017-08-01to2018-07-31" unitRef="USDPShares" decimals="INF">14.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2019-08-01to2019-10-31" unitRef="USDPShares" decimals="INF">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2018-08-01to2018-10-31" unitRef="USDPShares" decimals="INF">0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic contextRef="From2018-08-01to2019-07-31" unitRef="USDPShares" decimals="INF">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2017-08-01to2018-07-31" unitRef="USDPShares" decimals="INF">34.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2019-08-01to2019-10-31" unitRef="USDPShares" decimals="INF">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2018-08-01to2018-10-31" unitRef="USDPShares" decimals="INF">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">48360127</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">2591129</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">53186407</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2018-08-01to2018-10-31" unitRef="Shares" decimals="INF">54699198</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">48360127</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">1068101</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">53186407</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2018-08-01to2018-10-31" unitRef="Shares" decimals="INF">22806777</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <GNBT:ComprehensiveIncomeLossAndComprehensiveIncomeLossAvailableToCommonStockholders contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-9342613</GNBT:ComprehensiveIncomeLossAndComprehensiveIncomeLossAvailableToCommonStockholders>
    <GNBT:ComprehensiveIncomeLossAndComprehensiveIncomeLossAvailableToCommonStockholders contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">36349370</GNBT:ComprehensiveIncomeLossAndComprehensiveIncomeLossAvailableToCommonStockholders>
    <GNBT:ComprehensiveIncomeLossAndComprehensiveIncomeLossAvailableToCommonStockholders contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-9126239</GNBT:ComprehensiveIncomeLossAndComprehensiveIncomeLossAvailableToCommonStockholders>
    <GNBT:ComprehensiveIncomeLossAndComprehensiveIncomeLossAvailableToCommonStockholders contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">17875629</GNBT:ComprehensiveIncomeLossAndComprehensiveIncomeLossAvailableToCommonStockholders>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">1206</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-15272</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">294</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-1626</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:ShareBasedCompensation contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">3006203</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">787458</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">103194</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-08-01to2019-10-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">787458</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-08-01to2019-07-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">3012446</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherAssetImpairmentCharges contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">99519</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">426440</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">23780</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">203273</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">25664</us-gaap:DepreciationDepletionAndAmortization>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesDownsideProtection contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-3085502</GNBT:ChangeInFairValueOfDerivativeLiabilitiesDownsideProtection>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesDownsideProtection contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:ChangeInFairValueOfDerivativeLiabilitiesDownsideProtection>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesDownsideProtection contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">3033820</GNBT:ChangeInFairValueOfDerivativeLiabilitiesDownsideProtection>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesDownsideProtection contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:ChangeInFairValueOfDerivativeLiabilitiesDownsideProtection>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleNotes contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">988267</GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleNotes>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleNotes contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleNotes>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleNotes contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-1131156</GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleNotes>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleNotes contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleNotes>
    <GNBT:NoncashInterestExpenseFromIssuanceOnDebtDerivative contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">959976</GNBT:NoncashInterestExpenseFromIssuanceOnDebtDerivative>
    <GNBT:NoncashInterestExpenseFromIssuanceOnDebtDerivative contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:NoncashInterestExpenseFromIssuanceOnDebtDerivative>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">3121569</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">2065835</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">9285221</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">872164</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">2366230</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">1006344</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-9574193</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-2293214</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-1843805</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-356587</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-18587782</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-39027901</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-19545097</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">750241</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">33555</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-4024</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-721</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-49248</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">74360</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">163596</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-24605</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-1126424</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">2040</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">98184</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-242235</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-1387763</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">22797</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleWarrants contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-28215</GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleWarrants>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleWarrants contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleWarrants>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleWarrants contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-66456</GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleWarrants>
    <GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleWarrants contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:ChangeInFairValueOfDerivativeLiabilitiesConvertibleWarrants>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">2318793</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-8552</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">44854</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">1046369</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <GNBT:CashReceivedInAcquisitionOfBusiness contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">2280425</GNBT:CashReceivedInAcquisitionOfBusiness>
    <GNBT:CashReceivedInAcquisitionOfBusiness contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:CashReceivedInAcquisitionOfBusiness>
    <GNBT:CashReceivedInAcquisitionOfBusiness contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">49305</GNBT:CashReceivedInAcquisitionOfBusiness>
    <GNBT:CashReceivedInAcquisitionOfBusiness contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">1052537</GNBT:CashReceivedInAcquisitionOfBusiness>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-62091</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-292681</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">26487</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">6508726</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">453694</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">2041014</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">625967</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterest contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">0</GNBT:InvestmentInSubsidiaryByNoncontrollingInterest>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterest contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">327593</GNBT:InvestmentInSubsidiaryByNoncontrollingInterest>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterest contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">0</GNBT:InvestmentInSubsidiaryByNoncontrollingInterest>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterest contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">91027</GNBT:InvestmentInSubsidiaryByNoncontrollingInterest>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_custom_HemaDiagnosticSystemsMember" unitRef="USD" decimals="0">133679</GNBT:InvestmentInSubsidiaryByNoncontrollingInterest>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">6329910</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">2976745</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">534940</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">51625</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">935731</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedParties contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">230441</us-gaap:IncreaseDecreaseInNotesPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedParties contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">126101</us-gaap:IncreaseDecreaseInNotesPayableRelatedParties>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-747880</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-1832800</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">241769</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">1317375</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-1206</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">15272</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-294</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">1626</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">289917</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">8552</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">4451</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">6168</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <GNBT:AcquisitionOfOlaregenStockThroughIssuanceOfCommonStock contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">2000000</GNBT:AcquisitionOfOlaregenStockThroughIssuanceOfCommonStock>
    <GNBT:AcquisitionOfOlaregenStockThroughIssuanceOfCommonStock contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:AcquisitionOfOlaregenStockThroughIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">5592244</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5592244</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">5592244</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExerciseOfCallOption contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">1385730</GNBT:ExerciseOfCallOption>
    <GNBT:ExerciseOfCallOption contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:ExerciseOfCallOption>
    <GNBT:ConversionOfHdsDebtAndIssuanceOfCallOption contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">14056113</GNBT:ConversionOfHdsDebtAndIssuanceOfCallOption>
    <GNBT:ConversionOfHdsDebtAndIssuanceOfCallOption contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:ConversionOfHdsDebtAndIssuanceOfCallOption>
    <GNBT:AntigenDividen contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">0</GNBT:AntigenDividen>
    <GNBT:AntigenDividen contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">320000</GNBT:AntigenDividen>
    <GNBT:AcquisitionOfVenetoThroughIssuanceOfDebt contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">0</GNBT:AcquisitionOfVenetoThroughIssuanceOfDebt>
    <GNBT:AcquisitionOfVenetoThroughIssuanceOfDebt contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:AcquisitionOfVenetoThroughIssuanceOfDebt>
    <GNBT:AcquisitionOfRegentysThroughIssuanceOfDebt contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">0</GNBT:AcquisitionOfRegentysThroughIssuanceOfDebt>
    <GNBT:AcquisitionOfRegentysThroughIssuanceOfDebt contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:AcquisitionOfRegentysThroughIssuanceOfDebt>
    <GNBT:AcquisitionOfOlaregenThroughIssuanceOfDebt contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">0</GNBT:AcquisitionOfOlaregenThroughIssuanceOfDebt>
    <GNBT:AcquisitionOfOlaregenThroughIssuanceOfDebt contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:AcquisitionOfOlaregenThroughIssuanceOfDebt>
    <GNBT:ConversionOfDebtsToEquity contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">8257918</GNBT:ConversionOfDebtsToEquity>
    <GNBT:ConversionOfDebtsToEquity contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:ConversionOfDebtsToEquity>
    <srt:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;3 - Loans from Related Parties&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;NGDx&#13;received substantially all of its funding from a shareholder, who owned 98.9% of NGDx prior to the acquisition of NGDx by the&#13;Company. The loan is unsecured, matures on December 31, 2019 and bears interest at 0.75% per annum through January 19, 2017, and&#13;bears no interest thereafter. Upon acquisition of NGDx by the Company (see Note 9), the outstanding principal balance was $13,239,837&#13;and total accrued interest of $191,869. This loan was subject to a call option (Note 9) which, if exercised, the principal and&#13;accrued interest through January 18, 2017 would be eliminated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the January 18, 2017 Acquisition, Mr. Berkman, previous owner of NGDx and debt holder, agreed, under certain conditions to&#13;transfer the remaining 49% of the NGDx equity to the Company for a consideration of $1.00. On December 1, 2018, the Company and&#13;Mr. Berkman entered into an Agreement, Assignment and Release, pursuant to which Mr. Berkman transferred the remaining NGDx equity&#13;interests to the Company, waiving and releasing any conditions to such transfer. NGDx is now a wholly owned subsidiary of the&#13;Company. In addition to the assignment of the NGDx interests, Mr. Berkman released these loans in exchange for shares of the Company&amp;#8217;s&#13;common stock valued at the aggregate of such amount using the closing price for the common stock on November 30, 2018. The closing&#13;price was $18.99, resulting in 32,881 shares issuable to Mr. Berkman. This transaction resulted in Mr. Berkman&amp;#8217;s advances&#13;of $624,404 plus the loan and call option which resulted in additional paid in capital of $13,431,705 which was reclassified to&#13;the Company&amp;#8217;s stockholders&amp;#8217; equity as an extinguishment of debt for $14,056,109.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the January 7, 2019 acquisition of Regentys, the Company assumed $16,505 of loans payable to Regentys shareholders. During&#13;the year ended July 31, 2019, the Company repaid $3,305 of the principal balance and borrowed an additional $6,500. The outstanding&#13;balance as of July 31, 2019 was $19,700.&lt;/font&gt;&lt;/p&gt;</srt:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTextBlock>
    <srt:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;3 - Loans from Related Parties&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the acquisitions of Regentys, the Company assumed $19,700 of loans payable to Regentys shareholders. As part of the assets&#13;purchase agreement for Pantheon, the Company acquired 50% of the open accounts receivable. The amount collected on accounts receivable&#13;excluded from the acquisition, that is due to the prior owner of Pantheon, was $52,912. The balance of loans from related parties&#13;was $72,612 as of October 31, 2019.&lt;/font&gt;&lt;/p&gt;</srt:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTextBlock>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;4 - Commitments and Contingencies:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Pending&#13;Litigation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company is a defendant in one legal proceeding relating to alleged breach of contract and claims against certain of the Company&amp;#8217;s&#13;original buccal delivery patents. The Company is also a defendant in two legal proceedings brought by a former executive officer&#13;and her affiliate. These legal proceedings have been reported in the Company&amp;#8217;s prior periodic reports. No activity has occurred&#13;in these cases in several years, and the Company now considers them dormant.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc.,&#13;in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in&#13;addition to costs and further interest.&amp;#160;The Company responded to this statement of claim and asserted a counterclaim in the&#13;proceeding for $200,000 arising from the vendor&amp;#8217;s breach of contract and detinue, together with interest and costs. On November&#13;16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout&#13;of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout.&amp;#160;Each&#13;party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party&amp;#8217;s counsel until&#13;payment of the settlement amount.&amp;#160;Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without&#13;costs will be filed with the court.&amp;#160;If the Company fails to make the payment following completion of any post-spinout financing&#13;related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest&#13;of 3% per annum and costs fixed at $25,000. This has been accrued in the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;August 22, 2017, Generex received a letter from counsel for Three Brothers Trading LLC, d/b/a Alternative Execution Group (&amp;#8220;AEXG&amp;#8221;),&#13;claiming breach of a Memorandum of Understanding (&amp;#8220;MOU&amp;#8221;) between Generex and AEXG.&amp;#160;The MOU related to AEXG referring&#13;potential financing candidate to Generex.&amp;#160;The letter from AEXG counsel claimed that Generex&amp;#8217;s acceptance of $3,000,000&#13;in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other&#13;financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in&#13;cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney&amp;#8217;s fees and costs. On December 2,&#13;2018, an arbitrator awarded Three Brothers Trading LLC, d/b/a Alternative Execution Group (&amp;#8220;AEXG&amp;#8221;) an aggregate of&#13;$315,695 in damages, costs and fees as well as warrants exercisable for 84,000 shares of Generex Common Stock at an exercise price&#13;of $2.50 per share. The awards were made pursuant to claims under a Memorandum of Understanding (&amp;#8220;MOU&amp;#8221;) between Generex&#13;and AEXG related to AEXG referring potential financing candidate to Generex.&amp;#160;AEXG filed a petition to confirm the arbitrator&amp;#8217;s&#13;award in the United States District Court for the Southern District of New York. The petition includes a demand of $3,300,360&#13;as the value of the Warrants. The arbitrator did not award the specific amount of $3.3 million, but only liquidated damages in&#13;the amount of $220,000 and the value of 84,000 warrants &amp;#8220;as of today&amp;#8221; (the date of the award) plus attorney&amp;#8217;s&#13;fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees. As&#13;of July 31, 2019, the value of the warrants have a market value of $232,283. Between the warrants and the $220,000 of liquidated&#13;damages, the Company has accrued $452,283 related to this matter.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;June 28, 2018, the Company was named in respect of a claim by Burrard Pharmaceutical Enterprises Ltd. and Moa&amp;#8217;yeri Kayhan&#13;for unspecified damages and other remedies issued by the Supreme Court of British Columbia. The claim is made in connection with&#13;one advanced against Burrard and Kayhan by Middle East Pharmaceutical Factory L.L.C., a foreign corporation, for fraudulent or&#13;negligent misrepresentation. Middle East alleges that it was misled by Burrard and Kayhan into believing that Burrard had rights&#13;to distribute Generex product in the Middle East. Burrard and Kayhan allege that they did have rights in that regard, which the&#13;Company denies. The matter remains at the pleadings stage and the Company is investigating the facts.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to&#13;sell and sold its Note Due October 26, 2019 (&amp;#8220;Note&amp;#8221;) in the principal amount of $682,000&lt;b&gt;.&amp;#160;&lt;/b&gt;On January 25,&#13;2019, Generex received a letter from the purchaser&amp;#8217;s counsel stating that the Note was in default because Generex&amp;#8217;s&#13;common stock was not listed on NASDAQ within 90 days after the issuance of the Note. The letter demanded repayment in full. On&#13;February 12, 2019, the Purchaser filed a Motion for Summary&amp;#160;Judgment in lieu of complaint in the Supreme Court of New York,&#13;demanding the aggregate principal amount, default interest and costs.&amp;#160;Counsel for Generex and Alpha have engaged in settlement&#13;discussions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;March 21, 2019 Compass Bank filed suit against NuGenerex Distributions Solutions 2, L.L.C. in the District Court of Dallas County,&#13;Texas requesting damages of $3,413,000. In connection with the closing of the Veneto acquisition, Compass Bank had a lien on certain&#13;assets that were supposed to be transferred into the ownership of NuGenerex, a subsidiary of Generex. Those assets were never&#13;transferred due to regulatory impositions. Generex had listed Compass Bank as an intended third-party beneficiary to the transaction&#13;in relation to the assets liened and Veneto ceased payments upon the loan which the lien generated from. Compass bank filed suit&#13;against 6 parties involved in the transaction to collect on the loan, including NuGenerex. NuGenerex&amp;#8217;s position is the contract&#13;was frustrated by the assets that were liened were never transferred, NuGenerex did not receive any benefit from the agreement,&#13;and thus NuGenerex is not responsible to Compass Bank for repayment of a loan on assets not transferred. Generex intends to implead&#13;Brooks Houghton for indemnification who was retained to perform due diligence on the transaction.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2019 Brooks Houghton threatened litigation by way of a FINRA Dispute Resolution. Brooks Houghton, who the managing representative&#13;is Mr. Centonfanti a prior board member, was under contract to perform due diligence on the Veneto transaction, as well as other&#13;unrelated items. The Veneto transaction closed three times, each time with a reduction in price due to material negative circumstances.&#13;Brook Houghton, who was under contract to perform due diligence, claims their fee should be paid on the initial closing price&#13;not the ultimate resolution of the matter. The company offered to compensate Brooks Houghton pursuant to agreement, 3% on the&#13;most recent closing price for Veneto for which Brooks Houghton may have performed some level of work on, payable in kind, and&#13;Brooks Houghton declined the offer. Brooks Houghton is claiming $450,000 for the first closing of Veneto, $714,000 for the second&#13;closing of Veneto, $882,353 for the Regentys acquisition, and $705,882 for Olaregen.&amp;#160;The company is awaiting service. As&#13;of July 31, 2019, the Company has accrued for the full $2,752,235 balance.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;With&#13;respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses&#13;its position both with respect to accrued liabilities and other potential exposures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Lease&#13;Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;There&#13;are rental agreements in effect at Hema Diagnostics Systems, Empire State Pharmacy Inc. and Regentys Corporation which have the&#13;following commitments as of July 31, 2019: $112,801 in fiscal year 2020 and $39,879 in fiscal year 2021.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intellectual&#13;Property&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;connection with the Company&amp;#8217;s acquisition of Olaregen, intellectual property was acquired that had a valuation of $650,000&#13;prior to being acquired and revalued. This initial $650,000 valuation represented the initial payment remitted by Olaregen in&#13;accordance with the $4 million signed commitment agreement entered into with Activation Therapeutics, Inc. The remaining $3.35&#13;million balance is to be paid in quarterly installments equal to 10% of quarterly net sales generated by Activation Therapeutics&#13;assuming the Exellagen average selling price per unit exceeds $800. In the event that the average selling price per unit is less&#13;than $800 per unit, cost of goods sold shall be excluded from the computation of net sales.&lt;/font&gt;&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;4 - Commitments and Contingencies:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Pending&#13;Litigation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company is a defendant in one legal proceeding relating to alleged breach of contract and claims against certain of the Company&amp;#8217;s&#13;original buccal delivery patents. The Company is also a defendant in two legal proceedings brought by a former executive officer&#13;and her affiliate. These legal proceedings have been reported in the Company&amp;#8217;s prior periodic reports. No activity has occurred&#13;in these cases in several years, and the Company now considers them dormant.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc.,&#13;in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in&#13;addition to costs and further interest.&amp;#160;The Company responded to this statement of claim and also asserted a counterclaim&#13;in the proceeding for $200,000 arising from the vendor&amp;#8217;s breach of contract and detinue, together with interest and costs.&#13;On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following&#13;the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such&#13;spinout.&amp;#160;Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party&amp;#8217;s&#13;counsel until payment of the settlement amount.&amp;#160;Following payment to the plaintiff, the parties agree that a Consent Dismissal&#13;Order without costs will be filed with the court.&amp;#160;If the Company fails to make the payment following completion of any post-spinout&#13;financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus&#13;interest of 3% per annum and costs fixed at $25,000. This has been accrued in the unaudited condensed interim consolidated financial&#13;statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;August 22, 2017, Generex received a letter from counsel for Three Brothers Trading LLC, d/b/a Alternative Execution Group (&amp;#8220;AEXG&amp;#8221;),&#13;claiming breach of a Memorandum of Understanding (&amp;#8220;MOU&amp;#8221;) between Generex and AEXG.&amp;#160;The MOU related to AEXG referring&#13;potential financing candidate to Generex.&amp;#160;The letter from AEXG counsel claimed that Generex&amp;#8217;s acceptance of $3,000,000&#13;in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other&#13;financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in&#13;cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney&amp;#8217;s fees and costs. On December 2,&#13;2018, an arbitrator awarded Three Brothers Trading LLC, d/b/a Alternative Execution Group (&amp;#8220;AEXG&amp;#8221;) an aggregate of&#13;$315,695 in damages, costs and fees as well as warrants exercisable for 84,000 shares of Generex Common Stock at an exercise price&#13;of $2.50 per share. The awards were made pursuant to claims under a Memorandum of Understanding (&amp;#8220;MOU&amp;#8221;) between Generex&#13;and AEXG related to AEXG referring potential financing candidate to Generex.&amp;#160;AEXG filed a petition to confirm the arbitrator&amp;#8217;s&#13;award in the United States District Court for the Southern District of New York. The petition includes a demand of $3,300,360&#13;as the value of the Warrants. The arbitrator did not award the specific amount of $3.3 million, but only liquidated damages in&#13;the amount of $220,000 and the value of 84,000 warrants &amp;#8220;as of today&amp;#8221; (the date of the award) plus attorney&amp;#8217;s&#13;fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees. The&#13;petition to confirm the arbitrator&amp;#8217;s award and Generex&amp;#8217;s opposition were remanded by the Court to the arbitrator and&#13;returned for clarification. The arbitrator stated that he was unable to add any clarification, as he did not take evidence on&#13;the issue of warrant valuation. The parties are awaiting the court&amp;#8217;s response to the Arbitrator&amp;#8217;s statement. As of&#13;October 31, 2019, the value of the warrants have a market value of $65,613. Between the warrants and the $220,000 of liquidated&#13;damages, the Company has accrued $285,613 related to this matter.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;June 28, 2018, the Company was named in respect of a claim by Burrard Pharmaceutical Enterprises Ltd. and Moa&amp;#8217;yeri Kayhan&#13;for unspecified damages and other remedies issued by the Supreme Court of British Columbia. The claim is made in connection with&#13;one advanced against Burrard and Kayhan by Middle East Pharmaceutical Factory L.L.C., a foreign corporation, for fraudulent or&#13;negligent misrepresentation. Middle East alleges that it was misled by Burrard and Kayhan into believing that Burrard had rights&#13;to distribute Generex product in the Middle East. Burrard and Kayhan allege that they did have rights in that regard, which the&#13;Company denies. The matter remains at the pleadings stage and the Company is investigating the facts.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to&#13;sell and sold its Note Due October 26, 2019 (&amp;#8220;Note&amp;#8221;) in the principal amount of $682,000&lt;b&gt;. &lt;/b&gt;On January 25, 2019,&#13;Generex received a letter from the purchaser&amp;#8217;s counsel stating that the Note was in default because Generex&amp;#8217;s common&#13;stock was not listed on NASDAQ within 90 days after the issuance of the Note. The letter demanded repayment in full. On February&#13;12, 2019, the Purchaser filed a Motion for Summary&amp;#160;Judgment in lieu of complaint in the Supreme Court of New York, demanding&#13;the aggregate principal amount, default interest and costs.&amp;#160;Counsel for Generex and Alpha have engaged in settlement discussions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;March 21, 2019 Compass Bank filed suit against NuGenerex Distributions Solutions 2, L.L.C. in the District Court of Dallas County,&#13;Texas requesting damages of $3,413,000. In connection with the closing of the Veneto acquisition, Compass Bank had a lien on certain&#13;assets that were supposed to be transferred into the ownership of NuGenerex, a subsidiary of Generex. Those assets were never&#13;transferred due to regulatory impositions. Generex had listed Compass Bank as an intended third party beneficiary to the transaction&#13;in relation to the assets liened and Veneto ceased payments upon the loan which the lien generated from. Compass bank filed suit&#13;against 6 parties involved in the transaction to collect on the loan, including NuGenerex. NuGenerex&amp;#8217;s position is the contract&#13;was frustrated by the assets that were liened were never transferred, NuGenerex did not receive any benefit from the agreement,&#13;and thus NuGenerex is not responsible to Compass Bank for repayment of a loan on assets not transferred. Generex intends to implead&#13;Brooks Houghton for indemnification who was retained to perform due diligence on the transaction.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2019 Brooks Houghton threatened litigation by way of a FINRA Dispute Resolution. Brooks Houghton, who the managing representative&#13;is Mr. Centonfanti a prior board member, was under contract to perform due diligence on the Veneto transaction, as well as other&#13;unrelated items. The Veneto transaction closed three times, each time with a reduction in price due to material negative circumstances.&#13;Brook Houghton, who was under contract to perform due diligence, claims their fee should be paid on the initial closing price&#13;not the ultimate resolution of the matter. The company offered to compensate Brooks Houghton pursuant to agreement, 3% on the&#13;most recent closing price for Veneto for which Brooks Houghton may have performed some level of work on, payable in kind, and&#13;Brooks Houghton declined the offer. Brooks Houghton is claiming $450,000 for the first closing of Veneto, $714,000 for the second&#13;closing of Veneto, $882,353 for the Regentys acquisition, and $705,882 for Olaregen.&amp;#160;The company is awaiting service. As&#13;of October 31, 2019, the Company has accrued for the full $2,752,235 balance.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;With&#13;respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses&#13;its position both with respect to accrued liabilities and other potential exposures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intellectual&#13;Property&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;connection with the Company&amp;#8217;s acquisition of Olaregen, intellectual property was acquired that had a valuation of $650,000&#13;prior to being acquired and revalued. This initial $650,000 valuation represented the initial payment remitted by Olaregen in&#13;accordance with the $4 million signed commitment agreement entered into with Activation Therapeutics, Inc. The remaining $3.35&#13;million balance is to be paid in quarterly installments equal to 10% of quarterly net sales generated by Activation Therapeutics&#13;assuming the Exellagen average selling price per unit exceeds $800. In the event that the average selling price per unit is less&#13;than $800 per unit, cost of goods sold shall be excluded from the computation of net sales.&lt;/font&gt;&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;5 &amp;#8211; Property and Equipment&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;and equipment, net consisted of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&#13;    and technological assets&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;163,168&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,365&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery&#13;    and equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;386,929&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture&#13;    and fixtures&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;73,227&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,879&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    Improvements&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,596&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21,501&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;639,920&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;52,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less&#13;    accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(132,927&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(21,209&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;499,993&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,536&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&#13;expense related to property and equipment amounted to $170,605 and $21,782 for the years ended July 31, 2019 and 2018, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For&#13;the year ended July 31, 2019, the Company had $292,681 of disposals and $11,208 of impairment of long-lived assets. The $292,681&#13;of disposals pertains to Veneto and was mostly the result of their shift in business operations during March 2019 described in&#13;Notes 1 and 2. The $11,208 impairment of long-lived assets pertains to Grainland Pharmacies Holdings, LLC which ceased to operate&#13;&amp;#8211; see Note 13.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;7 &amp;#8211; Property and Equipment&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;and equipment, net consisted of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&#13;    and technological assets&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;163,168&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;163,168&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery&#13;    and equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,576&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;386,929&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture&#13;    and fixtures&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;89,123&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;73,227&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    Improvements&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,596&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,596&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;769,463&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;639,920&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less&#13;    accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(237,575&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(139,927&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;531,888&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;499,993&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&#13;expense related to property and equipment for the three months ended October 31, 2019 and October 31, 2018 was $48,847 and $25,664,&#13;respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;8 &amp;#8211; Inventory&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following components:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw&#13;    materials&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;77,782&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    goods&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;285,226&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,075&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    Inventory&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;363,008&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,075&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;6 &amp;#8211; Inventory&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following components:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw&#13;    materials&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;74,444&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;77,782&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    goods&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,819&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;285,226&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    Inventory&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;727,263&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;363,008&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;14 &amp;#8211; Derivative Liability&lt;/u&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms&#13;of the convertible notes are variable based on certain factors, such as the future price of the Company&amp;#8217;s common stock.&#13;The number of shares of common stock to be issued is based on the future price of the Company&amp;#8217;s common stock. The number&#13;of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of&#13;shares of common stock issuable could exceed the Company&amp;#8217;s authorized share limit, the equity environment is tainted&amp;#160;and&#13;all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded&#13;Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative&#13;liabilities on the issuance date. The Company&amp;#8217;s estimate of fair value used quoted market prices of the underlying financial&#13;instrument and valued the warrants using a multinomial lattice models.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table presents the activity for derivative liabilities measured at estimated fair value:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative&#13;    Liability - Convertible Notes&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative&#13;    Liability - Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative&#13;    Liability - Downside Protection&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of August 1, 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; text-indent: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Additions&#13;    during the year&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,178,241&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;353,464&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,424,338&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,956,043&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change&#13;    in fair value&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;988,267&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(28,214&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,085,502&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,125,449&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change&#13;    due to exercise / redemptions&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,010,312&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,010,312&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,156,196&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;325,250&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,338,836&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,820,282&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;10 &amp;#8211; Derivative Liability&lt;/u&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms&#13;of the convertible notes are variable based on certain factors, such as the future price of the Company&amp;#8217;s common stock.&#13;The number of shares of common stock to be issued is based on the future price of the Company&amp;#8217;s common stock. The number&#13;of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of&#13;shares of common stock issuable could exceed the Company&amp;#8217;s authorized share limit, the equity environment is tainted,&amp;#160;and&#13;all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded&#13;Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative&#13;liabilities on the issuance date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Based&#13;on the various convertible notes described in Note 13, the fair value of applicable derivative liabilities on notes, warrants&#13;and change in fair value of derivative liability are as follows as of October 31, 2019:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;following&#13;table presents the activity for derivative liabilities measured at estimated fair value:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Derivative Liability - Convertible Notes&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Derivative Liability - Downside Protection&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;Balance as of July 31, 2019&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;4,156,196&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;325,250&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;3,338,836&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Additions during the period&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,021,996&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;30,353&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,052,349&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,131,157&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(66,456&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,033,820&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,836,207&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Change due to exercise / redemptions&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,875,052&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(36,432&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,911,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance as of October 31, 2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,171,983&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;252,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;6,372,656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;b&gt;8, 797,354&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Basis&#13;of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;financial statements include all of the Company&amp;#8217;s subsidiaries, including those operating outside the United States and&#13;are prepared in accordance with US GAAP. The consolidated financial statements include the accounts of the Company and all of&#13;its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated. The subsidiaries&#13;included in the Company&amp;#8217;s consolidated financial statements are: Generex Pharmaceuticals, Inc.; Generex (Bermuda), Inc.(dormant);&#13;Antigen Express, Inc.; 1097346 Ontario, Inc.(inactive); NuGenerex Diagnostics LLC &amp;#8220;NGDx,&amp;#8221; formerly known as Hema Diagnostic&#13;Systems, LLC; Hema Diagnostics Systems Panama S.A.(dissolved); Rapid Medical Diagnostics Corporation; NuGenerex Distribution Solutions,&#13;LLC; Grainland Pharmacy Inc.(inactive); Empire State Pharmacy Inc (inactive); NuGenerex Medical Marketing (inactive); Regentys&#13;Corporation (51%); and Olaregen Therapeutix Inc. (51%).&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Basis&#13;of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited consolidated financial&#13;statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in&#13;the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q&#13;and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S.&amp;#160;GAAP&#13;for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments,&#13;considered necessary for a fair presentation have been included.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s fiscal year ends on July&amp;#160;31&#13;of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the three months ended&#13;October 31, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending July&amp;#160;31, 2020.&#13;The balance sheet at October 31, 2019 does not include all of the information and footnotes required by U.S.&amp;#160;GAAP for complete&#13;financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company&amp;#8217;s audited&#13;financial statements and notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended July 31,&#13;2019 as filed with the U.S.&amp;#160;Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Business&#13;Combinations&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&#13;combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the&#13;fair value at the date of acquisition of the assets given, equity instruments issued, or liabilities incurred or assumed. Acquisition&#13;related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized&#13;directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a&amp;#160;business&amp;#160;combination&amp;#160;are&#13;measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any&amp;#160;non-controlling&amp;#160;interest,&#13;over the fair value of the identifiable net assets acquired.&lt;/font&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Business&#13;Combinations&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 0; margin-left: 0; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued,&#13;or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the&#13;issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent&#13;liabilities assumed in a&amp;#160;business&amp;#160;combination&amp;#160;are measured at fair value on the acquisition date. Goodwill is measured&#13;as the excess of the acquisition cost and the amount of any&amp;#160;non-controlling&amp;#160;interest, over the fair value of the identifiable&#13;net assets acquired.&lt;/font&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash&#13;and Cash Equivalents&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company considers&lt;b&gt;&amp;#160;&lt;/b&gt;all highly liquid investments purchased with an original maturity of three months or less to be&#13;cash equivalents.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RevenueRecognitionInterest contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revenue&#13;Recognition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;It&#13;is the Company&amp;#8217;s policy that revenues from product sales is recognized in accordance with ASC 606 &amp;#8220;Revenue Recognition.&amp;#8221;&amp;#160;Five&#13;basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable&#13;rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services&#13;to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects&#13;to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to&#13;the performance obligations in the contract, which requires the company to allocate the transaction price to each performance&#13;obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract;&#13;and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service&#13;to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC&#13;606 has not changed the timing and nature of the Company&amp;#8217;s revenue recognition and there has been no material effect on&#13;the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient&#13;using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with&#13;the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed&#13;the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment&#13;on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy&#13;inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of&#13;the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition&#13;have been met.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed&#13;and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company&#13;and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services&#13;model, laboratory services are provided prior to insurance company approval; as a result, the seller&amp;#8217;s price to buyer is&#13;not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected&#13;revenues associated with similar tests and recognizes the revenue when testing results have been provided (v).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from Olaregen and NGDx is recognized upon payment at the time the product(s) is released (shipment delivered using a common carrier),&#13;and the control is transferred which is simultaneous to when payment received and accepted.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with&#13;the third-parties&amp;#8217; sales that the Company facilitates is to be remitted (iii), and as such, the revenue is&#13;considered earned upon completion of the third parties&amp;#8217; sales of such products (iv). Like pharmacy services described&#13;above, revenue is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using&#13;common carrier or delivered by the pharmacies own personnel) (v).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Provisions&#13;for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based&#13;on historical and anticipated rates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis.&#13;In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the&#13;arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier&#13;selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The&#13;Company&amp;#8217;s obligations under its client contracts for which revenues are reported using the gross method are separate and&#13;distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these&#13;contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products&#13;sold, regardless of whether the Company is paid by its clients. The Company&amp;#8217;s responsibilities under its client contracts&#13;typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to&#13;the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber&#13;prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing.&#13;Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network&#13;claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts&#13;under which the Company acts as an agent, revenue is recognized using the net method.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2019, the Company changed its business model to no longer utilize their existing pharmacies. This shift resulted in breaking&#13;their existing lease agreements with their pharmacies, lab and lab related equipment leases which resulted in a liability of $784,999&#13;as of July 31, 2019 and disposing the majority of applicable leasehold improvements, reduction of employees and no longer holding&#13;and selling inventory. Going forward Veneto will conduct business exclusively through their management services organization and&#13;by entering into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and&#13;salaries. This was made practicable due to the decrease in overall script volume coupled with delays in the Company being able&#13;to receive operating licenses from various government agencies.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionInterest>
    <us-gaap:RevenueRecognitionInterest contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revenue&#13;Recognition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;It&#13;is the Company&amp;#8217;s policy that revenues from product sales is recognized in accordance with ASC 606 &amp;#8220;Revenue Recognition.&amp;#8221;&amp;#160;Five&#13;basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable&#13;rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services&#13;to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects&#13;to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to&#13;the performance obligations in the contract, which requires the company to allocate the transaction price to each performance&#13;obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract;&#13;and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service&#13;to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC&#13;606 has not changed the timing and nature of the Company&amp;#8217;s revenue recognition and there has been no material effect on&#13;the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient&#13;using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with&#13;the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed&#13;the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment&#13;on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy&#13;inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of&#13;the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition&#13;have been met.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed&#13;and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company&#13;and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services&#13;model, laboratory services are provided prior to insurance company approval; as a result, the seller&amp;#8217;s price to buyer is&#13;not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected&#13;revenues associated with similar tests and recognizes the revenue when testing results have been provided (v).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Revenue from NGDx is recognized upon&#13;payment at the time the product(s) is released (shipment delivered using a common carrier), and the control is transferred which&#13;is simultaneous to when payment received and accepted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Revenue from product sales of Olaregen&amp;#8217;s&#13;Excellagen&amp;#174; is recorded at the net sales price, or &amp;#8220;transaction price,&amp;#8221; which includes estimates of variable consideration&#13;that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government&#13;rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of&#13;revenue. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of&#13;variable consideration based on factors such as the Company&amp;#8217;s historical experience, contractual arrangement and specific&#13;known market events and trends. Collectability of revenue is reasonably assured based on historical evidence of collectability&#13;between the Company and its customers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Revenue from the provision of management&#13;services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements&#13;in place typically specify that a percentage of the gross margin associated with the third-parties&amp;#8217; sales that the Company&#13;facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties&amp;#8217;&#13;sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription is dispensed&#13;(picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel) (v).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Provisions&#13;for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based&#13;on historical and anticipated rates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis.&#13;In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the&#13;arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier&#13;selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The&#13;Company&amp;#8217;s obligations under its client contracts for which revenues are reported using the gross method are separate and&#13;distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these&#13;contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products&#13;sold, regardless of whether the Company is paid by its clients. The Company&amp;#8217;s responsibilities under its client contracts&#13;typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to&#13;the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber&#13;prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing.&#13;Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network&#13;claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts&#13;under which the Company acts as an agent, revenue is recognized using the net method.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionInterest>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intangible&#13;Assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;costs of in-process research and development (&amp;#8220;IPR&amp;#38;D&amp;#8221;), related to the Company&amp;#8217;s business combination with&#13;NGDx, were recorded at fair value on the acquisition date. IPR&amp;#38;D intangible assets are considered indefinite-lived intangible&#13;assets until completion or abandonment of the associated research and development efforts. IPR&amp;#38;D is not amortized, but is&#13;reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may&#13;be impaired. The Company also acquired licenses to operate pharmacies which were recorded at cost. They are evaluated annually&#13;for possible impairment. Management determined that as of July 31, 2019, the IPR&amp;#38;D and licenses are not impaired.&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Impairment&#13;or Disposal of Long-Lived Assets and Intangibles&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for the impairment or disposal of long-lived assets according to FASB ASC Topic 360,&amp;#160;&lt;i&gt;Property, Plant&#13;and Equipment&amp;#160;&lt;/i&gt;(&amp;#8220;ASC 360&amp;#8221;). ASC 360 clarifies the accounting for the impairment of long-lived assets and for&#13;long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets&#13;are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary,&#13;impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally&#13;based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary&#13;to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;July 31, 2019, we recorded an asset impairment charge of $287,587 for an intangible assets acquired in 2018, comprised of $188,069&#13;and $99,519 for the Empire State Pharmacy and Grainland Pharmacy assets, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Research&#13;and Development Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expenditures&#13;for research and development are expensed as incurred and include, among other costs, those related to the production of experimental&#13;drugs, including payroll costs, and amounts incurred for conducting clinical trials. Amounts expected to be received from governments&#13;under research and development tax credit arrangements are offset against current research and development expense.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Income&#13;Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income&#13;taxes are accounted for under the asset and liability method prescribed by FASB ASC Topic 740. These standards require a company&#13;to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical&#13;merits of the position. If the more likely than not threshold is met, a company must measure the tax position to determine the&#13;amount to recognize in the financial statements. Deferred income taxes are recorded for temporary differences between financial&#13;statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates&#13;expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if&#13;it is more likely than not that some or all of the deferred tax asset will not be realized.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Property&#13;and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property,&#13;equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of&#13;the assets, or when applicable, the term of the lease, whichever is shorter. Major renewals or replacements that substantially&#13;extend the useful life of an asset are capitalized and depreciated. Property and equipment are depreciated using the straight-line&#13;method over the estimated useful lives of the assets, which are generally as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 60%; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;    shorter of the expected useful life of the improvement or the lease term&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&#13;    and technological assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3-5&#13;    years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery&#13;    and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3-5&#13;    years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture&#13;    and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3-7&#13;    years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Assets&#13;acquired through finance lease arrangements or long-term rental arrangements that transfer substantially all the risks and rewards&#13;associated with ownership of the asset to&amp;#160;the Company (as lessee) are capitalized.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Capitalized&#13;patent costs represent legal costs incurred to establish patents and a portion of the acquisition price paid attributed to patents&#13;upon the acquisition of Antigen in August 2003 and the acquisition of NGDx in January 2017.&amp;#160; When patents reach a mature&#13;stage, any associated legal costs are comprised mostly of maintenance fees and costs of national applications and are expensed&#13;as incurred.&amp;#160; Capitalized patent costs are amortized on a straight-line basis over the remaining life of the patent.&amp;#160;&#13;As patents are abandoned, the net book value of the patent is written off.&lt;/font&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with FASB Accounting Standards&#13;Codification 350-10, &amp;#8220;Intangibles&amp;#8212;Goodwill and Other,&amp;#8221; (&amp;#8220;ASC 350-10&amp;#8221;) goodwill and intangible assets&#13;with indefinite lives are reviewed by us at least annually for impairment. For purposes of these analyses, the estimate of fair&#13;value is based on the income approach, which estimates the fair value based on future discounted cash flows. The estimate of future&#13;discounted cash flows is based on assumptions and projections that are believed to be currently reasonable and supportable. If&#13;it is determined the carrying value of goodwill or other intangible assets to be impaired, then the carrying value is reduced.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;purchase price of acquisitions is allocated to the assets acquired and liabilities assumed based upon their respective fair values&#13;and are subject to change during the twelve month period subsequent to the acquisition date. We engage independent third-party&#13;valuation firms to assist us in determining the fair values of assets acquired and liabilities assumed at the time of acquisition.&#13;Such valuations require us to make significant estimates and assumption, including projections of future events and operating&#13;performance. Fair value estimates are derived from established market values of comparable assets, or internal calculations of&#13;estimated future net cash flows. Our estimate of future cash flows is based on assumptions and projections we believe to be currently&#13;reasonable and supportable.&lt;/font&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock-Based&#13;Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees,&#13;such as grants of stock options and restricted stock, be recognized in the consolidated financial statements based on their fair&#13;value at the grant date and recognized as compensation expense over their vesting periods, which typically conform to the performance&#13;period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model&#13;and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable.&#13;The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments&#13;issued to consultants and other non-employees.&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net&#13;Income (Loss) per Common Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;earnings per share is computed by dividing income (loss) available to common stockholders by the weighted average number of common&#13;shares outstanding during the year. Diluted earnings per share gives effect to all dilutive potential common shares outstanding&#13;during the year. The computation of diluted earnings per share does not assume conversion, exercise or contingent exercise of&#13;securities that would have an anti-dilutive effect on earnings.&amp;#160;Diluted earnings per share is calculated using the treasury&#13;stock method.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Comprehensive&#13;Income/(Loss)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;comprehensive income/(loss), which includes only foreign currency translation adjustments, is shown in the consolidated statements&#13;of operations and comprehensive loss and in the consolidated statements of changes in stockholders&amp;#8217; deficiency.&lt;/font&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Use&#13;of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of&#13;the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company evaluates its estimates, including those related to long lived assets (including patents) impairment valuations, derivatives&#13;and contingencies and litigation, on an ongoing basis. The Company bases its estimates on historical experience and on various&#13;other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments&#13;about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ&#13;from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Critical&#13;accounting estimates are reviewed and discussed with the Board of Directors. The Company considers an accounting estimate to be&#13;critical if it requires assumptions to be made that were uncertain at the time the estimate was made, if changes in the estimate&#13;or if different estimates that could have been selected would have a material impact on our results of operations or financial&#13;condition.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:UseOfEstimates contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Use&#13;of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect&#13;the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <GNBT:RedeemableNoncontrollingInterestPoliciesTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Redeemable&#13;Non-Controlling Interest&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;a result of the acquisition of Regentys, which had redeemable convertible preferred stock classified as a mezzanine instrument&#13;outside of the its equity accounts, such amounts are reclassified as redeemable non-controlling interest as the carrying value&#13;determined by the purchase price allocation at the time of the acquisition of Regentys.&lt;/font&gt;&lt;/p&gt;</GNBT:RedeemableNoncontrollingInterestPoliciesTextBlock>
    <GNBT:DerivativeFinancialInstrumentsPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Derivative&#13;Financial Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;a result of the early adoption of ASU 2017-11 in the second quarter of the fiscal year 2019, the Company has no derivative financials&#13;instruments with down round features classified as a liability at July 31, 2019.&lt;/font&gt;&lt;/p&gt;</GNBT:DerivativeFinancialInstrumentsPolicyTextBlock>
    <GNBT:AdoptionOfNewAccountingStandardsPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Adoption&#13;of New Accounting Standards&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;have reviewed the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) accounting pronouncements and interpretations thereof&#13;that have effective dates during the periods reported and in future periods. The Company does not believe that any new or modified&#13;principles will have a material impact on the Company&amp;#8217;s reported financial position or operations in the near term. The&#13;applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606)&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASC&#13;    815-40 (formerly SFAS No. 133 &amp;#8220;Accounting for derivative instruments and hedging activities&amp;#8221;), requires that embedded&#13;    derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their&#13;    issuance date and in accordance with ASC 815-40-15 (formerly EITF-00-19&amp;#160;&amp;#8220;Accounting for derivative financial instruments&#13;    indexed to, and potentially settled in, a company&amp;#8217;s own stock&amp;#8221;) to determine whether they should be considered&#13;    a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value,&#13;    the Company uses the Black-Scholes option pricing formula and present value pricing. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-08 &amp;#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue&#13;    Gross versus Net).&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-10, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-11, &amp;#8220;Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because&#13;    of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF (Emerging Issue&#13;    Task Force) Meeting.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-12, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-20, &amp;#8220;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2018-07, &amp;#8220;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2017-13, &amp;#8220;Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840) and&#13;    Leases (Topic 842). Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and&#13;    Rescission of Prior SEC Staff Announcements and Observer Comments.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;standards provide companies with a single model for use in accounting for revenue arising from contracts with customers that supersedes&#13;current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize&#13;revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and&#13;rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements&#13;retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment.&amp;#160;The&#13;guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The&#13;guidance was adopted as of August 1, 2018. The Company found that the adoption did not have a material effect on the Company&amp;#8217;s&#13;consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;January 2016, the FASB issued ASU No.&amp;#160;2016-01,&amp;#160;&lt;i&gt;Financial Instruments&amp;#8212;Overall: Recognition and Measurement of&#13;Financial Assets and Financial Liabilities&amp;#160;&lt;/i&gt;(&amp;#8220;ASU 2016-01&amp;#8221;). This standard affects the accounting for equity&#13;instruments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&#13;In February 2018, the FASB issued ASU 2018-03, &amp;#8220;Technical Corrections and Improvements to Financial Instruments (Subtopic&#13;825-10) &amp;#8211; Recognition and Measurement of Financial Assets and Financial Liabilities&amp;#8221;. This update was issued to clarify&#13;certain narrow aspects of guidance concerning the recognition of financial assets and liabilities established in ASU No. 2016-01,&amp;#160;&amp;#8220;Financial&#13;Instruments&amp;#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&amp;#8221;.&amp;#160;This&#13;includes an amendment to clarify that an entity measuring an equity security using the measurement alternative may change its&#13;measurement approach to a fair valuation method in accordance with Topic 820, Fair Value Measurement, through an irrevocable election&#13;that would apply to that security and all identical or similar investments of the same issued. The update is effective for fiscal&#13;years beginning after December 15, 2017 and interim periods within those fiscal years beginning after June 15, 2018. The guidance&#13;was adopted as of August 1, 2018 and did not have a material effect on the Company&amp;#8217;s consolidated financial statements and&#13;related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and&#13;Cash Payments (&amp;#8220;ASU 2016-15&amp;#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing&#13;diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The&#13;standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2)&#13;settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds&#13;from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions&#13;received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable&#13;cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years,&#13;beginning after December 15, 2017 on a retrospective basis. The guidance was adopted as of August 1, 2018 and did not have a material&#13;effect on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;November 2016, the FASB issued ASU 2016-18,&amp;#160;&lt;i&gt;Statement of Cash Flows (Topic 230): Restricted Cash,&amp;#160;&lt;/i&gt;which requires&#13;that a statement of cash flows should include the total of cash, cash equivalents, and amounts generally described as restricted&#13;cash or restricted cash equivalents when reconciling the beginning-of-period and end-of-period total amounts. The update is effective&#13;for fiscal years beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material&#13;effect on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;January 2017, the FASB issued ASU 2017-01, &amp;#8220;Business Combinations (Topic 805): Clarifying the Definition of a Business.&amp;#8221;&#13;These amendments clarify the definition of a business. The amendments affect all companies and other reporting organizations that&#13;must determine whether they have acquired or sold a business. The definition of a business affects many areas of accounting including&#13;acquisitions, disposals, goodwill, and consolidation. The amendments are intended to help companies and other organizations evaluate&#13;whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This update is effective&#13;for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance was adopted as&#13;of August 1, 2018 and did not have a material effect on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2017, the FASB issued ASU 2017-09, &amp;#8220;Compensation-Stock Compensation&amp;#8221; (Topic 718): Scope of Modification Accounting.&#13;The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require&#13;an entity to apply modification accounting under Topic 718 Compensation-Stock Compensation. An entity should account for the effects&#13;of a modification unless all the following are met: 1. The fair value (or calculated value or intrinsic value, if such an alternative&#13;measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such&#13;an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification&#13;does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required&#13;to estimate the value immediately before and after the modification. 2. The vesting conditions of the modified award are the same&#13;as the vesting conditions of the original award immediately before the original award is modified. 3. The classification of the&#13;modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately&#13;before the original award is modified. The ASU is effective for all entities for annual periods, including interim periods within&#13;those annual periods, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material&#13;effect on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;</GNBT:AdoptionOfNewAccountingStandardsPolicyTextBlock>
    <GNBT:AdoptionOfNewAccountingStandardsPolicyTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Adoption&#13;of New Accounting Standards&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;have reviewed the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) accounting pronouncements and interpretations thereof&#13;that have effective dates during the periods reported and in future periods. The Company does not believe that any new or modified&#13;principles will have a material impact on the Company&amp;#8217;s reported financial position or operations in the near term. The&#13;applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued ASU No.&amp;#160;2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;&amp;#160;(&amp;#8220;ASU 2016-02&amp;#8221;).&amp;#160;In January 2018,&#13;the FASB issued ASU 2018-01, which provides additional implementation guidance on the previously issued ASU 2016-02. Under the&#13;new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at&#13;the commencement date: (1) a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured&#13;on a discounted basis; and (2) a right-of-use asset, which is an asset that represents the lessee's right to use, or control the&#13;use of, a specified asset for the lease term. On August 1, 2019, we adopted ASU 2016-02 and its related amendments, which changed&#13;our accounting for leases. As a result of this change, we recognized right-of-use assets and lease liabilities on the consolidated&#13;balance sheet for all leases with a term longer than 12 months and classified them as operating leases. The right-of-use assets&#13;and lease liabilities have been measured by the present value of remaining lease payments over the lease term using our incremental&#13;borrowing rates or implicit rates, when readily determinable. See Note 5 of Notes to Unaudited Condensed Consolidated Financial&#13;Statements contained elsewhere in this report for additional details related to our adoption of the new lease accounting standard.&lt;/font&gt;&lt;/p&gt;</GNBT:AdoptionOfNewAccountingStandardsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently&#13;Issued Accounting Standards&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued ASU No.&amp;#160;2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;&amp;#160;(&amp;#8220;ASU 2016-02&amp;#8221;).&amp;#160;In January 2018,&#13;the FASB issued ASU 2018-01, which provides additional implementation guidance on the previously issued ASU 2016-02. Under the&#13;new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at&#13;the commencement date: (1) a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured&#13;on a discounted basis; and (2) a right-of-use asset, which is an asset that represents the lessee's right to use, or control the&#13;use of, a specified asset for the lease term. The Company is required to adopt ASU 2016-02 for fiscal years, and for interim periods&#13;within those fiscal years, beginning after December 15, 2018. This ASU will be effective for us in the first quarter of 2019 which&#13;begins with interim period ending October 31, 2019. We do not anticipate the adoption of this ASU to have a material impact to&#13;our financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;January 2017, the FASB issued ASU 2017-04,&amp;#160;&lt;i&gt;Simplifying the Test for Goodwill Impairment&amp;#160;&lt;/i&gt;(Topic 350), which eliminates&#13;Step 2 from the goodwill impairment test. Instead, an entity should perform its annual or interim goodwill impairment test by&#13;comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which&#13;the carrying amount exceeds the reporting unit's fair value, not to exceed the total amount of goodwill allocated to the reporting&#13;unit. The Company will adopt the standard effective August 1, 2020. The Company is evaluating the effect that ASU 2017-04 will&#13;have on its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2017, the FASB issued ASU&amp;#160;2017-11,&amp;#160;&lt;i&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic&#13;480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II.&amp;#160;Replacement&#13;of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily&#13;Redeemable&amp;#160;Non-controlling&amp;#160;Interests with a Scope Exception.&lt;/i&gt;&amp;#160;Part&amp;#160;I of this update addresses the complexity&#13;of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked&#13;instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity&#13;offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants&#13;and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion&#13;option. Part&amp;#160;II of this update addresses the difficulty of navigating&amp;#160;&lt;i&gt;Topic 480, Distinguishing Liabilities from&#13;Equity&lt;/i&gt;, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending&#13;content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments&#13;of certain nonpublic entities and certain mandatorily redeemable&amp;#160;non-controlling&amp;#160;interests. The amendments in Part II&#13;of this update do not have an accounting effect. This ASU is effective for interim and annual reporting periods beginning after&#13;December&amp;#160;15, 2018. Early adoption is permitted, including adoption in an interim period. The Company early adopted the ASU&#13;2017-11 in the second quarter as of January 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2018, the FASB issued ASU&amp;#160;2018-02,&amp;#160;&lt;i&gt;Income Statement&amp;#160;&amp;#8211; Reporting Comprehensive Income (Topic 220):&#13;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/i&gt;, which was issued to address the income&#13;tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing&#13;due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment&#13;of the TCJA on December&amp;#160;22, 2017 that changed the Company&amp;#8217;s federal income tax rate from 35% to 21% effective January&#13;1, 2018 and the establishment of a territorial-style system for taxing foreign-source income of domestic multinational corporations.&#13;In December 2017, the SEC issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Act (&amp;#8220;SAB118&amp;#8221;),&#13;which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment. The&#13;Company remeasured its deferred tax assets and liabilities as of July 31, 2018, applying the reduced corporate income tax rate&#13;and recorded a provisional decrease to the deferred tax assets of $31,876,520, with a corresponding adjustment to the valuation&#13;allowance. In the fourth quarter of fiscal year ended July 31, 2019, we completed our analysis to determine the effect of the&#13;Tax Act and there were no material adjustments as of July 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2018, the FASB issued ASU 2018-13, &amp;#8220;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure&#13;Requirements for Fair Value Measurement&amp;#8221;, which adds disclosure requirements to Topic 820 for the range and weighted average&#13;of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual&#13;reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently&#13;Issued Accounting Standards&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;January 2017, the FASB issued ASU 2017-04,&amp;#160;&lt;i&gt;Simplifying the Test for Goodwill Impairment&amp;#160;&lt;/i&gt;(Topic 350), which eliminates&#13;Step 2 from the goodwill impairment test. Instead, an entity should perform its annual or interim goodwill impairment test by&#13;comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which&#13;the carrying amount exceeds the reporting unit's fair value, not to exceed the total amount of goodwill allocated to the reporting&#13;unit. The Company will adopt the standard effective August 1, 2020. The Company is evaluating the effect that ASU 2017-04 will&#13;have on its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2017, the FASB issued ASU&amp;#160;2017-11,&amp;#160;&lt;i&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic&#13;480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II.&amp;#160;Replacement&#13;of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily&#13;Redeemable&amp;#160;Non-controlling&amp;#160;Interests with a Scope Exception.&lt;/i&gt;&amp;#160;Part&amp;#160;I of this update addresses the complexity&#13;of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked&#13;instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity&#13;offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants&#13;and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion&#13;option. Part&amp;#160;II of this update addresses the difficulty of navigating&amp;#160;&lt;i&gt;Topic 480, Distinguishing Liabilities from&#13;Equity&lt;/i&gt;, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending&#13;content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments&#13;of certain nonpublic entities and certain mandatorily redeemable&amp;#160;non-controlling&amp;#160;interests. The amendments in Part II&#13;of this update do not have an accounting effect. This ASU is effective for interim and annual reporting periods beginning after&#13;December&amp;#160;15, 2018. Early adoption is permitted, including adoption in an interim period. The Company early adopted the ASU&#13;2017-11 in the second quarter as of January 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2018, the FASB issued ASU&amp;#160;2018-02,&amp;#160;&lt;i&gt;Income Statement&amp;#160;&amp;#8211; Reporting Comprehensive Income (Topic 220):&#13;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/i&gt;, which was issued to address the income&#13;tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing&#13;due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment&#13;of the TCJA on December&amp;#160;22, 2017 that changed the Company&amp;#8217;s federal income tax rate from 35% to 21% effective January&#13;1, 2018 and the establishment of a territorial-style system for taxing foreign-source income of domestic multinational corporations.&#13;In December 2017, the SEC issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Act (&amp;#8220;SAB118&amp;#8221;),&#13;which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment. The&#13;Company remeasured its deferred tax assets and liabilities as of July 31, 2018, applying the reduced corporate income tax rate&#13;and recorded a provisional decrease to the deferred tax assets of $31,876,520, with a corresponding adjustment to the valuation&#13;allowance. In the fourth quarter of fiscal year ended July 31, 2019, we completed our analysis to determine the effect of the&#13;Tax Act and there were no material adjustments as of July 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2018, the FASB issued ASU 2018-13, &amp;#8220;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure&#13;Requirements for Fair Value Measurement&amp;#8221;, which adds disclosure requirements to Topic 820 for the range and weighted average&#13;of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual&#13;reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;and equipment, net consisted of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&#13;    and technological assets&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;163,168&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,365&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery&#13;    and equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;386,929&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture&#13;    and fixtures&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;73,227&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,879&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    Improvements&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,596&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21,501&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;639,920&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;52,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less&#13;    accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(132,927&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(21,209&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;499,993&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,536&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;and equipment, net consisted of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&#13;    and technological assets&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;163,168&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;163,168&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery&#13;    and equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,576&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;386,929&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture&#13;    and fixtures&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;89,123&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;73,227&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    Improvements&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,596&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,596&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;769,463&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;639,920&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less&#13;    accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(237,575&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(139,927&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;531,888&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;499,993&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following components:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw&#13;    materials&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;77,782&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    goods&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;285,226&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,075&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    Inventory&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;363,008&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,075&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following components:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw&#13;    materials&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;74,444&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;77,782&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    goods&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,819&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;285,226&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    Inventory&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;727,263&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;363,008&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;assets consist of the following at July 31:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In-Process&#13;    Research &amp;#38; Development&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,761,427&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,911,377&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreements&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,210,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Developed&#13;    Software/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    Intangibles&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;51,274&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;327,654&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,153,701&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,239,031&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less&#13;    accumulated amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(319,432&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(27,994&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,834,269&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,211,037&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;assets consist of the following at:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;October 31,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 0pt"&gt;In-Process Research &amp;#38; Development&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;8,761,427&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;8,761,427&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,566,700&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,210,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0pt"&gt;Developed software/technology&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;172,500&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;131,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Vendor agreements and other intangibles&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;775,674&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;51,274&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11,276,301&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;10,153,701&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(473,859&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(319,432&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;10,802,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;9,834,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;amortization expense&amp;#160;(in thousands) for the next five years and thereafter is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&amp;#160;Ending&amp;#160;July&amp;#160;31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 44%; text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;434,117&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;434,118&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;164,895&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,787&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,138&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,898&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,082,952&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The remaining estimated amortization expense&amp;#160;for the next five&#13;years and thereafter is as follows:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&amp;#160;Ending&amp;#160;July&amp;#160;31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 45%; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;570,708&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;616,744&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;246,324&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;94,511&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68,491&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;444,658&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,041,435&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;net purchase price of NGDx was determined to be as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    Price at Closing&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Shares&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&#13;    Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Purchase&#13;    price:&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 46%; text-align: left; padding-left: 6.75pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common&#13;    Stock at closing&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.23&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,117,011&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,721&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 6.75pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common&#13;    Stock after closing&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.23&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;420&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 6.75pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common&#13;    Stock post reverse stock split&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.23&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,830,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,097,100&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    purchase price&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,947,431&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,350,916&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock>
    <GNBT:FairValueAssumptionsUsedInAccountingForWarrantsTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The key inputs used in the fair&#13;value calculations were as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    1,&amp;#160;&lt;br /&gt; 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&amp;#160;&lt;br /&gt; 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    price&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.50&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.50&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Time&#13;    to expiration&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.14&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.47&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.01&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.77&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    volatility&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;138.61&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;143.97&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    price at valuation date&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.9&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:FairValueAssumptionsUsedInAccountingForWarrantsTableTextBlock>
    <GNBT:FairValueAssumptionsUsedInAccountingForCallOptionsTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following assumptions were used in estimating the value of the Call Option:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    1,&amp;#160;&lt;br /&gt; 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&amp;#160;&lt;br /&gt; 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.52&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.44&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    volatility&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;164.43&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;129.95&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&#13;    Term&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.13&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.47&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    price at valuation date&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.9043&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0976&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:FairValueAssumptionsUsedInAccountingForCallOptionsTableTextBlock>
    <GNBT:EstimatedAmortizationExpenseTableTextBlock contextRef="From2018-08-01to2019-07-31_custom_VenetoMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preliminary amounts assigned to the identifiable intangible assets, the estimated useful lives, and the estimated amortization&#13;expense related to these identifiable intangible assets are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&amp;#160;&lt;br /&gt;&#13;    Fair&amp;#160;&lt;br /&gt; Value&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&amp;#160;&lt;br /&gt;&#13;    Estimated&amp;#160;&lt;br /&gt; Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Developed&#13;    Software/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Referral&#13;    Base&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreements&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;680,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;811,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ending July 31, 2019, the amounts assigned to the identifiable intangible assets, the estimated useful lives, and the&#13;estimated amortization expense related to these identifiable intangible assets were revalued as follows:&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&amp;#160;&lt;br /&gt;&#13;    Fair&amp;#160;&lt;br /&gt; Value&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&amp;#160;&lt;br /&gt;&#13;    Estimated&amp;#160;&lt;br /&gt; Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Developed&#13;    Software/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;397,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Referral&#13;    Base&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreements&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,870,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,277,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:EstimatedAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;components of the acquired intangible assets were as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&amp;#160;&lt;br /&gt;&#13;    Fair&amp;#160;&lt;br /&gt; Value&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&#13;    Estimated Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In-process&#13;    research and development&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,980,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;790,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,770,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unaudited&#13;pro forma results of operations for the year ended July 31, 2019 and 2018 as though the Company acquired Veneto, Olaregen and&#13;Regentys (the &amp;#8220;Acquired Companies&amp;#8221;) on the first day of each fiscal year are set forth below.&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&#13;    Ended&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,217,169&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,137,821&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cost&#13;    of revenues&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,143,586&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,236,850&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&#13;    profit&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,073,583&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,900,971&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating&#13;    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,338,328&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;45,146,085&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating&#13;    loss&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,264,744&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,245,114&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    income (expense)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,469,732&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;523,226&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    loss&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,795,012&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,721,888&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    loss attributable to noncontrolling interests&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,606,316&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(230,222&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    Income (loss) Available to Common Stockholders&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,188,696&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,491,666&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Comprehensive&#13;    net loss&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,188,696&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,491,666&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic&#13;    and diluted earnings per share&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.05&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.29&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Unaudited pro forma results of operations for&#13;the three months ended October 31, 2019 and 2018 as though the Company acquired MediSource and Pantheon on the first day of each&#13;fiscal year are set forth below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Three months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;October 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: justify"&gt;Revenues&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;721,661&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,141,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Cost of revenues&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;133,618&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;987,409&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Gross profit&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;588,043&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,153,591&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5,136,754&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,629,854&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Operating loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,548,711&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,476,262&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,763,836&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19,389,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Net loss&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(9,312,547&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;17,913,682&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Comprehensive net loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(9,312,547&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;17,913,682&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table presents the activity for derivative liabilities measured at estimated fair value:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative&#13;    Liability - Convertible Notes&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative&#13;    Liability - Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative&#13;    Liability - Downside Protection&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of August 1, 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; text-align: left; text-indent: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Additions&#13;    during the year&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,178,241&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;353,464&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,424,338&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,956,043&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change&#13;    in fair value&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;988,267&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(28,214&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,085,502&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,125,449&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change&#13;    due to exercise / redemptions&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,010,312&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,010,312&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,156,196&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;325,250&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,338,836&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,820,282&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Following&#13;table presents the activity for derivative liabilities measured at estimated fair value:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Derivative Liability - Convertible Notes&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Derivative Liability - Downside Protection&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;Balance as of July 31, 2019&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;4,156,196&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;325,250&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;3,338,836&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Additions during the period&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,021,996&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;30,353&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,052,349&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,131,157&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(66,456&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,033,820&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,836,207&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Change due to exercise / redemptions&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,875,052&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(36,432&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,911,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance as of October 31, 2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,171,983&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;252,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;6,372,656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;b&gt;8, 797,354&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The following assumptions were used in the Black-Scholes option-pricing model:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 72%; padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&#13;                                         Ended&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;        31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$0.11&#13;    &amp;#8211; 1.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected&#13;    term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&#13;    to 10 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.03%&#13;    - 3.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;135.2%&#13;    - 222.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected&#13;    dividend&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    price at valuation date&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$0.11&#13;    &amp;#8211; $1.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The following assumptions were used in the Black-Scholes option-pricing model:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October&#13;    31, &lt;br /&gt; 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    price&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.01&#13;                                         &amp;#8211; 2.09&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Time&#13;    to expiration&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.51%&#13;                                         - 1.59%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    volatility&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;153.4&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected&#13;    dividend&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    price at valuation date&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.01&#13;                                         &amp;#8211; 2.09&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">-409386468</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">-418727875</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">-427853820</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">3252439</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">10981</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;6 - Stockholders&amp;#8217; Equity:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common&#13;Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;November 13, 2018, the Company declared a stock dividend on its outstanding Common Stock for stockholders of record date to be&#13;determined (the &amp;#8220;Record Date&amp;#8221;). As a result, all stockholders on the Record Date received twenty new shares of Common&#13;Stock for each share of Common Stock owned by them as of that date. Proportional adjustments for the reverse stock split were&#13;made to the Company&amp;#8217;s outstanding stock options, and warrants including all share and per-share data, for all amounts and&#13;periods presented in the condensed interim consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 18, 2017, the Company issued 1,117,431&#13;shares of common stock for the acquisition of 51% of NGDx and is obligated to issue 4,830,000 shares of common stock upon the conclusion&#13;of the Company&amp;#8217;s reverse stock splitwhich were issued on October 26, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 30, 2019, the Company declared a&#13;dividend to holders of Generex common shares of its subsidiary Antigen Express, Inc., d/b/a NuGenerex Immuno-Oncology. On February&#13;25, 2019, Generex shareholders received a dividend of one share of Antigen Express, Inc. for every four shares of Generex common&#13;stock which amounted to an issuance of 15,076,849 shares, representing approximately 3.77% ownership of Antigen. The fair value&#13;of the shares issued amounted to $1,070,456 and was recorded as a dividend with a corresponding increase to noncontrolling interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2019, the Company issued 4,000,000 shares&#13;of common stock and a $2 million note payable for the acquisition of 592,682 shares of Series A Preferred Stock of Olaregen pursuant&#13;to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated&#13;on May 10, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In&#13;July 2019, the Company issued 1,920,376 shares of common stock for the conversion debt in the amount of $4,350,571.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During&#13;the fourth quarter of 2019, the Company converted a note payable of $53,000 for 30,000 shares of common stock with a fair value&#13;of $69,000. The difference between the fair value of the common stock and the outstanding balance of the note payable was recorded&#13;as a loss on extinguishment of debt. As of July 31, 2019, the shares were yet to be issued by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of July 31, 2018,&#13;302,614 shares remained to be issued resulting in common stock payable of $2,168,951. During the year ended July 31, 2019, 1,238,517&#13;shares of common stock payable were issued. As of July 31, 2019, 588,658 shares remain to be issued resulting in common stock payable&#13;of $1,123,188.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series&#13;H and Series I Convertible Preferred Stock&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has authorized 109,000 shares of designated non-voting Series H Convertible Preferred Stock with a stated value of $1,000&#13;per share and authorized 6,000 shares of designated non-voting Series I Convertible Preferred Stock with a stated value of $47.61&#13;per share pursuant to the Purchase Agreement dated March 27, 2017. The Series H Preferred Stock was scheduled to be sold in four&#13;tranches to the Purchaser. Under the Securities Purchase Agreement, in the event the Purchaser failed to purchase 100% of the&#13;shares of Preferred Stock at any given Closing, the Company can decline to sell any further securities to the Purchaser (the &amp;#8220;Purchase&#13;Agreement&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Series H and Series I Convertible Preferred Stock are convertible at the option of the holder at any time into shares of the Company&amp;#8217;s&#13;common stock at an effective conversion price of $0.12 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Neither&#13;Series H nor Series I Convertible Preferred Stock have special dividend rights. If the Company pays dividends on its common stock,&#13;the holders of the preferred stock will receive dividends in the amount they would have received had they converted the preferred&#13;stock to common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;closing of the first tranche on March 28, 2017, the Company issued 63,000 shares of Series H Preferred Stock for a purchase price&#13;of $3,000,000. The proceeds of this sale were paid directly on the Company&amp;#8217;s behalf to Emmaus as an additional deposit under&#13;the Company&amp;#8217;s Emmaus LOI. The full amount of such proceeds was repaid to the Company in July 2017 upon termination of the&#13;Emmaus LOI. On December 1, 2018, after payment of the dividend, B-H Sanford, LLC, converted all of its holding of the Company&amp;#8217;&#13;Series H Convertible Preferred Stock owned by it into 25,200,000 shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prior&#13;to payment of Generex&amp;#8217;s 20 for 1 common stock dividend, on November 30, 2018, Joseph Moscato, the Company&amp;#8217;s President&#13;and Chief Executive Officer, and Lawrence Salvo, a member of the Company&amp;#8217;s Board of Directors, converted&amp;#160;all shares&#13;of the Company&amp;#8217; Series I Convertible Preferred Stock&amp;#160;owned by them.&amp;#160;Mr. Moscato received 3,276,000 shares of the&#13;Company&amp;#8217;s Common Stock upon conversion.&amp;#160;Mr. Salvo&amp;#160;received 3,354,645 shares of the Company&amp;#8217;s Common Stock&#13;upon conversion.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Non-controlling&#13;Interest&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Mr.&#13;Berkman agreed, under certain conditions to transfer the remaining 49% of the NGDx equity to the Company for a consideration of&#13;$1.00. On December 1, 2018, the Company and Mr. Berkman entered into an Agreement, Assignment and Release, pursuant to which Mr.&#13;Berkman transferred the remaining NGDx equity interests to the Company, waiving and releasing any conditions to such transfer.&#13;As of December 1, 2018, NGDx is a wholly owned subsidiary of the Company. During the year ended in July 31, 2019, there was a&#13;net loss attributable to the non-controlling interest (49%) in NGDx of $122,692 and contributions made of $133,679. As of July&#13;31, 2019, and 2018, the non-controlling interest in NGDx was $0 and $5,576,272, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the Company&amp;#8217;s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161&#13;shares of Regentys common stock. As of July 31, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192&#13;Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares&#13;that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the Company&amp;#8217;s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632&#13;shares of Olaregen common stock. As of July 31, 2019, Olaregen had a total of 5,648,819 shares of common stock and 592,683 Series&#13;A voting preferred stock for a total of 6,241,502 total voting shares outstanding. As such, there are 2,958,870 of shares that&#13;belong to non-controlling interest shareholders which represents a 47.41% non-controlling interest.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;November 1, 2018, the Company completed its second closing of Veneto Holdings, L.L.C. (&amp;#8220;Veneto&amp;#8221;) which granted the&#13;Company Rapport Services, LLC (&amp;#8220;Rapport&amp;#8221;) through the ownership of the units of Class B membership interests providing&#13;control of Rapport as only the Class B Member is entitled to elect the nominees to the Board of Managers, which constitute a one&#13;percent (1%) ownership in Rapport. The remaining interests represent a 99% non-controlling interest.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;11 - Stockholders&amp;#8217; Equity:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common&#13;Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;November 13, 2018, the Company declared a stock dividend on its outstanding Common Stock for stockholders of record date to be&#13;determined (the &amp;#8220;Record Date&amp;#8221;). As a result, all stockholders on the Record Date received twenty new shares of Common&#13;Stock for each share of Common Stock owned by them as of that date. Proportional adjustments for the reverse stock split were&#13;made to the Company&amp;#8217;s outstanding stock options, and warrants including all share and per-share data, for all amounts and&#13;periods presented in the condensed interim consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;During the three months&#13;ended October 31, 2019, 296,793 shares of common stock payable were issued. As of October 31, 2019, 286,377 shares remain to be&#13;issued resulting in common stock payable $215,793.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;During the first quarter&#13;of 2020, the Company issued 1,164,190 shares of common stock for the conversion of approximately $1,736,900 of debt.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In August 2019, the Company&#13;issued 400,000 and 560,000 shares of common stock valued at $2.50 per share for the acquisition of MediSource and Pantheon, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 12, 2019, 20,375,900 outstanding shares of common&#13;stock were cancelled by the Company held by Joe Moscato TTEE Friends of Generex Biotechnology Investment Trust U/A/D 4/2/2019,&#13;a trust formed for the benefit the Company and any 80% controlled subsidiary of the Company by several shareholders contributing&#13;in the aggregate 33,175,900 shares of the Company&amp;#8217;s Common Stock and 8,293,975 shares of&amp;#160; Antigen Express, Inc, d/b/a&#13;NuGenerex Immuno-Oncology commons shares (the &amp;#8220;Friends of Generex Trust&amp;#8221;), similar to the Stock Control Agreement&#13;previously entered into by the same shareholders on December 1, 2018 filed in an 8-K filed on December 3, 2019, incorporated herein&#13;by reference.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Non-controlling&#13;Interest&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the Company&amp;#8217;s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161&#13;shares of Regentys common stock. As of October 31, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192&#13;Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares&#13;that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Pursuant to the Company&amp;#8217;s&#13;acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common&#13;stock. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust&#13;and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock&#13;Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated&#13;on May 10, 2019. On August 16, 2019, the Company entered into a Share Exchange Agreement to purchase an additional 900,000 shares&#13;of common stock in Olaregen from other shareholders of Olaregen in exchange for 1,905,912 shares of Generex common stock contributed&#13;and provided by the Friends of Generex Trust and 476,478 shares of Antigen common stock contributed and provided by the Friends&#13;of Generex Trust. In September 2019, the Company converted all of the Series A Preferred Stock of Olaregen into common stock of&#13;Olaregen.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 25, 2019, we issued a stock dividend&#13;to our shareholders, whereby our shareholders received one (1) share of NGIO for every four (4) shares of our stock held on the&#13;dividend date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of October 31, 2019, Olaregen had a total&#13;of 6,236,390 shares of common stock and zero Series A voting preferred stock outstanding. As such, there are 1,461,075 of shares&#13;that belong to non-controlling interest shareholders which represents a 23.43% non-controlling interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 1, 2018, the Company completed&#13;its second closing of Veneto Holdings, L.L.C. (&amp;#8220;Veneto&amp;#8221;) which granted the Company Rapport Services, LLC (&amp;#8220;Rapport&amp;#8221;)&#13;through the ownership of the units of Class B membership interests providing control of Rapport as only the Class B Member is&#13;entitled to elect the nominees to the Board of Managers, which constitute a one percent (1%) ownership in Rapport. The remaining&#13;interests represent a 99% non-controlling interest.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <GNBT:RedeemableNoncontrollingInterestTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;7 &amp;#8211; Redeemable Non-Controlling Interest:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the Company&amp;#8217;s acquisition of 51% of the outstanding capital stock of Regentys, Regentys had authorized 7,500,000 shares&#13;of redeemable Series A Convertible Preferred Stock (&amp;#8220;Preferred Stock A&amp;#8221;), with a par value of $0.0001 and redemption&#13;value of $1.46 per share of which 2,793,192 Preferred Stock A was outstanding as of the date of acquisition and as of July 31,&#13;2019. Preferred Stock may be converted into common stock at the initial conversion ratio of 1:1 which ratio shall be adjusted&#13;in accordance with stock dividends, splits, combinations and other similar events, including the sale of additional shares of&#13;common or preferred stock and the holders of Preferred Stock A are entitled to vote, together with the holders of Regentys common&#13;stock, on all matters submitted to stockholders of Regentys for a vote.&amp;#160;At any time after November 1, 2026, the holders of&#13;the Company&amp;#8217;s Series A Preferred Stock will have the right to require the Company to redeem all or a portion of their shares&#13;for cash at a redemption price equal to its liquidation value. Accordingly, this Preferred Stock A was valued to be $4,073,898&#13;at the time of acquisition of Regentys and reclassified as Redeemable Non-Controlling Interest outside of stockholders&amp;#8217;&#13;deficit on the condensed interim consolidated balance sheets.&lt;/font&gt;&lt;/p&gt;</GNBT:RedeemableNoncontrollingInterestTextBlock>
    <GNBT:RedeemableNoncontrollingInterestTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;12 &amp;#8211; Redeemable Non-Controlling Interest:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the Company&amp;#8217;s acquisition of 51% of the outstanding capital stock of Regentys, Regentys had authorized 7,500,000 shares&#13;of redeemable Series A Convertible Preferred Stock (&amp;#8220;Preferred Stock A&amp;#8221;), with a par value of $0.0001 and redemption&#13;value of $0.65 per share of which 2,793,192 Preferred Stock A was outstanding as of the date of acquisition and as of October&#13;31, 2019. Preferred Stock may be converted into common stock at the initial conversion ratio of 1:1 which ratio shall be adjusted&#13;in accordance with stock dividends, splits, combinations and other similar events, including the sale of additional shares of&#13;common or preferred stock and the holders of Preferred Stock A are entitled to vote, together with the holders of Regentys common&#13;stock, on all matters submitted to stockholders of Regentys for a vote.&amp;#160;At any time after November 1, 2026, the holders of&#13;the Company&amp;#8217;s Series A Preferred Stock will have the right to require the Company to redeem all or a portion of their shares&#13;for cash at a redemption price equal to its liquidation value. Accordingly, this Preferred Stock A was valued to be $4,073,898&#13;at the time of acquisition of Regentys and reclassified as Redeemable Non-Controlling Interest outside of stockholders&amp;#8217;&#13;deficit on the consolidated balance sheets.&lt;/font&gt;&lt;/p&gt;</GNBT:RedeemableNoncontrollingInterestTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Derivative&#13;Liability&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s derivative financial instruments are measured at fair value using the Monte Carlo, Black Scholes and multinomial&#13;lattice models which takes into account, as of the valuation date, factors including the current exercise price, the expected&#13;life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock and&#13;the risk-free interest rate for the term of the instrument.&amp;#160;&amp;#160;The liability is revalued at each reporting period and&#13;changes in fair value are recognized in the consolidated statements of operations and comprehensive loss under the caption &amp;#8220;Change&#13;in fair value of derivative liabilities.&amp;#8221;&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories,&#13;which consist of both raw materials and finished goods, is valued at the lower of cost or net realizable value. Inventory&#13;costs are comprised primarily of product, labor, freight and duty. The Company writes down inventory for estimated&#13;obsolescence equal to the difference between the cost of inventory and the estimated market value based upon assumptions&#13;about future demand and market conditions. For the year ending July 31, 2019, the Company had a write down of inventory for&#13;$645,351 related to obsolescence which is classified as cost of goods sold.&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Foreign&#13;Currency Transactions and Translations&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;functional and reporting currency of the Company and most of its subsidiaries is the United States Dollar. One subsidiary, Generex&#13;Pharmaceuticals, Inc., has a functional currency of the Canadian Dollar. Foreign denominated assets and liabilities of the Company&#13;are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Revenue and expense&#13;accounts are translated at an average of exchange rates which were in effect during the period. Translation adjustments that arise&#13;from translating the foreign subsidiary&amp;#8217;s financial statements from its functional currency to the Company&amp;#8217;s reporting&#13;currency are recorded in the other comprehensive loss component of stockholders&amp;#8217; equity. Gains and losses resulting from&#13;foreign currency transactions are included in the consolidated statement of operations and comprehensive loss.&lt;/font&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <GNBT:PurchasePriceAllocatedAsOfAcquisitionDateTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;finalized our allocation of the purchase price as of December 28, 2018. The final allocation of the purchase price as of January&#13;31, 2019, is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&#13;    Allocation as of December 28,&amp;#160;&lt;br /&gt; 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Allocation&#13;    Adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Final&#13;    Allocation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 46%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;    assets (licenses)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;276,380&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;276,380&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;    and equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,879&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,879&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computer&#13;    software acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,980&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,980&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    Improvements&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;17,761&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;17,761&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;320,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;320,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration:&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;    Payable&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;320,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;320,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:PurchasePriceAllocatedAsOfAcquisitionDateTableTextBlock>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Options&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Exercise Price per Share&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Remaining Life (Years)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt"&gt;Outstanding &amp;#8211; August 1, 2018&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;379,998&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1.48&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1.11&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;69,843&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(147,777&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Outstanding - July 31, 2018&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;232,221&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;10,719&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9,976,125&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.71&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7.59&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,821,821&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,219,671&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(0.43&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;8.18&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Outstanding - July 31, 2019&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7,988,675&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7.21&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;15,961,391&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price per Share&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Remaining Life (Years)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    Intrinsic Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,988,675&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.84&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.21&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,961,391&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,003,000&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.09&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.92&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&#13;    or expired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(130,000&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.11&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.65&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - October 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,861,675&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.98&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.71&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,859,392&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The following is a listing of&#13;the Company&amp;#8217;s liabilities required to be measured at fair value on a recurring basis and where they are classified within&#13;the fair value hierarchy as of July 31, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Call option&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The following is a listing&#13;of the Company&amp;#8217;s liabilities required to be measured at fair value on a recurring basis and where they are classified within&#13;the fair value hierarchy as of July 31, 2019 and July 31, 2018:&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2019&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Derivative liability&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrants to be issued&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;2 &amp;#8211; Summary of Significant Accounting Policies:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Basis&#13;of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;financial statements include all of the Company&amp;#8217;s subsidiaries, including those operating outside the United States and&#13;are prepared in accordance with US GAAP. The consolidated financial statements include the accounts of the Company and all of&#13;its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated. The subsidiaries&#13;included in the Company&amp;#8217;s consolidated financial statements are: Generex Pharmaceuticals, Inc.; Generex (Bermuda), Inc.(dormant);&#13;Antigen Express, Inc.; 1097346 Ontario, Inc.(inactive); NuGenerex Diagnostics LLC &amp;#8220;NGDx,&amp;#8221; formerly known as Hema Diagnostic&#13;Systems, LLC; Hema Diagnostics Systems Panama S.A.(dissolved); Rapid Medical Diagnostics Corporation; NuGenerex Distribution Solutions,&#13;LLC; Grainland Pharmacy Inc.(inactive); Empire State Pharmacy Inc (inactive); NuGenerex Medical Marketing (inactive); Regentys&#13;Corporation (51%); and Olaregen Therapeutix Inc. (51%).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Business&#13;Combinations&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&#13;combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the&#13;fair value at the date of acquisition of the assets given, equity instruments issued, or liabilities incurred or assumed. Acquisition&#13;related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized&#13;directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a&amp;#160;business&amp;#160;combination&amp;#160;are&#13;measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any&amp;#160;non-controlling&amp;#160;interest,&#13;over the fair value of the identifiable net assets acquired.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash&#13;and Cash Equivalents&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company considers&lt;b&gt;&amp;#160;&lt;/b&gt;all highly liquid investments purchased with an original maturity of three months or less to be&#13;cash equivalents.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Capitalized&#13;patent costs represent legal costs incurred to establish patents and a portion of the acquisition price paid attributed to patents&#13;upon the acquisition of Antigen in August 2003 and the acquisition of NGDx in January 2017.&amp;#160; When patents reach a mature&#13;stage, any associated legal costs are comprised mostly of maintenance fees and costs of national applications and are expensed&#13;as incurred.&amp;#160; Capitalized patent costs are amortized on a straight-line basis over the remaining life of the patent.&amp;#160;&#13;As patents are abandoned, the net book value of the patent is written off.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revenue&#13;Recognition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;It&#13;is the Company&amp;#8217;s policy that revenues from product sales is recognized in accordance with ASC 606 &amp;#8220;Revenue Recognition.&amp;#8221;&amp;#160;Five&#13;basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable&#13;rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services&#13;to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects&#13;to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to&#13;the performance obligations in the contract, which requires the company to allocate the transaction price to each performance&#13;obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract;&#13;and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service&#13;to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC&#13;606 has not changed the timing and nature of the Company&amp;#8217;s revenue recognition and there has been no material effect on&#13;the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient&#13;using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with&#13;the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed&#13;the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment&#13;on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy&#13;inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of&#13;the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition&#13;have been met.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed&#13;and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company&#13;and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services&#13;model, laboratory services are provided prior to insurance company approval; as a result, the seller&amp;#8217;s price to buyer is&#13;not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected&#13;revenues associated with similar tests and recognizes the revenue when testing results have been provided (v).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from Olaregen and NGDx is recognized upon payment at the time the product(s) is released (shipment delivered using a common carrier),&#13;and the control is transferred which is simultaneous to when payment received and accepted.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i);&#13;however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties&amp;#8217;&#13;sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the&#13;third parties&amp;#8217; sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription&#13;is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel)&#13;(v).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Provisions&#13;for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based&#13;on historical and anticipated rates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis.&#13;In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the&#13;arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier&#13;selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The&#13;Company&amp;#8217;s obligations under its client contracts for which revenues are reported using the gross method are separate and&#13;distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these&#13;contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products&#13;sold, regardless of whether the Company is paid by its clients. The Company&amp;#8217;s responsibilities under its client contracts&#13;typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to&#13;the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber&#13;prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing.&#13;Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network&#13;claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts&#13;under which the Company acts as an agent, revenue is recognized using the net method.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2019, the Company changed its business model to no longer utilize their existing pharmacies. This shift resulted in breaking&#13;their existing lease agreements with their pharmacies, lab and lab related equipment leases which resulted in a liability of $784,999&#13;as of July 31, 2019 and disposing the majority of applicable leasehold improvements, reduction of employees and no longer holding&#13;and selling inventory. Going forward Veneto will conduct business exclusively through their management services organization and&#13;by entering into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and&#13;salaries. This was made practicable due to the decrease in overall script volume coupled with delays in the Company being able&#13;to receive operating licenses from various government agencies.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intangible&#13;Assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;costs of in-process research and development (&amp;#8220;IPR&amp;#38;D&amp;#8221;), related to the Company&amp;#8217;s business combination with&#13;NGDx, were recorded at fair value on the acquisition date. IPR&amp;#38;D intangible assets are considered indefinite-lived intangible&#13;assets until completion or abandonment of the associated research and development efforts. IPR&amp;#38;D is not amortized, but is&#13;reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may&#13;be impaired. The Company also acquired licenses to operate pharmacies which were recorded at cost. They are evaluated annually&#13;for possible impairment. Management determined that as of July 31, 2019, the IPR&amp;#38;D and licenses are not impaired.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Impairment&#13;or Disposal of Long-Lived Assets and Intangibles&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for the impairment or disposal of long-lived assets according to FASB ASC Topic 360,&amp;#160;&lt;i&gt;Property, Plant&#13;and Equipment&amp;#160;&lt;/i&gt;(&amp;#8220;ASC 360&amp;#8221;). ASC 360 clarifies the accounting for the impairment of long-lived assets and for&#13;long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets&#13;are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary,&#13;impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally&#13;based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary&#13;to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;July 31, 2019, we recorded an asset impairment charge of $287,587 for an intangible assets acquired in 2018, comprised of $188,069&#13;and $99,519 for the Empire State Pharmacy and Grainland Pharmacy assets, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Derivative&#13;Liability&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s derivative financial instruments are measured at fair value using the Monte Carlo, Black Scholes and multinomial&#13;lattice models which takes into account, as of the valuation date, factors including the current exercise price, the expected&#13;life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock and&#13;the risk-free interest rate for the term of the instrument.&amp;#160;&amp;#160;The liability is revalued at each reporting period and&#13;changes in fair value are recognized in the consolidated statements of operations and comprehensive loss under the caption &amp;#8220;Change&#13;in fair value of derivative liabilities.&amp;#8221;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Research&#13;and Development Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expenditures&#13;for research and development are expensed as incurred and include, among other costs, those related to the production of experimental&#13;drugs, including payroll costs, and amounts incurred for conducting clinical trials. Amounts expected to be received from governments&#13;under research and development tax credit arrangements are offset against current research and development expense.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Income&#13;Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income&#13;taxes are accounted for under the asset and liability method prescribed by FASB ASC Topic 740. These standards require a company&#13;to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical&#13;merits of the position. If the more likely than not threshold is met, a company must measure the tax position to determine the&#13;amount to recognize in the financial statements. Deferred income taxes are recorded for temporary differences between financial&#13;statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates&#13;expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if&#13;it is more likely than not that some or all of the deferred tax asset will not be realized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories,&#13;which consist of both raw materials and finished goods, is valued at the lower of cost or net realizable value. Inventory&#13;costs are comprised primarily of product, labor, freight and duty. The Company writes down inventory for estimated&#13;obsolescence equal to the difference between the cost of inventory and the estimated market value based upon assumptions&#13;about future demand and market conditions. For the year ending July 31, 2019, the Company had a write down of inventory for&#13;$645,351 related to obsolescence which is classified as cost of goods sold.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Property&#13;and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property,&#13;equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of&#13;the assets, or when applicable, the term of the lease, whichever is shorter. Major renewals or replacements that substantially&#13;extend the useful life of an asset are capitalized and depreciated. Property and equipment are depreciated using the straight-line&#13;method over the estimated useful lives of the assets, which are generally as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 60%; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;    shorter of the expected useful life of the improvement or the lease term&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&#13;    and technological assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3-5&#13;    years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery&#13;    and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3-5&#13;    years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture&#13;    and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3-7&#13;    years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Assets&#13;acquired through finance lease arrangements or long-term rental arrangements that transfer substantially all the risks and rewards&#13;associated with ownership of the asset to&amp;#160;the Company (as lessee) are capitalized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Goodwill&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with FASB Accounting Standards&#13;Codification 350-10, &amp;#8220;Intangibles&amp;#8212;Goodwill and Other,&amp;#8221; (&amp;#8220;ASC 350-10&amp;#8221;) goodwill and intangible assets&#13;with indefinite lives are reviewed by us at least annually for impairment. For purposes of these analyses, the estimate of fair&#13;value is based on the income approach, which estimates the fair value based on future discounted cash flows. The estimate of future&#13;discounted cash flows is based on assumptions and projections that are believed to be currently reasonable and supportable. If&#13;it is determined the carrying value of goodwill or other intangible assets to be impaired, then the carrying value is reduced.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;purchase price of acquisitions is allocated to the assets acquired and liabilities assumed based upon their respective fair values&#13;and are subject to change during the twelve month period subsequent to the acquisition date. We engage independent third-party&#13;valuation firms to assist us in determining the fair values of assets acquired and liabilities assumed at the time of acquisition.&#13;Such valuations require us to make significant estimates and assumption, including projections of future events and operating&#13;performance. Fair value estimates are derived from established market values of comparable assets, or internal calculations of&#13;estimated future net cash flows. Our estimate of future cash flows is based on assumptions and projections we believe to be currently&#13;reasonable and supportable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock-Based&#13;Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees,&#13;such as grants of stock options and restricted stock, be recognized in the consolidated financial statements based on their fair&#13;value at the grant date and recognized as compensation expense over their vesting periods, which typically conform to the performance&#13;period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model&#13;and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable.&#13;The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments&#13;issued to consultants and other non-employees.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net&#13;Income (Loss) per Common Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;earnings per share is computed by dividing income (loss) available to common stockholders by the weighted average number of common&#13;shares outstanding during the year. Diluted earnings per share gives effect to all dilutive potential common shares outstanding&#13;during the year. The computation of diluted earnings per share does not assume conversion, exercise or contingent exercise of&#13;securities that would have an anti-dilutive effect on earnings.&amp;#160;Diluted earnings per share is calculated using the treasury&#13;stock method.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Comprehensive&#13;Income/(Loss)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;comprehensive income/(loss), which includes only foreign currency translation adjustments, is shown in the consolidated statements&#13;of operations and comprehensive loss and in the consolidated statements of changes in stockholders&amp;#8217; deficiency.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Foreign&#13;Currency Transactions and Translations&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;functional and reporting currency of the Company and most of its subsidiaries is the United States Dollar. One subsidiary, Generex&#13;Pharmaceuticals, Inc., has a functional currency of the Canadian Dollar. Foreign denominated assets and liabilities of the Company&#13;are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Revenue and expense&#13;accounts are translated at an average of exchange rates which were in effect during the period. Translation adjustments that arise&#13;from translating the foreign subsidiary&amp;#8217;s financial statements from its functional currency to the Company&amp;#8217;s reporting&#13;currency are recorded in the other comprehensive loss component of stockholders&amp;#8217; equity. Gains and losses resulting from&#13;foreign currency transactions are included in the consolidated statement of operations and comprehensive loss.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value of Financial Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&#13;value is defined under FASB ASC Topic 820 as the exchange price that would be received for an asset or paid to transfer a liability&#13;(an exit price) in the principal or the most advantageous market for an asset or liability in an orderly transaction between participants&#13;on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize&#13;the use of unobservable inputs. The standard describes a fair value hierarchy based on the levels of inputs, of which the first&#13;two are considered observable and the last unobservable, that may be used to measure fair value. The levels are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    1 - Quoted prices in active markets for identical assets or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets&#13;    or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable&#13;    market data for substantially the full term of the assets or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    3 - Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets&#13;    or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s financial instruments consist of cash and cash equivalents, trade receivables, other receivables, payables, and&#13;short term and long term debt. The carrying values of cash and cash equivalents, trade receivables, other receivables, and payables&#13;approximate their fair value due to their short maturities. The carrying value of long term debt approximates the&amp;#160;&lt;/font&gt;fair&#13;value of debt&lt;font style="font-size: 10pt"&gt;&amp;#160;of similar terms and remaining maturities available to the company.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;July 31, 2019, the Company did not have any assets measured at fair value on a recurring basis. The following is a listing of&#13;the Company&amp;#8217;s liabilities required to be measured at fair value on a recurring basis and where they are classified within&#13;the fair value hierarchy as of July 31, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Call option&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The following is a listing&#13;of the Company&amp;#8217;s liabilities required to be measured at fair value on a recurring basis and where they are classified within&#13;the fair value hierarchy as of July 31, 2019 and July 31, 2018:&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2019&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Derivative liability&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrants to be issued&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Use&#13;of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of&#13;the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company evaluates its estimates, including those related to long lived assets (including patents) impairment valuations, derivatives&#13;and contingencies and litigation, on an ongoing basis. The Company bases its estimates on historical experience and on various&#13;other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments&#13;about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ&#13;from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Critical&#13;accounting estimates are reviewed and discussed with the Board of Directors. The Company considers an accounting estimate to be&#13;critical if it requires assumptions to be made that were uncertain at the time the estimate was made, if changes in the estimate&#13;or if different estimates that could have been selected would have a material impact on our results of operations or financial&#13;condition.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Redeemable&#13;Non-Controlling Interest&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;a result of the acquisition of Regentys, which had redeemable convertible preferred stock classified as a mezzanine instrument&#13;outside of the its equity accounts, such amounts are reclassified as redeemable non-controlling interest as the carrying value&#13;determined by the purchase price allocation at the time of the acquisition of Regentys.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;Derivative&#13;Financial Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;a result of the early adoption of ASU 2017-11 in the second quarter of the fiscal year 2019, the Company has no derivative financials&#13;instruments with down round features classified as a liability at July 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Adoption&#13;of New Accounting Standards&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;have reviewed the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) accounting pronouncements and interpretations thereof&#13;that have effective dates during the periods reported and in future periods. The Company does not believe that any new or modified&#13;principles will have a material impact on the Company&amp;#8217;s reported financial position or operations in the near term. The&#13;applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606)&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASC&#13;    815-40 (formerly SFAS No. 133 &amp;#8220;Accounting for derivative instruments and hedging activities&amp;#8221;), requires that embedded&#13;    derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their&#13;    issuance date and in accordance with ASC 815-40-15 (formerly EITF-00-19&amp;#160;&amp;#8220;Accounting for derivative financial instruments&#13;    indexed to, and potentially settled in, a company&amp;#8217;s own stock&amp;#8221;) to determine whether they should be considered&#13;    a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value,&#13;    the Company uses the Black-Scholes option pricing formula and present value pricing. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-08 &amp;#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue&#13;    Gross versus Net).&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-10, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-11, &amp;#8220;Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because&#13;    of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF (Emerging Issue&#13;    Task Force) Meeting.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-12, &amp;#8220;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2016-20, &amp;#8220;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2018-07, &amp;#8220;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-top: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-top: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASU&#13;    2017-13, &amp;#8220;Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840) and&#13;    Leases (Topic 842). Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and&#13;    Rescission of Prior SEC Staff Announcements and Observer Comments.&amp;#8221;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;standards provide companies with a single model for use in accounting for revenue arising from contracts with customers that supersedes&#13;current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize&#13;revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and&#13;rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements&#13;retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment.&amp;#160;The&#13;guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The&#13;guidance was adopted as of August 1, 2018. The Company found that the adoption did not have a material effect on the Company&amp;#8217;s&#13;consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;January 2016, the FASB issued ASU No.&amp;#160;2016-01,&amp;#160;&lt;i&gt;Financial Instruments&amp;#8212;Overall: Recognition and Measurement of&#13;Financial Assets and Financial Liabilities&amp;#160;&lt;/i&gt;(&amp;#8220;ASU 2016-01&amp;#8221;). This standard affects the accounting for equity&#13;instruments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&#13;In February 2018, the FASB issued ASU 2018-03, &amp;#8220;Technical Corrections and Improvements to Financial Instruments (Subtopic&#13;825-10) &amp;#8211; Recognition and Measurement of Financial Assets and Financial Liabilities&amp;#8221;. This update was issued to clarify&#13;certain narrow aspects of guidance concerning the recognition of financial assets and liabilities established in ASU No. 2016-01,&amp;#160;&amp;#8220;Financial&#13;Instruments&amp;#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&amp;#8221;.&amp;#160;This&#13;includes an amendment to clarify that an entity measuring an equity security using the measurement alternative may change its&#13;measurement approach to a fair valuation method in accordance with Topic 820, Fair Value Measurement, through an irrevocable election&#13;that would apply to that security and all identical or similar investments of the same issued. The update is effective for fiscal&#13;years beginning after December 15, 2017 and interim periods within those fiscal years beginning after June 15, 2018. The guidance&#13;was adopted as of August 1, 2018 and did not have a material effect on the Company&amp;#8217;s consolidated financial statements and&#13;related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and&#13;Cash Payments (&amp;#8220;ASU 2016-15&amp;#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing&#13;diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The&#13;standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2)&#13;settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds&#13;from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions&#13;received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable&#13;cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years,&#13;beginning after December 15, 2017 on a retrospective basis. The guidance was adopted as of August 1, 2018 and did not have a material&#13;effect on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;November 2016, the FASB issued ASU 2016-18,&amp;#160;&lt;i&gt;Statement of Cash Flows (Topic 230): Restricted Cash,&amp;#160;&lt;/i&gt;which requires&#13;that a statement of cash flows should include the total of cash, cash equivalents, and amounts generally described as restricted&#13;cash or restricted cash equivalents when reconciling the beginning-of-period and end-of-period total amounts. The update is effective&#13;for fiscal years beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material&#13;effect on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;January 2017, the FASB issued ASU 2017-01, &amp;#8220;Business Combinations (Topic 805): Clarifying the Definition of a Business.&amp;#8221;&#13;These amendments clarify the definition of a business. The amendments affect all companies and other reporting organizations that&#13;must determine whether they have acquired or sold a business. The definition of a business affects many areas of accounting including&#13;acquisitions, disposals, goodwill, and consolidation. The amendments are intended to help companies and other organizations evaluate&#13;whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This update is effective&#13;for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance was adopted as&#13;of August 1, 2018 and did not have a material effect on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2017, the FASB issued ASU 2017-09, &amp;#8220;Compensation-Stock Compensation&amp;#8221; (Topic 718): Scope of Modification Accounting.&#13;The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require&#13;an entity to apply modification accounting under Topic 718 Compensation-Stock Compensation. An entity should account for the effects&#13;of a modification unless all the following are met: 1. The fair value (or calculated value or intrinsic value, if such an alternative&#13;measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such&#13;an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification&#13;does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required&#13;to estimate the value immediately before and after the modification. 2. The vesting conditions of the modified award are the same&#13;as the vesting conditions of the original award immediately before the original award is modified. 3. The classification of the&#13;modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately&#13;before the original award is modified. The ASU is effective for all entities for annual periods, including interim periods within&#13;those annual periods, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material&#13;effect on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently&#13;Issued Accounting Standards&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued ASU No.&amp;#160;2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;&amp;#160;(&amp;#8220;ASU 2016-02&amp;#8221;).&amp;#160;In January 2018,&#13;the FASB issued ASU 2018-01, which provides additional implementation guidance on the previously issued ASU 2016-02. Under the&#13;new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at&#13;the commencement date: (1) a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured&#13;on a discounted basis; and (2) a right-of-use asset, which is an asset that represents the lessee's right to use, or control the&#13;use of, a specified asset for the lease term. The Company is required to adopt ASU 2016-02 for fiscal years, and for interim periods&#13;within those fiscal years, beginning after December 15, 2018. This ASU will be effective for us in the first quarter of 2019 which&#13;begins with interim period ending October 31, 2019. We do not anticipate the adoption of this ASU to have a material impact to&#13;our financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;January 2017, the FASB issued ASU 2017-04,&amp;#160;&lt;i&gt;Simplifying the Test for Goodwill Impairment&amp;#160;&lt;/i&gt;(Topic 350), which eliminates&#13;Step 2 from the goodwill impairment test. Instead, an entity should perform its annual or interim goodwill impairment test by&#13;comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which&#13;the carrying amount exceeds the reporting unit's fair value, not to exceed the total amount of goodwill allocated to the reporting&#13;unit. The Company will adopt the standard effective August 1, 2020. The Company is evaluating the effect that ASU 2017-04 will&#13;have on its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2017, the FASB issued ASU&amp;#160;2017-11,&amp;#160;&lt;i&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic&#13;480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II.&amp;#160;Replacement&#13;of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily&#13;Redeemable&amp;#160;Non-controlling&amp;#160;Interests with a Scope Exception.&lt;/i&gt;&amp;#160;Part&amp;#160;I of this update addresses the complexity&#13;of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked&#13;instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity&#13;offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants&#13;and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion&#13;option. Part&amp;#160;II of this update addresses the difficulty of navigating&amp;#160;&lt;i&gt;Topic 480, Distinguishing Liabilities from&#13;Equity&lt;/i&gt;, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending&#13;content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments&#13;of certain nonpublic entities and certain mandatorily redeemable&amp;#160;non-controlling&amp;#160;interests. The amendments in Part II&#13;of this update do not have an accounting effect. This ASU is effective for interim and annual reporting periods beginning after&#13;December&amp;#160;15, 2018. Early adoption is permitted, including adoption in an interim period. The Company early adopted the ASU&#13;2017-11 in the second quarter as of January 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2018, the FASB issued ASU&amp;#160;2018-02,&amp;#160;&lt;i&gt;Income Statement&amp;#160;&amp;#8211; Reporting Comprehensive Income (Topic 220):&#13;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/i&gt;, which was issued to address the income&#13;tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing&#13;due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment&#13;of the TCJA on December&amp;#160;22, 2017 that changed the Company&amp;#8217;s federal income tax rate from 35% to 21% effective January&#13;1, 2018 and the establishment of a territorial-style system for taxing foreign-source income of domestic multinational corporations.&#13;In December 2017, the SEC issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Act (&amp;#8220;SAB118&amp;#8221;),&#13;which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment. The&#13;Company remeasured its deferred tax assets and liabilities as of July 31, 2018, applying the reduced corporate income tax rate&#13;and recorded a provisional decrease to the deferred tax assets of $31,876,520, with a corresponding adjustment to the valuation&#13;allowance. In the fourth quarter of fiscal year ended July 31, 2019, we completed our analysis to determine the effect of the&#13;Tax Act and there were no material adjustments as of July 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2018, the FASB issued ASU 2018-13, &amp;#8220;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure&#13;Requirements for Fair Value Measurement&amp;#8221;, which adds disclosure requirements to Topic 820 for the range and weighted average&#13;of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual&#13;reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;2 &amp;#8211; Summary of Significant Accounting Policies:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Basis&#13;of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited consolidated financial&#13;statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in&#13;the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q&#13;and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S.&amp;#160;GAAP&#13;for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments,&#13;considered necessary for a fair presentation have been included.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s fiscal year ends on July&amp;#160;31&#13;of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the three months ended&#13;October 31, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending July&amp;#160;31, 2020.&#13;The balance sheet at October 31, 2019 does not include all of the information and footnotes required by U.S.&amp;#160;GAAP for complete&#13;financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company&amp;#8217;s audited&#13;financial statements and notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended July 31,&#13;2019 as filed with the U.S.&amp;#160;Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Use&#13;of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect&#13;the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Business&#13;Combinations&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 0; margin-left: 0; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued,&#13;or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the&#13;issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent&#13;liabilities assumed in a&amp;#160;business&amp;#160;combination&amp;#160;are measured at fair value on the acquisition date. Goodwill is measured&#13;as the excess of the acquisition cost and the amount of any&amp;#160;non-controlling&amp;#160;interest, over the fair value of the identifiable&#13;net assets acquired.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revenue&#13;Recognition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;It&#13;is the Company&amp;#8217;s policy that revenues from product sales is recognized in accordance with ASC 606 &amp;#8220;Revenue Recognition.&amp;#8221;&amp;#160;Five&#13;basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable&#13;rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services&#13;to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects&#13;to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to&#13;the performance obligations in the contract, which requires the company to allocate the transaction price to each performance&#13;obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract;&#13;and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service&#13;to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC&#13;606 has not changed the timing and nature of the Company&amp;#8217;s revenue recognition and there has been no material effect on&#13;the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient&#13;using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with&#13;the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed&#13;the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment&#13;on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy&#13;inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of&#13;the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition&#13;have been met.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue&#13;from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed&#13;and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company&#13;and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services&#13;model, laboratory services are provided prior to insurance company approval; as a result, the seller&amp;#8217;s price to buyer is&#13;not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected&#13;revenues associated with similar tests and recognizes the revenue when testing results have been provided (v).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Revenue from NGDx is recognized upon&#13;payment at the time the product(s) is released (shipment delivered using a common carrier), and the control is transferred which&#13;is simultaneous to when payment received and accepted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Revenue from product sales of Olaregen&amp;#8217;s&#13;Excellagen&amp;#174; is recorded at the net sales price, or &amp;#8220;transaction price,&amp;#8221; which includes estimates of variable consideration&#13;that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government&#13;rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of&#13;revenue. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of&#13;variable consideration based on factors such as the Company&amp;#8217;s historical experience, contractual arrangement and specific&#13;known market events and trends. Collectability of revenue is reasonably assured based on historical evidence of collectability&#13;between the Company and its customers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Revenue from the provision of management&#13;services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements&#13;in place typically specify that a percentage of the gross margin associated with the third-parties&amp;#8217; sales that the Company&#13;facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties&amp;#8217;&#13;sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription is dispensed&#13;(picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel) (v).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Provisions&#13;for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based&#13;on historical and anticipated rates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis.&#13;In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the&#13;arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier&#13;selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The&#13;Company&amp;#8217;s obligations under its client contracts for which revenues are reported using the gross method are separate and&#13;distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these&#13;contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products&#13;sold, regardless of whether the Company is paid by its clients. The Company&amp;#8217;s responsibilities under its client contracts&#13;typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to&#13;the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber&#13;prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing.&#13;Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network&#13;claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts&#13;under which the Company acts as an agent, revenue is recognized using the net method.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Adoption&#13;of New Accounting Standards&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;have reviewed the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) accounting pronouncements and interpretations thereof&#13;that have effective dates during the periods reported and in future periods. The Company does not believe that any new or modified&#13;principles will have a material impact on the Company&amp;#8217;s reported financial position or operations in the near term. The&#13;applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued ASU No.&amp;#160;2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;&amp;#160;(&amp;#8220;ASU 2016-02&amp;#8221;).&amp;#160;In January 2018,&#13;the FASB issued ASU 2018-01, which provides additional implementation guidance on the previously issued ASU 2016-02. Under the&#13;new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at&#13;the commencement date: (1) a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured&#13;on a discounted basis; and (2) a right-of-use asset, which is an asset that represents the lessee's right to use, or control the&#13;use of, a specified asset for the lease term. On August 1, 2019, we adopted ASU 2016-02 and its related amendments, which changed&#13;our accounting for leases. As a result of this change, we recognized right-of-use assets and lease liabilities on the consolidated&#13;balance sheet for all leases with a term longer than 12 months and classified them as operating leases. The right-of-use assets&#13;and lease liabilities have been measured by the present value of remaining lease payments over the lease term using our incremental&#13;borrowing rates or implicit rates, when readily determinable. See Note 5 of Notes to Unaudited Condensed Consolidated Financial&#13;Statements contained elsewhere in this report for additional details related to our adoption of the new lease accounting standard.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently&#13;Issued Accounting Standards&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;January 2017, the FASB issued ASU 2017-04,&amp;#160;&lt;i&gt;Simplifying the Test for Goodwill Impairment&amp;#160;&lt;/i&gt;(Topic 350), which eliminates&#13;Step 2 from the goodwill impairment test. Instead, an entity should perform its annual or interim goodwill impairment test by&#13;comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which&#13;the carrying amount exceeds the reporting unit's fair value, not to exceed the total amount of goodwill allocated to the reporting&#13;unit. The Company will adopt the standard effective August 1, 2020. The Company is evaluating the effect that ASU 2017-04 will&#13;have on its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2017, the FASB issued ASU&amp;#160;2017-11,&amp;#160;&lt;i&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic&#13;480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II.&amp;#160;Replacement&#13;of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily&#13;Redeemable&amp;#160;Non-controlling&amp;#160;Interests with a Scope Exception.&lt;/i&gt;&amp;#160;Part&amp;#160;I of this update addresses the complexity&#13;of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked&#13;instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity&#13;offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants&#13;and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion&#13;option. Part&amp;#160;II of this update addresses the difficulty of navigating&amp;#160;&lt;i&gt;Topic 480, Distinguishing Liabilities from&#13;Equity&lt;/i&gt;, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending&#13;content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments&#13;of certain nonpublic entities and certain mandatorily redeemable&amp;#160;non-controlling&amp;#160;interests. The amendments in Part II&#13;of this update do not have an accounting effect. This ASU is effective for interim and annual reporting periods beginning after&#13;December&amp;#160;15, 2018. Early adoption is permitted, including adoption in an interim period. The Company early adopted the ASU&#13;2017-11 in the second quarter as of January 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2018, the FASB issued ASU&amp;#160;2018-02,&amp;#160;&lt;i&gt;Income Statement&amp;#160;&amp;#8211; Reporting Comprehensive Income (Topic 220):&#13;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/i&gt;, which was issued to address the income&#13;tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing&#13;due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment&#13;of the TCJA on December&amp;#160;22, 2017 that changed the Company&amp;#8217;s federal income tax rate from 35% to 21% effective January&#13;1, 2018 and the establishment of a territorial-style system for taxing foreign-source income of domestic multinational corporations.&#13;In December 2017, the SEC issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Act (&amp;#8220;SAB118&amp;#8221;),&#13;which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment. The&#13;Company remeasured its deferred tax assets and liabilities as of July 31, 2018, applying the reduced corporate income tax rate&#13;and recorded a provisional decrease to the deferred tax assets of $31,876,520, with a corresponding adjustment to the valuation&#13;allowance. In the fourth quarter of fiscal year ended July 31, 2019, we completed our analysis to determine the effect of the&#13;Tax Act and there were no material adjustments as of July 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2018, the FASB issued ASU 2018-13, &amp;#8220;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure&#13;Requirements for Fair Value Measurement&amp;#8221;, which adds disclosure requirements to Topic 820 for the range and weighted average&#13;of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual&#13;reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;&lt;u&gt;Note 9 &amp;#8211;&#13;Notes Payable&lt;/u&gt;&amp;#160;&lt;/b&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to&#13;sell and sold its Note Due October 26, 2019 (&amp;#8220;Note&amp;#8221;) in the principal amount of $682,000&lt;b&gt;.&amp;#160;&lt;/b&gt;The purchase&#13;price of the Note was $550,000 from which Generex was required to pay the $15,000 fee of the investor&amp;#8217;s counsel. The remaining&#13;$147,000 of principal amount represents original issue discount. The Note does not bear any stated interest in addition to the&#13;original issue discount. The effective interest is 27.5%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;November 25, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed&#13;to sell and sold its Note due November 26, 2019 (&amp;#8220;Note&amp;#8221;) in the principal amount of $1,060,000. The purchase price&#13;of the Note was $1,000,000. The remaining $60,000 of principal amount represents original issue discount. The Note does not bear&#13;any stated interest in addition to the original issue discount. In May 2019, the Company issued 400,000 shares of common stock&#13;for full satisfaction of this Note.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 24, 2019, Generex entered into Securities Purchase Agreements with three investors pursuant to which the Company agreed&#13;to sell and sold convertible notes bearing interest at 10% per annum (the &amp;#8220;Notes&amp;#8221;) in the aggregate principal amount&#13;of $2,110,000. The purchase price of the Notes was $2,010,000 and the remaining $100,000 of principal amount represents original&#13;issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time&#13;into shares of the Company&amp;#8217;s common stock at an effective conversion price determined as follows: the lesser of a price&#13;determined as of the date of closing; and 70% of the lowest trading price of the common stock on the ten days prior to conversion.&#13;The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value.&#13;Pursuant to the Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 120,570&#13;shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the&#13;Notes (Note 14) resulting in full discount of the Notes. In July 2019, the Company issued 1,065,826 shares of common stock for&#13;the conversion of $1,425,000 of principal and $76,976 of accrued interest. Out of the 1,065,826 shares, 266,793 were recorded&#13;as common stock payable until the shares were delivered in August 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to&#13;sell and sold convertible notes bearing interest at 10% per annum (the &amp;#8220;Notes&amp;#8221;) in the aggregate principal amount&#13;of $1,500,000. The purchase price of the Notes was $1,425,000 and the remaining $75,000 of principal amount represents original&#13;issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time&#13;into shares of the Company&amp;#8217;s common stock at an effective conversion price determined as follows: the lesser of a price&#13;determined as of the date of closing; and 70% of the lowest trading price of the common stock on the ten days prior to conversion.&#13;The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value.&#13;Pursuant to the Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 102,143&#13;shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the&#13;Notes (Note 14) resulting in full discount of the Notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;April 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to sell&#13;and sold convertible notes bearing interest at 10% per annum (the &amp;#8220;Notes&amp;#8221;) in the aggregate principal amount of $1,060,000.&#13;The purchase price of the Notes was $1,010,000 and the remaining $50,000 of principal amount represents original issue discount.&#13;Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of&#13;the Company&amp;#8217;s common stock at an effective conversion price determined as follows: the lesser of a price determined as of&#13;the date of closing; and 70% of the lowest trading price of the common stock on the ten days prior to conversion. The embedded&#13;conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. Pursuant to the&#13;Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 176,968 shares of common&#13;stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Notes (Note 14)&#13;resulting in full discount of the Notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2019, the Company consummated a Stock Purchase Agreement entered into January 14, 2019 to which the Company agreed to sell&#13;and sold $2,000,000 Promissory Note bearing interest at 7% per annum (the &amp;#8220;Notes&amp;#8221;) originally due and payable on August&#13;1, 2019. The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to sell&#13;and sold convertible notes bearing interest at 9% per annum (the &amp;#8220;Notes&amp;#8221;) in the aggregate principal amount of $446,600.&#13;The purchase price of the Notes was $400,000 and the remaining $46,600 of principal amount represents original issue discount.&#13;Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of&#13;the Company&amp;#8217;s common stock at an effective conversion price determined as follows: the lesser of a price determined as of&#13;the date of closing; and 80% of the lowest volume weighted average trading price of the common stock on the ten days prior to&#13;conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at&#13;fair value. The fair value of the derivative liability as of the date of issuance was $206,548 and was recorded as a discount&#13;of the Notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For&#13;the year ending July 31, 2019, amortization of debt discount was $3,008,849 leaving a remaining debt discount balance as of July&#13;31, 2019 of $1,938,994.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;December 28, 2017, the Company through its wholly owned subsidiary NuGenerex, completed the acquisition of the assets and 100%&#13;of the membership interests of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings,&#13;LLC, pursuant to the bills of sale for a consideration of $320,000 Promissory Note due and payable in full on June 28, 2018 bearing&#13;an annual interest rate of 3%. The note was extended by six months and set to mature with the same terms on December 28, 2018.&#13;The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the second closing of the acquisition of certain operating assets of Veneto Holdings, L.L.C. and its affiliates, Generex&amp;#8217;s&#13;wholly owned subsidiary agreed to assume outstanding debt of Veneto subsidiaries to Compass Bank, including obligations under&#13;a term loan and a revolving line of credit. Claiming three separate types of default, Compass Bank has demanded payment in full&#13;of amounts due under the term loan and revolving line of credit, in an aggregate amount of approximately $3,413,000. Generex believes&#13;it has defenses to such demand, including that the bank was not an intended beneficiary of the subsidiary&amp;#8217;s agreement to&#13;assume the debt.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to its acquisition of Regentys, the Company inherited convertible notes with several investors which collectively held a principal&#13;plus of $615,000 as of the date of acquisition. During the year ended July 31, 2019, $187,500 was converted into common stock&#13;of Regentys and $51,625 was repaid in cash. As of July 31, 2019, the remaining principal balance was $353,375 with an unamortized&#13;debt discount balance of $3,719. These notes have an accrued interest balance of $24,940 as of July 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;&lt;i&gt;Deferred Tax Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;a result of the acquisition of Regentys and Olaregen, the purchase price allocation attributed to deferred tax liability was $889,782&#13;and $1,040,173, respectfully. The Company has deferred tax assets of over $68 million with a full allowance equally to the to&#13;the amount of the deferred tax asset. Although the Company deferred tax assets are in excess of deferred tax liabilities totaling&#13;$1,502,122 , the Company cannot offset the deferred tax liabilities against its deferred tax assets since the Company acquired&#13;less than the 80% of both Regentys and Olaregen preventing the Company to consolidate its income tax returns with Regentys and&#13;Olaregen for tax purposes. Therefore, the deferred tax liabilities will be reported separately until such time that the Company&#13;determines otherwise. In addition, the Company acquired approximately 51% of each of Regentys and Olaregen, less than the 80%&#13;required to permit the Company to consolidate with Regentys and Olaregen for tax purposes. Therefore, the deferred tax liabilities&#13;will be reported separately until such time that the Company determines otherwise.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;9 &amp;#8211; Notes Payable&lt;/u&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to&#13;sell and sold its Note Due October 26, 2019 (&amp;#8220;Note&amp;#8221;) in the principal amount of $682,000&lt;b&gt;.&amp;#160;&lt;/b&gt;The purchase&#13;price of the Note was $550,000 from which Generex was required to pay the $15,000 fee of the investor&amp;#8217;s counsel. The remaining&#13;$147,000 of principal amount represents original issue discount. The Note does not bear any stated interest in addition to the&#13;original issue discount. The effective interest is 27.5%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 24, 2019, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to&#13;sell and sold its convertible note bearing interest at 10% per annum (the &amp;#8220;Notes&amp;#8221;) in the principal amount of $530,000.&#13;The purchase price of the Notes was $505,000 and the remaining $25,000 of principal amount represents original issue discount.&#13;Pursuant to the Securities Purchase Agreement, Generex also sold warrants to the investors to purchase 30,285 shares of common&#13;stock with the fair value of the warrants as of the date of issuance in excess of the Notes resulting in full discount of the&#13;Notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to&#13;sell and sold each investor a $750,000 convertible note bearing interest at 10% per annum (the &amp;#8220;Notes&amp;#8221;). The total&#13;purchase price of the Notes was $1,425,000 and the remaining $75,000 of principal amount represents original issue discount. Subject&#13;to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company&amp;#8217;s&#13;common stock at an effective conversion price determined as follows: the lesser of a price determined as of the date of closing;&#13;and 70% of the lowest trading price of the common stock on the ten days prior to conversion. The embedded conversion feature of&#13;these Notes was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase&#13;Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 102,143 shares of common stock. The fair&#13;value of the derivative liability and warrants as of the date of issuance was in excess of the Notes (Note 14) resulting in full&#13;discount of the Notes. One of the notes went into default during the quarter. Pursuant to a settlement agreement, the Company&#13;agreed to settle the debt by making a $900,000 payment and converting $350,000 of the remaining principal into common stock of&#13;the Company. The Company recognized a loss on settlement of debt of $403,214.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;April 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to sell&#13;and sold convertible notes bearing interest at 10% per annum (the &amp;#8220;Notes&amp;#8221;) in the aggregate principal amount of $1,060,000.&#13;The purchase price of the Notes was $1,000,000 and the remaining $60,000 of principal amount represents original issue discount.&#13;Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of&#13;the Company&amp;#8217;s common stock at an effective conversion price determined as follows: the lesser of a price determined as of&#13;the date of closing; and 70% of the lowest trading price of the common stock on the ten days prior to conversion. The embedded&#13;conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. Pursuant to the&#13;Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 176,968 shares of common&#13;stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Notes (Note 14)&#13;resulting in full discount of the Notes. During the quarter, $110,000 of principal was converted into common stock of the Company,&#13;leaving a remaining principal balance of $950,000 at October 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2019, the Company consummated a Stock Purchase Agreement entered into January 14, 2019 to which the Company agreed to sell&#13;and sold $2,000,000 Promissory Note bearing interest at 7% per annum (the &amp;#8220;Notes&amp;#8221;) originally due and payable on August&#13;1, 2019. The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to sell&#13;and sold convertible notes bearing interest at 9% per annum (the &amp;#8220;Notes&amp;#8221;) in the aggregate principal amount of $446,600.&#13;The purchase price of the Notes was $400,000 and the remaining $46,600 of principal amount represents original issue discount.&#13;Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of&#13;the Company&amp;#8217;s common stock at an effective conversion price determined as follows: the lesser of a price determined as of&#13;the date of closing; and 80% of the lowest volume weighted average trading price of the common stock on the ten days prior to&#13;conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at&#13;fair value. The fair value of the derivative liability as of the date of issuance was $206,548 and was recorded as a discount&#13;of the Notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2019, the Company borrowed $1,000,000 from an investor, bearing 10% interest per annum, with an original issue discount&#13;of $150,000. $1,150,000 is due in one year from the date of issuance.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In August and September&#13;2019, the Company entered into Securities Purchase Agreements with three investors pursuant to which the Company agreed to sell&#13;and sold convertible notes bearing interest between 9% and 10% per annum (the &amp;#8220;Notes&amp;#8221;) in the aggregate principal&#13;amount of $2,222,500. The purchase price of the Notes was $1,976,745 and the remaining $245,755 of principal amount represents&#13;original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at&#13;any time into shares of the Company&amp;#8217;s common stock at an effective conversion price determined as follows: 80% of the lowest&#13;trading price of the common stock on the ten or twenty days prior to conversion. The embedded conversion feature of these Notes&#13;was deemed to require bifurcation and liability classification, at fair value. The fair value of the derivative liability as of&#13;the date of issuance was $1,052,349 and was recorded as a discount of the Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For&#13;the quarter ending October 31, 2019, amortization of debt discount was $2,065,835 leaving a remaining debt discount balance as&#13;of October 31, 2019 of $1,473,842.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;December 28, 2017, the Company through its wholly owned subsidiary NuGenerex, completed the acquisition of the assets and 100%&#13;of the membership interests of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings,&#13;LLC, pursuant to the bills of sale for a consideration of $320,000 Promissory Note due and payable in full on June 28, 2018 bearing&#13;an annual interest rate of 3%. The note was extended by six months and set to mature with the same terms on December 28, 2018.&#13;The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the second closing of the acquisition of certain operating assets of Veneto Holdings, L.L.C. and its affiliates, Generex&amp;#8217;s&#13;wholly owned subsidiary agreed to assume outstanding debt of Veneto subsidiaries to Compass Bank, including obligations under&#13;a term loan and a revolving line of credit. Claiming three separate types of default, Compass Bank has demanded payment in full&#13;of amounts due under the term loan and revolving line of credit, in an aggregate amount of approximately $3,413,000. Generex believes&#13;it has defenses to such demand, including that the bank was not an intended beneficiary of the subsidiary&amp;#8217;s agreement to&#13;assume the debt.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to its acquisition of Regentys, the Company inherited convertible notes with several investors which collectively held a principal&#13;plus of $615,000 as of the date of acquisition. As of October 31, 2019, the remaining principal balance was $349,656 with an unamortized&#13;debt discount balance of $3,719. These notes have an accrued interest balance of $39,191 as of October 31, 2019.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;13 &amp;#8211; Acquisitions:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;NuGenerex&#13;Diagnostics LLC:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 18, 2017, the Company acquired a 51% interest in NuGenerex Diagnostics LLC (&amp;#8220;NGDx&amp;#8221;), formerly Hema Diagnostic&#13;Systems, LLC, pursuant to the Acquisition Agreement. At closing, the Company acquired 4,950 of NGDx&amp;#8217;s 10,000 previously&#13;outstanding limited liability company units in exchange for 1,117,011 shares of Generex common stock valued at $253,721, plus&#13;420 shares of Generex common stock issued to NGDx in exchange for 300 new limited liability company units. The Acquisition Agreement&#13;also provides the Company with a call option to acquire the remaining 49% of NGDx and a retirement of NGDx shareholder loans in&#13;the amount of $13,431,706 (including interest) (the &amp;#8220;Call Option&amp;#8221;) for the aggregate purchase price of $1. On November&#13;30, 2018, the call option was exercised, and the Company acquired the remaining 49% of NGDx.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Following&#13;the closing and the completion of Company&amp;#8217;s reverse stock split, the Company was required to issue an additional 4,830,000&#13;shares of common stock and issue a warrant to a former shareholder of NGDx to acquire 15,000,000 additional shares of Generex&#13;common stock for $2.50 per share. The issue of this warrant is contingent upon the Company obtaining approval from its shareholders&#13;for an increase in its authorized share capital. The total consideration was valued at $1,350,916 on the date of the acquisition.&#13;As of July 31, 2019, all warrants relating to this acquisition have been issued which resulted in additional paid in capital of&#13;$9,032,435.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;Fair Value of the&#13;NGDx Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;The intangible assets acquired includes In&amp;#8211;Process Research &amp;#38; Development (&amp;#8220;IPR&amp;#38;D&amp;#8221;).&#13;The Fair Value of the IPR&amp;#38;D intangible asset using an Asset Cost Accumulation methodology as of January 18, 2017 (the &amp;#8220;Valuation&#13;Date&amp;#8221;) was determined to be $2,911,377. Intangible assets are generally amortized on a straight-line basis over the useful&#13;lives of the assets. The Company is currently not amortizing the in-process research and development until it becomes commercially&#13;viable and placed in service. At the time when the intangible assets are placed in service the Company will determine a useful&#13;life.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The net&#13;purchase price of NGDx was determined to be as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    Price at Closing&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Shares&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&#13;    Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Purchase&#13;    price:&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 46%; text-align: left; padding-left: 6.75pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common&#13;    Stock at closing&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.23&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,117,011&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,721&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 6.75pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common&#13;    Stock after closing&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.23&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;420&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 6.75pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common&#13;    Stock post reverse stock split&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.23&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,830,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,097,100&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    purchase price&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,947,431&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,350,916&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of January 18, 2017, the issue of the warrant to acquire 15,000,000 additional common shares of Generex was contingent upon shareholder&#13;approval of an increase in the Company&amp;#8217;s authorized capital stock. No warrant could be issued by the Company until such&#13;time that an increase in authorized capital has been approved. At the time of closing, management was not of the opinion that&#13;it is more likely than not that the warrant will be issued, and the Call Option will be exercised, accordingly no values have&#13;been attributed to the warrant and Call Option at closing. During 2017, management made a redetermination and estimated that it&#13;was more likely than not that the shareholder approval to increase authorized share capital would be obtained and the Call Option&#13;would be exercised.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;December 1, 2018, pursuant to the Acquisition Agreement the Company issued the warrant to 15,000,000 additional common shares&#13;of Generex to Stephen L. Berkman. The Warrant is exercisable until December 1, 2019 at an exercise price of $2.50 per share. The&#13;Warrant contains a provision prohibiting the exercise of the Warrant to the extent that, after exercise, Mr. Berkman would own&#13;more than 9.99% of the Company&amp;#8217;s common stock. The Warrant was issued pursuant to the January 18, 2017 Acquisition Agreement&#13;among the Company, NGDx, Stephen L. Berkman and the other equity owners of NGDx.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Simultaneously,&#13;on December 1, 2018, Company exercised the Call Option and acquired the remaining 49% non-controlling interest in NGDx. Accordingly,&#13;the fair values of the warrants and call option was updated through the issuance and exercise date and the change in the fair&#13;value of the contingent purchase consideration of a loss of $4,397,507 and a gain of $15,147,591 was recorded and included in&#13;the condensed interim consolidated statements of operations and comprehensive income for the year ending July 31, 2019.&amp;#160;&lt;font style="background-color: white"&gt;The&#13;Company adopted a sequencing policy and determined that the warrants with fixed exercise price were excluded from derivative consideration.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;The&#13;remaining fair value of the call option and the warrant payable remaining at the time of exercise of the call option and issuance&#13;of the warrant was charged against additional paid-in capital as an elimination of non-controlling interest for a loss of $6,951,015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value Assumptions Used in Accounting for the Warrant&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company used the Black-Scholes option-pricing model to calculate the fair value of the warrant. The Black-Scholes option-pricing&#13;model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current&#13;stock price, the estimated volatility of the stock price in the future, and the dividend rate. The key inputs used in the fair&#13;value calculations were as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    1,&amp;#160;&lt;br /&gt; 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&amp;#160;&lt;br /&gt; 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    price&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.50&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.50&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Time&#13;    to expiration&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.14&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.47&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.01&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.77&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    volatility&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;138.61&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;143.97&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    price at valuation date&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.9&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value Assumptions Used in Accounting for Call Option&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company used the Monte Carlo model to calculate the fair value of the call option. The valuations are based on assumptions as&#13;of the valuation date with regard to the value of the asset acquired net of impairment, the risk-free interest rate, the estimated&#13;volatility of the stock price in the future, the time to expiration and the stock price at the date of valuation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following assumptions were used in estimating the value of the Call Option:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December&#13;    1,&amp;#160;&lt;br /&gt; 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&amp;#160;&lt;br /&gt; 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.52&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.44&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    volatility&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;164.43&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;129.95&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&#13;    Term&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.13&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.47&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    price at valuation date&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.9043&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0976&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Grainland&#13;and Empire Pharmacies:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;December 28, 2017, the Company through its wholly owned subsidiary NuGenerex, completed the acquisition of the assets and 100%&#13;of the membership interests of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings,&#13;LLC, pursuant to the bills of sale for a consideration of $320,000 Promissory Note due and payable in full on June 28, 2018 bearing&#13;an annual interest rate of 3%. The note was extended by six months and set to mature with the same terms on December 28, 2018.&#13;The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;finalized our allocation of the purchase price as of December 28, 2018. The final allocation of the purchase price as of January&#13;31, 2019, is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&#13;    Allocation as of December 28,&amp;#160;&lt;br /&gt; 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Allocation&#13;    Adjustments&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Final&#13;    Allocation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 46%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;    assets (licenses)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;276,380&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;276,380&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;    and equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,879&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,879&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computer&#13;    software acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,980&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,980&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    Improvements&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;17,761&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;17,761&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;320,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;320,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration:&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;    Payable&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;320,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;320,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;entire value of the intangible assets represents the licenses obtained to operate a pharmacy in the respective state of each of&#13;the acquired pharmacies. Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets.&#13;The Company is currently not amortizing the pharmacy license until the pharmacies becomes commercially viable and operations begin&#13;in the acquired pharmacies. At the time, when the licenses are placed in service, the Company will determine a useful life.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Since&#13;acquisition, Grainland Pharmacy Holdings, LLC ceased to operate. Accordingly, the value allocated to its tangible assets, leasehold&#13;improvements and licenses acquired for $99,519 was charged to impairment of long-lived assets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Since&#13;acquisition, Empire State Pharmacy Holdings, LLC ceased to operate. Accordingly, the value allocated to its Intangible Assets&#13;Arising on Acquisition acquired for $188,068 was charged to impairment of long-lived assets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Veneto:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 3, 2018, the Company entered into an Asset Purchase Agreement (the &amp;#8220;Agreement&amp;#8221;) with Veneto Holdings, L.L.C.&#13;(&amp;#8220;Veneto&amp;#8221;) to purchase certain assets of Veneto.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effective&#13;as at October 3, 2018, NuGenerex Distribution Solutions, LLC assigned the Veneto Asset Purchase Agreement to NuGenerex Distribution&#13;Solutions 2, LLC.&amp;#160; The sole member of that LLC is NuGenerex Management Services, Inc., a wholly-owned subsidiary of Generex&#13;Biotechnology Corporation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;aggregate purchase price for the Assets is $35,000,000 including the Promissory Note. At the Second Closing, the Company will&#13;pay the principal of the Promissory Note plus interest to Veneto, (i) $9,000,000 will be paid by the Company into a trust or other&#13;fiduciary account acceptable to Veneto to be used exclusively for satisfaction of certain contingent liabilities of Veneto and&#13;subsidiaries of Veneto not being acquired by the Company, (ii) $3,000,000 will be paid by the Company into an escrow account to&#13;secure potential obligations of Veneto in respect of the Second Closing date working capital and under the indemnification provisions&#13;of the Agreement and (iii) the balance will be payable directly to Veneto in cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company had also entered into a temporary fee-for-service arrangement with Veneto and one of its subsidiaries for Veneto to provide&#13;management, personnel, operational, administrative and other services with respect to the First Closing Assets pending the Second&#13;Closing. At the Second Closing, all of Veneto personnel providing these services became employees or consultants of the Company,&#13;and, therefore, Veneto no longer provides these services.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;the First Closing, the Promissory Note issued to Veneto in the original principal amount of $15,000,000 with interest at an annual&#13;rate of 5.0% and guaranteed by Generex and Joseph Moscato, and secured by a first priority security interest in the Company&amp;#8217;s&#13;assets other than the First Closing Assets was subsequently cancelled upon the issuance of the new promissory note on the Second&#13;Closing in the principal amount of $35,000,000 with an annual of 12.0% and guaranteed by Generex and Joseph Moscato.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;November 1, 2018 the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto&amp;#8217;s&#13;management services organization business and two additional ancillary services. The aggregate price for the First Closing Assets&#13;and the Second Closing Assets was $30,000,000. The Company issued a promissory note in the principal amount of $35,000,000 (the&#13;&amp;#8220;&lt;u&gt;New Note&lt;/u&gt;&amp;#8221;) consisting of the $30,000,000 purchase price and a $5,000,000 original issue discount, as the sole&#13;consideration payable on the Second Closing Date. In addition, we agreed to assume approximately $3.8 million in outstanding institutional&#13;debt of Veneto subsidiaries, but will have the use of Veneto cash which would otherwise have been applied to paying down the debt.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;There was $62,500 of&#13;accrued interest on the first closing $15,000,000 note and an additional $1,716,129 of accrued interest on the second closing $35,000,000&#13;promissory note for a total of $1,778,629 accrued interest through March 28, 2019 when the Company entered into an Amendment Agreement&#13;(the &amp;#8220;&lt;u&gt;Amendment&lt;/u&gt;&amp;#8221;). This Amendment between with Veneto and the equity owners of Veneto (the &amp;#8220;Veneto Members&amp;#8221;)&#13;to restructure the payment of the obligation that in satisfaction of all obligations the Company would cause to be delivered 8,400,000&#13;shares of the Company&amp;#8217;s common stock (the &amp;#8220;Generex Shares&amp;#8221;) to be delivered on or before April 22, 2019; plus&#13;an aggregate 5,500,000 shares of the Company&amp;#8217;s subsidiary, common stock of Antigen Express, Inc.(&amp;#8220;Antigen Shares&amp;#8221;).&#13;The Company and the Veneto Members further agreed to certain downside protection between $2.50 per share and $1.50 per share subject&#13;to terms and conditions contained in the agreement. The Generex Shares were delivered on May 23, 2019, but due to the current and&#13;ongoing litigation with the Veneto Members, the Antigen Shares have not been delivered.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As a result of the Amended&#13;Agreement entered into on March 28, 2019 (&amp;#8220;the&amp;#160;&lt;u&gt;Amendment&lt;/u&gt;&amp;#8221;) with Veneto and the equity owners of Veneto&#13;(the &amp;#8220;Veneto Members&amp;#8221;) to restructure the Promissory Note, the Company was evaluated for downside protection associated&#13;with the 8,400,000 issued shares in lieu of cash payments against the Promissory Note. Based on the valuation as of the date of&#13;agreement on March 28, 2019, an allocation of $6,424,338 was allocated to derivative liability for downside protection. As of&#13;July 31, 2019, the downside protection had a market change of $3,085,502 and held a value of $3,338,836.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value of the Veneto Acquisition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the preliminary purchase price as of the Veneto acquisition as of the First Closing&#13;and the Second Closing:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8220;First&#13;    Closing&amp;#8221; completed on&amp;#160;&lt;br /&gt; October 3, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8220;Second&#13;    Closing&amp;#8221; completed on&amp;#160;&lt;br /&gt; November 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 46%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&#13;    and cash equivalents&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,410,150&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,410,150&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    receivable, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,935,078&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,935,078&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory,&#13;    net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,068,856&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,068,856&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95,804&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95,804&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;    and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,590&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,590&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    receivables&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,014,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,014,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes&#13;    receivable - LT&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,387,763&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,387,763&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    assets, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;    assets, net&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,603&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,110,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,145,603&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,625,905&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,110,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,735,905&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    current liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,509,887&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,509,887&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes&#13;    payable&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    liabilities assumed&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,509,887&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,913,835&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    identifiable assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,116,018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,706,052&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,822,070&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,883,982&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,293,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,177,930&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    consideration transferred&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,000,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,000,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the revalued purchase price as of the Veneto acquisition as of the First Closing&#13;and the Second Closing during the year ending July 31, 2019:&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8220;First&#13;    Closing&amp;#8221; completed on&amp;#160;&lt;br /&gt; October 3, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8220;Second&#13;    Closing&amp;#8221; completed on&amp;#160;&lt;br /&gt; November 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 46%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&#13;    and cash equivalents&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,410,150&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 5%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,410,150&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    receivable, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,430,638&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,490,638&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory,&#13;    net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,068,856&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,068,856&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95,804&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;95,804&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;    and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,590&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;652,590&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    receivables&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,014,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,014,316&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes&#13;    receivable - LT&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,387,763&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,387,763&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    assets, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,745&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;    assets, net&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,603&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;811,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;846,603&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,181,465&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;811,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,992,465&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    current liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,065,448&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,065,448&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes&#13;    payable&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    liabilities assumed&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,065,448&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,403,948&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,469,396&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    identifiable assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,116,017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,592,948&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,523,069&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,051,769&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    consideration transferred&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18,574,838&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;accordance with the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification&amp;#174; (&amp;#8220;ASC&amp;#8221;)&#13;Topic 310, &amp;#8220;Receivables&amp;#8221;, this agreement is classified as a note receivable and carried at their net realizable value&#13;net of allowance of credit losses when management determines that it is probable a loss has been incurred. Notes receivable are&#13;charged off against the allowance for credit losses when management determines that the notes receivable are uncollectible and&#13;the Company ceases collection efforts. The Company recognizes a portion of the note as interest income in the accompanying consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;note receivable for $1,387,763 acquired during the first closing of Veneto on October 3, 2018 was to be automatically converted&#13;per the purchase agreement into 6% ownership of a third-party company. Due to the ongoing litigation with Veneto, management has&#13;not been able to obtain evidence that this note was converted into 6% ownership of the third-party company. In July 2019, Management&#13;reviewed all aspects of this transactions and concluded that it has no reason to believe that this amount will be recovered, as&#13;such they deem the note receivable of $1,387,763 to be fully impaired.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of July 31, 2019, the note receivable balance had increased to $1,443,083 due to $55,300 of additional accrued interest. The Company&#13;has elected to record an allowance for credit loss of $1,387,763 as of July 31, 2019 to fully reserve for the principal portion&#13;of the note receivable. The remaining $55,300 of accrued interest was written off and netted against interest income in the consolidated&#13;financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;significant intangible assets identified in the purchase price allocation discussed above include developed software and technology,&#13;referral base (recurring revenue from the MSO investments and their use of Company owned pharmacies) and non-compete agreements&#13;with continued employment of key employees. Tradenames and trademarks were not valued as tradenames and trademarks will not be&#13;maintained going forward. To value the developed software and technology, the Company utilized the relief from royalty method,&#13;a form of the income approach to value the developed software and technology which assumes a limited technology life and market&#13;share adjusted by assumed obsolescence with a terminal value. The referral base was valued using a multi-period excess earnings&#13;method, a form of the income approach. The Company utilized the with and without method, a form of the income approach to value&#13;non-compete agreements with Generex.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preliminary amounts assigned to the identifiable intangible assets, the estimated useful lives, and the estimated amortization&#13;expense related to these identifiable intangible assets are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&amp;#160;&lt;br /&gt;&#13;    Fair&amp;#160;&lt;br /&gt; Value&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&amp;#160;&lt;br /&gt;&#13;    Estimated&amp;#160;&lt;br /&gt; Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Developed&#13;    Software/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Referral&#13;    Base&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreements&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;680,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;811,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;assets are generally amortized on a straight-line basis over the useful lives of the assets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&#13;initially represented the excess of the purchase price over the fair market value of net assets acquired. Goodwill for Veneto&#13;Acquisition was $8.9 million as of the date of the First Closing and $16.3 million as of the date of the Second Closing. Based&#13;on the Amended Agreement (the &amp;#8220;&lt;u&gt;Amendment&lt;/u&gt;&amp;#8221;) entered into on March 28, 2019 referred to above which stipulated&#13;that in lieu any cash payments, the Company would deliver shares of the Company&amp;#8217;s common stock (the &amp;#8220;Generex Shares&amp;#8221;).&#13;Additionally, in pursuant to ASC 805 and specifically, ASC 805-10-25-14, the Company recognized the change in assets and liabilities&#13;as a result of facts and circumstances that existed as of the acquisition date that would have resulted in the recognition of&#13;the assets and liabilities with the corresponding decrease of goodwill from $24.2 million to $13.6 million.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ending July 31, 2019, the amounts assigned to the identifiable intangible assets, the estimated useful lives, and the&#13;estimated amortization expense related to these identifiable intangible assets were revalued as follows:&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&amp;#160;&lt;br /&gt;&#13;    Fair&amp;#160;&lt;br /&gt; Value&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&amp;#160;&lt;br /&gt;&#13;    Estimated&amp;#160;&lt;br /&gt; Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Developed&#13;    Software/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;397,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Referral&#13;    Base&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreements&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,870,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,277,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Regentys&#13;and Olaregen:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest&#13;in both Regentys Corporation (&amp;#8220;Regentys&amp;#8221;) and Olaregen Therapeutix Inc. (&amp;#8220;Olaregen&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounted for the acquisitions of both Regentys and Olaregen as business combinations using the purchase method of accounting&#13;as prescribed in Accounting Standards Codification 805, Business Combinations (&amp;#8220;ASC 805&amp;#8221;) and ASC 820 &amp;#8211; Fair&#13;Value Measurements and Disclosures (&amp;#8220;ASC 820&amp;#8221;). In accordance with ASC 805 and ASC 820, the Company used its best&#13;estimates and assumptions to accurately assign fair value to the tangible assets acquired, identifiable intangible assets and&#13;liabilities assumed as of the acquisition dates. Goodwill as of the acquisition date is measured as the excess of purchase consideration&#13;over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair values assigned to Regentys&amp;#8217; and Olaregen&amp;#8217;s tangible and identifiable intangible assets acquired, and liabilities&#13;assumed are based on management&amp;#8217;s estimates and assumptions. The estimated fair values of these assets acquired, and liabilities&#13;assumed are considered preliminary and are based on the information that was available as of the date of the acquisition. The&#13;preliminary estimated fair values of assets acquired, and liabilities assumed, and identifiable intangible assets may be subject&#13;to change as additional information is received. Thus, the provisional measurements of fair value are subject to change. The Company&#13;expects to finalize the valuations as soon as practicable, but not later than one year from the closing date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Regentys:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;November 28, 2018, Generex and Regentys entered into a binding letter of intent (&amp;#8220;LOI&amp;#8221;) contemplating the Company&amp;#8217;s&#13;acquisition of 51% of the outstanding capital stock of Regentys for a total consideration of $15,000,000. On January 7, 2019 the&#13;Company completed a definitive Stock Purchase Agreement and related documents effecting the transactions contemplated by the LOI.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to a Stock Purchase Agreement between the Company and Regentys (the &amp;#8220;Purchase Agreement&amp;#8221;) the Company acquired 12,048,161&#13;newly issued shares of the Regentys common stock representing 51% percent of the issued and outstanding capital stock of Regentys&#13;(&amp;#8220;Regentys Shares&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;addition to $400,000 paid to Regentys upon signing of the LOI, the purchase price for the Regentys Shares will consist of the&#13;following cash payments, with the proceeds intended to be used for specific purposes, as noted:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$3,450,000&#13;    to initiate pre-clinical activities on or before January 15, 2019. As of the date this report was filed, the Company has paid&#13;    $650,000 and the remaining balance of $2,800,000 is payable on or before November 30, 2019 per extension in amended agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2,000,000&#13;    to initiate patient recruitment activities on or before May 1, 2019. As of the date this report was filed, the Company has&#13;    not yet paid this installment and the full balance of $2,000,000 is payable on or before November 30, 2019 per extension in&#13;    amended agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$3,000,000&#13;    to initiate a first-in-human pilot study on or before September 1, 2019.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$5,000,000&#13;    to initiate a human pivotal study on or before February 1, 2020.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$1,150,000&#13;    to submit a 510(k) de novo submission to the FDA on or about February 1, 2021.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company issued its Promissory Note in the amount of $14,600,000 (the &amp;#8220;Note&amp;#8217;) representing its obligation to pay the&#13;above amounts. The Note is secured by a pledge of the Regentys shares pursuant to a Pledge and Security Agreement. In the event&#13;that Generex does not make any of the first three payments listed above, at Regentys&amp;#8217; option either:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;    will forfeit all of the Regentys shares issued with no refund of amounts paid; or&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;    will issue shares of its common stock to Regentys equivalent to 110% of the value of the missing payment, which shares will&#13;    be registered for resale.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;the event Generex does not make either or both of the fourth and fifth payments, its share ownership of Regentys will be proportionately&#13;reduced.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;March 14, 2019, the Company and Regentys amended the Stock Purchase Agreement and Promissory Note to extend the due date of the&#13;remaining balance of the first tranche of Guaranteed Payments amounting to $2,800,000 on or before April 1, 2019. On October 31,&#13;2019, the Company and Regentys signed an extension to extend the due date on or before November 30, 2019. The extensions of the&#13;due date have no impact on the existing schedule of future payments or any additional terms within the Note. Regentys has not&#13;filed any notice of default as of the date of publication, and Generex continues to provide Regentys with business opportunities&#13;continuing the relationship.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value of the Regentys Acquisition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 10pt; border-bottom: Black 1pt solid"&gt;The following table summarizes the allocation of the preliminary purchase price as of the Regentys acquisition:&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Preliminary Allocations as of&amp;#160;&amp;#160;&amp;#160;&amp;#160;January 7, 2019&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Allocation Adjustments&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Revised Allocation&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 46%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;61,857&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;61,857&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;13,138&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,543&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;33,591&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,181,920&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(307,495&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,488,870&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(639,009&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;29,685&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(609,324&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Loans form related parties&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(16,506&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(399,999&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(416,505&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(889,782&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;30,320&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(859,462&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;In-Process research &amp;#38; development&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,510,680&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(119,630&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,391,050&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; font-style: italic; text-align: left"&gt;Non-Controlling interest, net of proceeds:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0.1in"&gt;Note receivable from Generex&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,345,205&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,791&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,345,414&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0.1in"&gt;Redeemable non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,073,898&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,073,898&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0.1in"&gt;Non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(9,870,762&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,791&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(9,870,762&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0.1in"&gt;Cash paid prior to the time of closing&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Total Fair Value of Assets Acquired&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,259,447&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(751,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;907,833&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; font-style: italic"&gt;Consideration:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Cash paid prior to the time of closing&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Note receivable from Generex&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,345,205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,791&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,342,414&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;13,485,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;748,823&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;13,834,581&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;redeemable non-controlling interest of $4,073,898, representing the Series Stock A, was determined by deducting the total consideration&#13;paid of $14,745,205 from the total purchase value totaling $28,689,865 based on a convergence method in an Option Pricing Model&#13;using the Regentys capital structure with 12,048,161 newly issued shares of the Regentys common stock representing 51% percent&#13;of the issued and outstanding capital stock of Regentys. See Note 7 &amp;#8211;&amp;#160;&lt;i&gt;Redeemable Non-Controlling Interest.&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Olaregen:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;November 27, 2018, Generex and Olaregen entered into a binding letter of intent (&amp;#8220;LOI&amp;#8221;) contemplating the Company&amp;#8217;s&#13;acquisition of 51% of the outstanding capital stock of Olaregen for a total consideration of twelve million dollars ($12,000,000).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of January 7, 2019, the Company completed a definitive Stock Purchase Agreement (&amp;#8220;Purchase Agreement&amp;#8221;) and related&#13;documents effecting the transactions contemplated by the LOI.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company acquired 3,282,632 newly issued shares of the Olaregen common stock representing 51% percent of the issued and outstanding&#13;capital stock of Olaregen (&amp;#8220;Olaregen Shares&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;addition to $400,000 paid to Olaregen upon signing of the LOI, the purchase price for the Olaregen Shares will consist of the&#13;following cash payments:&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$800,000&#13;    on or before January 15, 2019. The Company has paid this installment.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$800,000&#13;    on or before January 31, 2019. As of the date this report was filed, the Company has paid $491,500 of this installment and&#13;    remaining balance of $308,500 is payable on or before November 30, 2019 per extension in amended agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$3,000,000&#13;    on or before April 1, 2019. As of the date this report was filed, the Company has not yet paid this installment and the full&#13;    balance of $3,000,000 is payable on or before November 31, 2019 per extension in amended agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$1,000,000&#13;    On or before May 31, 2019. As of the date this report was filed, the Company has not yet paid this installment and the full&#13;    balance of $1,000,000 is payable on or before November 30, 2019 per extension in amended agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$6,000,000&#13;    on or before September 30, 2019.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;addition, during May 2019, Generex pursuant to a Stock Purchase Agreement purchased 592,682 shares of Series A Preferred Stock&#13;of Olaregen in exchange for 4,000,000 shares of the Company&amp;#8217;s common stock and a $2,000,000 Promissory Note bearing interest&#13;at 7% per annum (the &amp;#8220;Notes&amp;#8221;) originally due and payable on August 1, 2019. As of the date this report was filed,&#13;the Company has not yet paid the balance due of this Note.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company issued its Promissory Note in the amount of $11,600,000 (the &amp;#8220;Note&amp;#8217;) representing its obligation to pay the&#13;above amounts. The Note is secured by a pledge of the Olaregen shares pursuant to a Pledge and Security Agreement. In the event&#13;that Generex fails to pay the installment due on November 30, 2019, Generex will forfeit the shares allocated to that installment&#13;(1,600,000 Olaregen shares) and Olaregen will be entitled to &amp;#8220;claw back&amp;#8221; fifty percent (50%) of any and all shares&#13;paid for by the prior payments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;March 14, 2019, the Company and Olaregen amended the Stock Purchase Agreement and Promissory Note to extend the due date of the&#13;remaining balance of the second tranche of Guaranteed Payments amounting to $600,000 on or before April 1, 2019. The Company remitted&#13;additional payments of $200,000 on April 30, 2019 and $38,500 on May 17, 2019. On May 22, 2019, the Company and Olaregen amended&#13;the agreement to extend the due date of the remaining balance of the second tranche of Guaranteed Payments amounting to $361,500,&#13;the full balance of the third tranche amounting to $3,000,000 and the full balance of the fourth tranche amounting to $1,000,000&#13;(total of $4,361,500) on or before June 30, 2019. The extensions of the due date have no impact on the existing schedule of future&#13;payments or any additional terms within the Note. Olaregen has not filed any notice of default as of the date of publication,&#13;and Generex continues to provide Olaregen with business opportunities continuing the relationship.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;the event Generex does not make any other payments, its share ownership of Olaregen will be proportionately reduced.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Based&#13;on the Note, in the event any incremental payment is not paid when due, Olaregen has the option to increase the per share purchase&#13;price for all remaining purchased shares to $4.00 per share. Based on $1,400,000 of remitted payments and a Promissory Note balance&#13;of $10,400,000 prior to the first extension agreement on March 14, 2019, Olaregen elected the option to proportionally increase&#13;the per share purchase price to $4.00 for the remaining 2,899,658 of the total 3,282,632 shares to be acquired. The resulting&#13;penalty amounts to an additional $998,633 which has been accrued for the Company to remit to Olaregen pursuant to the acquisition.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;has a limited anti-dilution right under the Purchase Agreement, to ensure that Generex will retain 51% ownership in Olaregen for&#13;a period of time.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value of the Olaregen Acquisition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the preliminary purchase price as of the Olaregen acquisition:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Preliminary Allocations as of&amp;#160;&amp;#160;&amp;#160;&amp;#160;January 7, 2019&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Allocation Adjustments&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Revised Allocation&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 46%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;608,419&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(400,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;208,419&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,488&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,488&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Inventory&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;408,501&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;408,501&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;37,950&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;37,950&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(216,670&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(216,670&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Accrued liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(216,694&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(216,694&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,040,173&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;397,513&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(642,660&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;In-Process research &amp;#38; development&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,980,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,521,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,459,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;790,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(260,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;530,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; font-style: italic; text-align: left"&gt;Non-Controlling interest, net of proceeds:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Note receivable from Generex&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11,472,663&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11,472,663&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(11,999,559&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(11,999,559&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Cash paid prior to the time of closing&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Total Fair Value of Assets Acquired&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,844,925&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,383,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,461,440&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; font-style: italic"&gt;Consideration:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Cash paid prior to the time of closing&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Note receviable from Generex&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,472,663&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11,472,664&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;8,027,738&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,383,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;9,411,224&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;components of the acquired intangible assets were as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&amp;#160;&lt;br /&gt;&#13;    Fair&amp;#160;&lt;br /&gt; Value&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&#13;    Estimated Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In-process&#13;    research and development&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,980,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;790,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,770,000&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Unaudited&#13;Supplemental Pro Forma Data&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unaudited&#13;pro forma results of operations for the year ended July 31, 2019 and 2018 as though the Company acquired Veneto, Olaregen and&#13;Regentys (the &amp;#8220;Acquired Companies&amp;#8221;) on the first day of each fiscal year are set forth below.&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&#13;    Ended&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,217,169&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,137,821&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cost&#13;    of revenues&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,143,586&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,236,850&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&#13;    profit&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,073,583&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,900,971&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating&#13;    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,338,328&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;45,146,085&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating&#13;    loss&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,264,744&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,245,114&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    income (expense)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,469,732&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;523,226&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    loss&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,795,012&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,721,888&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    loss attributable to noncontrolling interests&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,606,316&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(230,222&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    Income (loss) Available to Common Stockholders&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,188,696&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,491,666&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Comprehensive&#13;    net loss&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,188,696&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,491,666&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic&#13;    and diluted earnings per share&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.05&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.29&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;16 &amp;#8211; Acquisitions: &lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;MediSource&#13;and Pantheon:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;August 1, 2019, the Company, through its wholly owned subsidiary NDS, closed on Asset Purchase Agreements (the &amp;#8220;APAs&amp;#8221;)&#13;for the purchase of substantially all the operating assets of MediSource Partners, LLC (&amp;#8220;MediSource&amp;#8221;) and Pantheon&#13;Medical - Foot &amp;#38; Ankle, LLC (&amp;#8220;Pantheon&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;MediSource&#13;contracts with vendors (including Pantheon) for nationwide distribution of implants and devices for spine, hips, knees, foot,&#13;ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, and stem cells), durable medical&#13;equipment, and soft goods. MediSource also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at&#13;the time of surgery.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pantheon&#13;sells a physician friendly, &amp;#8220;all-in-one,&amp;#8221; integrated kit that includes plates, screws, and tools required for orthopedic&#13;surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, Pantheon expects to develop and submit&#13;several new product lines to the FDA, which will include cannulated surgical screws and surgical staples, as well as a proprietary&#13;Hammertoe System.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The goal in acquiring these operating companies&#13;is that they expect to provide multiple and significant revenue streams through delivery of patient-focused healthcare products&#13;and services, thus generating value and ultimately creating goodwill upon acquisition.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Travis&#13;H. Bird was the CEO and principal owner of both Pantheon and MediSource.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Under&#13;the APAs:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;    will issue 400,000 shares of common stock in exchange for the Pantheon assets, and 560,000 shares of common stock in exchange&#13;    for the MediSource assets.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;    and NDS will pay up to $700,000 in cash to Pantheon as an earn out payment. No payment will be made unless the business conducted&#13;    by NDS using the former Pantheon assets has EBITDA in the twelve months following closing in excess of $500,000. If the Pantheon&#13;    business&amp;#8217;s EBITDA meets or exceeds $1,000,000, the entire $700,000 will be paid. If the Pantheon business&amp;#8217;s EBITDA&#13;    exceeds $500,000 but is less than $1,000,000, a pro rata portion of the $700,000 earn-out will be paid.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;    and NDS will pay up to $500,000 in cash to MediSource as an earn out payment. No payment will be made unless the business&#13;    conducted by NDS using the former MediSource assets has EBITDA in the twelve months following closing in excess of $130,000.&#13;    If the MediSource business&amp;#8217;s EBITDA meets or exceeds $500,000, the entire $500,000 will be paid. If the MediSource business&amp;#8217;s&#13;    EBITDA exceeds $130,000 but is less than $500,000, a pro rata portion of the $500,000 earn-out will be paid.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;    the event the EBITDA targets are met for one or both MediSource and Pantheon, Travis Bird will receive sales commissions equal&#13;    to 15% of net sales during the first year following closing, and 10% of net sales during the second year.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Both&#13;    MediSource and Pantheon agreed to waive the 1:1 stock dividend Generex announced it will issue if Generex is listed on NASDAQ.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Each&#13;    of Pantheon and MediSource will retain 50% of its cash on hand and 50% of its accounts receivable, with the remainder transferred&#13;    to NDS at closing.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;    and NDS will not assume any Pantheon or MediSource liabilities except for post-closing obligations under assumed contracts.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pantheon&#13;        and MediSource will not transfer their Medicare and Medicaid numbers.&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;closing, Mr. Bird will enter into an 18-month consulting agreement with NDS. As compensation, Mr. Bird will receive Generex common&#13;stock with a value of $250,000, as well as monthly payments equaling $97,222. The monthly payments shall be paid from any available&#13;cash from the operations of Pantheon and MediSource. Any remaining balance of such monthly payments will consist of common stock.&#13;The agreement specifies the shares are to be freely tradeable. In addition, Mr. Travis will agree to fully assign and exchange&#13;any ownership rights in any new technology he develops with the Company, in exchange for a payment of $500,000 in value of common&#13;stock for each completed item submitted to the FDA.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounted for the Acquisition&#13;of MediSource and Pantheon as a business combination using the purchase method of accounting as prescribed in Accounting Standards&#13;Codification 805, Business Combinations (&amp;#8220;ASC 805&amp;#8221;) and ASC 820 &amp;#8211; Fair Value Measurements and Disclosures (&amp;#8220;ASC&#13;820&amp;#8221;). In accordance with ASC 805 and ASC 820, we used our best estimates and assumptions to accurately assign fair value&#13;to the tangible assets acquired, identifiable intangible assets and liabilities assumed as of the acquisition dates. Goodwill&#13;as of the acquisition date is measured as the excess of purchase consideration over the fair value of tangible and identifiable&#13;intangible assets acquired and liabilities assumed.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value of the MediSource Acquisition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the preliminary purchase price as of the MediSource acquisition:&amp;#9;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&#13;    &lt;br /&gt;Allocation as of &lt;br /&gt;August 1, &lt;br /&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&#13;    and cash equivalents&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,895&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    current assets&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,864&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;    and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,992&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    payable and accrued liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(31,439&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    Tangible Assets&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,312&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tradename&#13;    / Trademarks&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;47,600&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&#13;    Contracts&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;346,800&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Competes&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;124,600&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    Fair Value of Assets Acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;522,312&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration:&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&#13;    value of common stock&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;479,980&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent&#13;    consideration&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;409,790&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration&#13;    included in consulting agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;104,168&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    Purchase Price&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;993,938&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,626&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value of the Pantheon Acquisition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the preliminary purchase price as of the Pantheon acquisition:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&#13;    &lt;br /&gt;Allocation as of &lt;br /&gt;August 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&#13;    and cash equivalents&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,410&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    receivable&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;133,269&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,336&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;266,071&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Medical&#13;    Equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;67,299&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    payable&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(53,242&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued&#13;    liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(15,573&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    Tangible Assets&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;436,570&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tradename&#13;    / Trademarks&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;55,400&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;IP/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,500&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;232,100&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer&#13;    Base&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;274,600&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,040,170&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration:&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&#13;    value of common stock&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;671,972&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent&#13;    consideration&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;354,292&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration&#13;    included in consulting agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;145,833&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,927&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;components of the acquired intangible assets were as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&#13;    &lt;br /&gt; Fair &lt;br /&gt; Value&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&#13;    Estimated Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tradename&#13;    / Trademarks&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;103,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;IP/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,500&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&#13;    Contracts&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;346,800&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer&#13;    Base&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;274,600&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;356,700&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,112,600&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Unaudited Supplemental Pro Forma Data&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Unaudited pro forma results of operations for&#13;the three months ended October 31, 2019 and 2018 as though the Company acquired MediSource and Pantheon on the first day of each&#13;fiscal year are set forth below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Three months Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;October 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: justify"&gt;Revenues&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;721,661&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,141,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Cost of revenues&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;133,618&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;987,409&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Gross profit&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;588,043&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,153,591&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5,136,754&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,629,854&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Operating loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,548,711&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1,476,262&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,763,836&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19,389,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Net loss&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(9,312,547&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;17,913,682&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Comprehensive net loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(9,312,547&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;17,913,682&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;16 - Stock-Based Compensation&lt;/u&gt;:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock&#13;Option Plans&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of July 31, 2019, the Company had three stockholder-approved stock incentive plans under which shares and options exercisable&#13;for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,835,000&#13;shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan) and 240,000,000 shares of&#13;common stock reserved for issuance under the 2017 Stock Option Plan (the 2017 Plan) and 1,200,000 shares of common stock reserved&#13;for issuance under the 2019 Stock Option Plan (the 2019 Plan). At July 31, 2019, there were 2,823,450, 232,022,875, 1,200,000&#13;shares of common stock reserved for future awards under the 2006 Plan, 2017 Plan and 2019 Plan, respectively. The Company issues&#13;new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance&#13;of restricted shares.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2006, 2017 and 2019 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select&#13;from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to&#13;determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to&#13;prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction&#13;of any provision of the Plans or any options granted hereunder is within the discretion of the Board.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal&#13;Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors&#13;and consultants are eligible to receive options which are not ISOs, i.e. &amp;#8220;Non-Qualified Options.&amp;#8221; The options granted&#13;by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides&#13;for restricted stock grants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of&#13;the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of&#13;the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected&#13;volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Options&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Exercise Price per Share&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Remaining Life (Years)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt"&gt;Outstanding &amp;#8211; August 1, 2018&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;379,998&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1.48&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1.11&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;69,843&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(147,777&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Outstanding - July 31, 2018&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;232,221&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;10,719&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9,976,125&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.71&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7.59&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,821,821&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,219,671&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(0.43&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;8.18&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Outstanding - July 31, 2019&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7,988,675&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7.21&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;15,961,391&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;intrinsic value is calculated as the difference between the market value and the exercise price of the shares on July 31, 2019.&#13;The market values as of July 31, 2019 was $2.80 based on the closing bid price for July 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;There&#13;were 3,369,842 vested common stock options under the Plan as of July 31, 2019. The compensation expense was $3,000,974 for the&#13;year ended July 31, 2019. There was additional compensation expense pertaining to the Regentys acquisition of $11,472 for the&#13;year ended July 31, 2019 for total compensation expense of $3,012,446. The Company had $3,263,569 of unrecognized compensation&#13;costs related to non-vested share-based compensation arrangements granted under the Plan at July 31, 2019 to be recognized over&#13;an average of 2.49 years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes&#13;option-pricing models requires the Company to make predictive assumptions regarding future stock price volatility, recipient exercise&#13;behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the&#13;expected term of the option. The following assumptions were used in the Black-Scholes option-pricing model:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 72%; padding-bottom: 1pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&#13;                                         Ended&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;        31, 2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$0.11&#13;    &amp;#8211; 1.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected&#13;    term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&#13;    to 10 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.03%&#13;    - 3.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;135.2%&#13;    - 222.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected&#13;    dividend&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    price at valuation date&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$0.11&#13;    &amp;#8211; $1.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;13 - Stock-Based Compensation&lt;/u&gt;:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock&#13;Option Plans&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of October 31, 2019, the Company had two stockholder-approved stock incentive plans under which shares and options exercisable&#13;for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,835,000&#13;shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan) and 240,000,000 shares of&#13;common stock reserved for issuance under the 2017 Stock Option Plan (the 2017 Plan). At October 31, 2019, there were 2,823,450&#13;and 231,149,875 the 2006 Plan and 2017 Plan, respectively. The Company issues new shares of common stock from the shares reserved&#13;under the respective Plans upon conversion or exercise of options and issuance of restricted shares.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2006 and 2017 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from&#13;among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine&#13;the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe,&#13;amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision&#13;of the Plans or any options granted hereunder is within the discretion of the Board.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal&#13;Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors&#13;and consultants are eligible to receive options which are not ISOs, i.e. &amp;#8220;Non-Qualified Options.&amp;#8221; The options granted&#13;by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides&#13;for restricted stock grants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of&#13;the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of&#13;the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected&#13;volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price per Share&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Remaining Life (Years)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    Intrinsic Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 40%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,988,675&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.84&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.21&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,961,391&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,003,000&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.09&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.92&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&#13;    or expired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(130,000&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.11&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.65&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - October 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,861,675&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.98&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.71&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,859,392&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;intrinsic value is calculated as the difference between the market value and the exercise price of the shares on October 31, 2019.&#13;The market values as of October 31, 2019 was $1.53 based on the closing bid price for October 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;There&#13;were 3,540,675 vested common stock options under the Plan as of October 31, 2019. The compensation expense was $787,458 for the&#13;three months ended October 31, 2019. The Company had $4,256,191 of unrecognized compensation costs related to non-vested share-based&#13;compensation arrangements granted under the Plan at October 31, 2019 to be recognized over an average of 2.67 years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes&#13;option-pricing models requires the Company to make predictive assumptions regarding future stock price volatility, recipient exercise&#13;behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the&#13;expected term of the option. The following assumptions were used in the Black-Scholes option-pricing model:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October&#13;    31, &lt;br /&gt; 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    price&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.01&#13;                                         &amp;#8211; 2.09&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Time&#13;    to expiration&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&#13;                                         years&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.51%&#13;                                         - 1.59%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;    volatility&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;153.4&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected&#13;    dividend&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    price at valuation date&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.01&#13;                                         &amp;#8211; 2.09&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;2019, the Company established a Direct Stock Purchase Plan (&amp;#8220;2019 Plan&amp;#8221;) pursuant to which eligible participants may&#13;acquire shares of common stock in lieu of certain cash obligations otherwise owed to participants during the 2019 calendar year.&#13;The 2019 Plan will automatically terminate on December 31, 2019. There was a total of 1,200,000 shares of common stock reserved&#13;under the plan of which no shares have been issues.&lt;/font&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">188069</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;1 &amp;#8211; Organization of Business and Going Concern:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;Biotechnology Corporation (&amp;#8220;Generex&amp;#8221; or the &amp;#8220;Company&amp;#8221;), was formed in the State of Delaware on September&#13;4, 1997 and its year-end is July 31. It is engaged primarily in the research and development of drug delivery systems and the&#13;use of the Company&amp;#8217;s proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal)&#13;cavity using a hand-held aerosol applicator; and through the Company&amp;#8217;s wholly-owned subsidiary, Antigen Express, Inc. (&amp;#8220;Antigen&amp;#8221;),&#13;has undertaken work on immunomedicines incorporating proprietary vaccine formulations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 18, 2017, the Company closed an Acquisition Agreement pursuant to which the Company acquired a 51% interest in NuGenerex&#13;Diagnostics LLC &amp;#8220;NGDx,&amp;#8221; formerly known as Hema Diagnostic Systems, LLC, a Florida limited liability company established&#13;in December 2000 to market and distribute rapid test devices including infectious diseases. Since 2002, NGDx has been developing&#13;an expanding line of rapid diagnostic tests (RDTs) including such diseases as Human Immunodeficiency Virus (HIV) &amp;#8211; 1/2,&#13;tuberculosis, malaria, hepatitis, syphilis, typhoid and dengue as well as other infectious diseases. Subsequently, on December&#13;1, 2018, the Company exercised its call option and closed the acquisition of the remaining 49% interest in NGDx to become a wholly&#13;owned subsidiary of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 3, 2018, the Company entered into an Asset Purchase Agreement with Veneto Holdings, L.L.C. (&amp;#8220;Veneto&amp;#8221;) to purchase&#13;certain assets of Veneto and its subsidiaries.&amp;#160;The Agreement bifurcated the closing. On October 3, 2018 (the &amp;#8220;First&#13;Closing&amp;#8221;), the Company purchased substantially all the operating assets of Veneto including (a)system of dispensing pharmacies,&#13;(b) one central adjudicating pharmacy, (c) a wholesale pharmaceutical purchasing company, and (d) an in-network laboratory. On&#13;November 1, 2018 the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto&amp;#8217;s&#13;management services organization business and two additional ancillary services.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2019, the Company changed its business model to no longer utilize their existing pharmacies. This shift resulted in breaking&#13;their existing lease agreements with their pharmacies, lab and lab related equipment which resulted in a liability of $744,958&#13;as of July 31, 2019 and disposing the applicable leasehold improvements, reduction of employees and no longer holding and selling&#13;inventory. Going forward Veneto will conduct business exclusively through their management services organization and by entering&#13;into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and salaries. This&#13;was made practicable due to the decrease in overall script volume coupled with delays in the Company being able to receive operating&#13;licenses from various government agencies.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest&#13;in both Regentys Corporation (&amp;#8220;Regentys&amp;#8221;) and Olaregen Therapeutix Inc. (&amp;#8220;Olaregen&amp;#8221;). Regentys is a regenerative&#13;medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York&#13;based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen,&#13;an FDA 510K cleared wound healing product.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Going&#13;Concern&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted&#13;in the United States of America (&amp;#8220;US GAAP&amp;#8221;), which contemplate continuation of the Company as a going concern. The&#13;Company has experienced recurring net losses and negative cash flows from operations since inception and has an accumulated deficit&#13;of approximately $418.7 million and a working capital deficiency of approximately $28 million at July 31, 2019. The Company has&#13;funded its activities to date almost exclusively from debt and equity financings.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company will continue to require substantial funds to implement its new investment acquisition plans.&amp;#160; Management&amp;#8217;s&#13;plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common&#13;stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing&#13;financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and&#13;strategic partners.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;conditions raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern for a period of twelve months&#13;from the balance sheet date. There are no assurances that such additional funding will be achieved and that the Company will succeed&#13;in its future operations. The unaudited condensed interim consolidated financial statements do not include any adjustments relating&#13;to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the&#13;Company be unable to continue as a going concern. The Company&amp;#8217;s inability to obtain required funding in the near future&#13;or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development&#13;plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan,&#13;its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have&#13;to cease operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;1 &amp;#8211; Organization of Business and Going Concern:&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Generex&#13;Biotechnology Corporation (&amp;#8220;Generex&amp;#8221; or the &amp;#8220;Company&amp;#8221;), was formed in the State of Delaware on September&#13;4, 1997 and its year-end is July 31. It is engaged primarily in the research and development of drug delivery systems and the&#13;use of the Company&amp;#8217;s proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal)&#13;cavity using a hand-held aerosol applicator; and through the Company&amp;#8217;s wholly-owned subsidiary, Antigen Express, Inc. (&amp;#8220;Antigen&amp;#8221;),&#13;has undertaken work on immunomedicines incorporating proprietary vaccine formulations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 18, 2017, the Company closed an Acquisition Agreement pursuant to which the Company acquired a 51% interest in NuGenerex&#13;Diagnostics LLC &amp;#8220;NGDx,&amp;#8221; formerly known as Hema Diagnostic Systems, LLC, a Florida limited liability company established&#13;in December 2000 to market and distribute rapid test devices including infectious diseases. Since 2002, NGDx has been developing&#13;an expanding line of rapid diagnostic tests (RDTs) including such diseases as Human Immunodeficiency Virus (HIV) &amp;#8211; 1/2,&#13;tuberculosis, malaria, hepatitis, syphilis, typhoid and dengue as well as other infectious diseases. Subsequently, on December&#13;1, 2018, the Company closed the acquisition of the remaining 49% interest in NGDx to become a wholly owned subsidiary of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 3, 2018, the Company entered into an Asset Purchase Agreement with Veneto Holdings, L.L.C. (&amp;#8220;Veneto&amp;#8221;) to purchase&#13;certain assets of Veneto and its subsidiaries.&amp;#160;The Agreement bifurcated the closing. On October 3, 2018 (the &amp;#8220;First&#13;Closing&amp;#8221;), the Company purchased substantially all the operating assets of Veneto including (a)system of dispensing pharmacies,&#13;(b) one central adjudicating pharmacy, (c) a wholesale pharmaceutical purchasing company, and (d) an in-network laboratory. On&#13;November 1, 2018 the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto&amp;#8217;s&#13;management services organization business and two additional ancillary services.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2019, the Company changed its business model to no longer utilize their existing pharmacies. Going forward Veneto will conduct&#13;business exclusively through their management services organization (&amp;#8220;MSO&amp;#8221;) and by entering into more ancillary provider&#13;service agreements with third party pharmacies as an effort to reduce fixed costs and salaries. This was made practicable due&#13;to the decrease in overall script volume coupled with delays in the Company being able to receive operating licenses from various&#13;government agencies.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest&#13;in both Regentys Corporation (&amp;#8220;Regentys&amp;#8221;) and Olaregen Therapeutix Inc. (&amp;#8220;Olaregen&amp;#8221;). Regentys is a regenerative&#13;medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York&#13;based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen,&#13;an FDA 510K cleared wound healing product. In the first quarter of 2020 the Company acquired increased its ownership of Olaregen&#13;to 77%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 1, 2019, the Company, through its&#13;wholly owned subsidiary NDS, closed on Asset Purchase Agreements (the &amp;#8220;APAs&amp;#8221;) for the purchase of substantially all&#13;the operating assets of MediSource Partners, LLC (&amp;#8220;MediSource&amp;#8221;) and Pantheon Medical - Foot &amp;#38; Ankle, LLC (&amp;#8220;Pantheon&amp;#8221;)&#13;(Note &amp;#8211; 16).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;MediSource contracts with vendors (including&#13;Pantheon) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries.&#13;Additional product lines include biologics (blood, bone, tissue, and stem cells), durable medical equipment, and soft goods. MediSource&#13;also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pantheon&#13;sells a physician friendly, &amp;#8220;all-in-one,&amp;#8221; integrated kit that includes plates, screws, and tools required for orthopedic&#13;surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, Pantheon expects to develop and submit&#13;several new product lines to the FDA, which will include cannulated surgical screws and surgical staples, as well as a proprietary&#13;Hammertoe System.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Going&#13;Concern&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;accompanying unaudited condensed interim consolidated financial statements have been prepared in conformity with US GAAP, which&#13;contemplate continuation of the Company as a going concern. The Company has experienced recurring net losses and negative cash&#13;flows from operations since inception and has an accumulated deficit of approximately $428 million and a working capital deficiency&#13;of approximately $32.5 million at October 31, 2019. The Company has funded its activities to date almost exclusively from debt&#13;and equity financings.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company will continue to require substantial funds to implement its new investment acquisition plans.&amp;#160; Management&amp;#8217;s&#13;plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common&#13;stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing&#13;financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and&#13;strategic partners.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;conditions raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern for a period of twelve months&#13;from the balance sheet date. There are no assurances that such additional funding will be achieved and that the Company will succeed&#13;in its future operations. The unaudited condensed interim consolidated financial statements do not include any adjustments relating&#13;to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the&#13;Company be unable to continue as a going concern. The Company&amp;#8217;s inability to obtain required funding in the near future&#13;or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development&#13;plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan,&#13;its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have&#13;to cease operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;11 - Net Income Per Share (&amp;#8220;EPS&amp;#8221;):&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Basic net income or&#13;loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted net income&#13;per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding&#13;for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury&#13;stock method. Common stock equivalents are included in the diluted income per share calculation only when option exercise prices&#13;are lower than the average market price of the common shares for the period presented.&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt"&gt;Weighted average number of common shares outstanding - Basic&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;48,360,127&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;1,068,100&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Potentially dilutive common stock&amp;#160;equivalents&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5,157,374&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,523,028&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Weighted average number of common and equivalent shares outstanding-Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;53,517,501&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,591,129&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The following table provides&#13;weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive,&#13;for the years ended July 31, 2019 and 2018, respectively.&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,831,301&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;17,850&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;15,399,681&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;18,230,982&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;17,850&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;15 - Net Income Per Share (&amp;#8220;EPS&amp;#8221;):&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic&#13;net income or loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted&#13;net income per share is calculated by dividing income available to common shareholders by the weighted average number of common&#13;shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock,&#13;using the treasury stock method. Common stock equivalents are included in the diluted income per share calculation only when option&#13;exercise prices are lower than the average market price of the common shares for the period presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended October 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt"&gt;Weighted average number of common shares outstanding - Basic&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;53,186,407&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;22,806,777&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Potentially dilutive common stock&amp;#160;equivalents&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;31,892,421&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average number of common and equivalent shares outstanding - Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;53,186,407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;54,699,198&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table provides weighted average number of common stock equivalents not included in diluted income per share, because&#13;the effects are anti-dilutive, for the three months ended October 31, 2019 and 2018, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Three&#13;    Months Ended October 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series&#13;    H Convertible Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,200,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series&#13;    I Convertible Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,636,000&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible&#13;    debt&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,744,548&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    options&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,871,675&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,747,850&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,405,395&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;28,021,618&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34,583,850&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;12 &amp;#8211; Goodwill and Intangible Assets&amp;#160;&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;assets consist of the following at July 31:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July&#13;    31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In-Process&#13;    Research &amp;#38; Development&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,761,427&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,911,377&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreements&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,210,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Developed&#13;    Software/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    Intangibles&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;51,274&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;327,654&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,153,701&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,239,031&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less&#13;    accumulated amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(319,432&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(27,994&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,834,269&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,211,037&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing&#13;the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible&#13;assets are placed in service the Company will determine a useful life.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization&#13;expense amounted to $255,835 and 2,571 for the years ended July 31, 2019 and 2018, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated&#13;amortization expense&amp;#160;(in thousands) for the next five years and thereafter is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&amp;#160;Ending&amp;#160;July&amp;#160;31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 44%; text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 43%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;434,117&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;434,118&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;164,895&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,787&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,138&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,898&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,082,952&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Changes&#13;in the value of goodwill:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;    of Veneto (revaluation)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,051,768&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;    of Regentys (revaluation)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,834,581&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;    of Olaregen (revaluation)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,411,224&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,297,573&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;8 &amp;#8211; Goodwill and Intangible Assets&amp;#160;&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;assets consist of the following at:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;October 31,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: left; padding-left: 0pt"&gt;In-Process Research &amp;#38; Development&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;8,761,427&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;8,761,427&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,566,700&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,210,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-left: 0pt"&gt;Developed software/technology&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;172,500&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;131,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Vendor agreements and other intangibles&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;775,674&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;51,274&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11,276,301&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;10,153,701&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(473,859&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(319,432&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;10,802,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;9,834,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible&#13;assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing&#13;the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible&#13;assets are placed in service the Company will determine a useful life.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization&#13;expense amounted to $154,426 and $646 for the three months ended October 31, 2019 and October 31, 2018, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The remaining estimated amortization expense&amp;#160;for the next five&#13;years and thereafter is as follows:&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year&amp;#160;Ending&amp;#160;July&amp;#160;31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amount&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 45%; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;570,708&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;616,744&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;246,324&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;94,511&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68,491&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;444,658&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,041,435&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Changes&#13;in the value of goodwill:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,297,573&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;    of MediSource and Pantheon&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;603,553&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of October 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,901,126&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <GNBT:WarrantsTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;15 - Warrants&lt;/u&gt;:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the Company&amp;#8217;s warrant activities is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price per Share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Remaining Life (Years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    Intrinsic Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 29%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    &amp;#8211; August 1, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - July 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,399,681&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - July 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,399,681&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;$&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For&#13;the year ended July 31, 2019, the Company issued 15,399,681 warrants which consisted of 399,681 issued to investors of convertible&#13;notes and 15,000,000 issued to a former shareholder of NGDx upon acquisition of the remaining 49% interest of the entity (Note&#13;9). All the warrants issued vested immediately upon issuance. Additionally, 84,000 warrants are to be issued to AEXG in connection&#13;with an arbitrator&amp;#8217;s award (Note 4).&lt;/font&gt;&lt;/p&gt;</GNBT:WarrantsTextBlock>
    <GNBT:WarrantsTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;14 - Warrants&lt;/u&gt;:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the Company&amp;#8217;s warrant activities is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price per Share&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Remaining Life (Years)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    Intrinsic Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,399,681&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.53&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.40&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,500,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;62,857&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.50&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.01&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(57,143&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.50&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - October 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,405,395&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.52&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.18&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended October 31, 2019, the Company issued 62,857 to investors of convertible notes and 57,143 warrants were&#13;forfeited upon settlement of a note. All the warrants issued vested immediately upon issuance. Additionally, 84,000 warrants are&#13;to be issued to AEXG in connection with an arbitrator&amp;#8217;s award (Note 4).&lt;/font&gt;&lt;/p&gt;</GNBT:WarrantsTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;17 - Subsequent Events:&lt;/u&gt;&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company has evaluated&#13;subsequent events occurring after the balance sheet date through the date the audited annual consolidated financial statements&#13;were issued in the unaudited condensed interim consolidated financial statements were issued.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 1, 2019 Generex&#13;finalized the acquisition of Pantheon Medical &amp;#8211; Foot &amp;#38; Ankle, LLC (&amp;#8220;Pantheon) through a stock purchase agreement&#13;and issued 560,000 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 1, 2019 Generex&#13;finalized the acquisition of MediSource Partners, LLC through a stock purchase agreement and issued 400,000 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 8, 2019, the&#13;Company converted $649,851 of principal into 384,000 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 12, 2019,&#13;the Company converted $45,000 of principal and $2,500 of interest into 30,666 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 12, 2019, the&#13;Company retained a consultant to provide financial advisory services in connection with and support of the various financing options&#13;and other services for the Company to raise up to Seven Million Dollars ($7,000,000) in debt capital for the Company payable upon&#13;funding equal to five (5%) of the principal amount funded by investors introduced by the Consultant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 13, 2019, the&#13;Company entered into a Public Secured Financing Facility Agreement with an investor pursuant to which the Company will receive&#13;a $5,000,000 financing facility bearing 13.50% interest per annum. The Company may receive subsequent financing in addition to&#13;the initial amount of $5,000,000 but shall not exceed a total of $7,000,000. The financing facility matures on August 13, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 14, 2019, the&#13;Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold a convertible&#13;note bearing interest at 10% per annum (the &amp;#8220;Note&amp;#8221;) in the principal amount of $1,100,000. Pursuant to the Securities&#13;Purchase Agreements, the Company also sold to the Investor warrants to purchase up to an aggregate 62,857 shares of common stock&#13;with the fair value of the warrants as of the date of issuance in excess of the Notes resulting in full discount of the Notes.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 15, 2019, the&#13;Company entered an agreement to pay an investor $900,000 for the prepayment of $666,667 owed under the note. Pursuant to the agreement,&#13;the Company converted $350,000 owed under the note into 230,351 shares of the Company&amp;#8217;s common stock based upon a conversion&#13;price of $1.51942 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 16, 2019, the&#13;Company entered into a Share Exchange Agreement to purchase an additional 900,000 shares in Olaregen Therapeutix Inc. from Olaregen&#13;Therapeutix LLC representing increasing Generex&amp;#8217;s ownership from approximately 62% to 76%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 19, 2019,&#13;the Company converted $60,000 of principal and $3,450 of interest into 46,110 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 12, 2019, the&#13;Company repaid in cash $100,149 in principal and $37,411 of interest.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 21, 2019, the&#13;Company converted $100,000 of principal and $5,699 of interest into 94,373 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On August 29, 2019, the&#13;Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold a convertible&#13;note bearing interest at 9% per annum (the &amp;#8220;Note&amp;#8221;) in the principal amount of $250,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On September 1, 2019, the Company retained&#13;a consultant to provide consulting services directly or through affiliated entities, certain management, administrative, marketing&#13;and/or clinical services to various ancillary healthcare for providers for a fee of $2,000,000; $250,000 payable in shares of common&#13;stock; and $1,750,000 payable in 18 equal installments of $97,222.22 per month payable in cash as is available from the operations&#13;of newly acquired subsidiaries Pantheon and MediSource, or shares of common stock issued monthly.On September 2, 2019 Generex signed&#13;a Memorandum of Understanding with Paradise Valley Family Medicine to form a partnership under NuGenerex Health, LLC for the provision&#13;of ancillary health services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On September 2, 2019 Generex signed a&#13;Memorandum of Understanding with Paradise Valley Family Medicine to form a partnership under NuGenerex Health, LLC for the provision&#13;of ancillary health services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 3, 2019, we declared a stock dividend&#13;on our outstanding Common Stock for stockholders of record date August 30, 2019 (the &amp;#8220;Record Date&amp;#8221;). As a result, all&#13;stockholders on the Record Date who hold their shares through the pay date of November 29, 2019 will receive one new share of Common&#13;Stock for each share of Common Stock owned by them as of that date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On September 2, 2019 Generex signed a&#13;Memorandum of Understanding with Arizona Endocrinology Center to form a partnership under NuGenerex Health, LLC for the provision&#13;of ancillary health services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On September 6, Generex signed a binding&#13;Letter of Intent with ALTuCELL, Inc (&amp;#8220;ALTuCELL&amp;#8221;), a clinical-stage development company with a broad intellectual property&#13;portfolio focused on cell encapsulation technology for the treatment of diabetes, autoimmune diseases, and inflammatory conditions&#13;to purchase 51% of ALTuCELL&amp;#8217;s equity in exchange for $2,000,000 in cash, $8,000,000 in the Company&amp;#8217;s common stock price&#13;at $2.50/share, and commitment to fund $5,000,000 towards ALTuCELL&amp;#8217;s development costs pursuant to a mutually agreed upon&#13;clinical development plan based upon a valuation of ALTuCELL equal to $29,500,000 On September 20, 2019, Generex paid ALTuCELL&#13;a preliminary payment of $50,000 to bind the agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 10, 2019, Generex and its subsidiaries,&#13;NuGenerex Distribution Solutions, LLC and NuGenerex Distributions Solutions 2, LLC (jointly &amp;#8220;NDS&amp;#8221;) filed an arbitration&#13;action against Veneto Holdings, LLC and certain affiliated entities holding shares of our common stock issued in connection with&#13;our acquisition of Veneto&amp;#8217;s assets, alleging, among other things, that Veneto never transferred the ownership rights in at&#13;least one pharmacy to NDS. This pharmacy was a necessary element in the operation of other assets transferred by Veneto. The ownership&#13;rights in this pharmacy was a substantial portion of the consideration for shares issued to Veneto and its affiliates, and, as&#13;a result, Generex contends the shares issued to Veneto and its affiliates were never fully paid for. The arbitration is pending&#13;before the American Arbitration Association in Delaware.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On September 10, 2019,&#13;the Company converted $100,000 of principal and $6,361 of interest into 75,737 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On September 12, 2019,&#13;20,375,900 shares of common stock held in trust for the benefit of the Company were cancelled by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On September 13, 2019,&#13;the Company converted 592,683 Preferred Shares of Olaregen Therapeutics, Inc. Series A Preferred Stock into Common Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On September 17, 2019,&#13;the Company converted $130,000 of principal and $8,522 of interest into 95,130 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On September 18, 2019,&#13;the Company converted $150,000 of principal and $9,699 of interest into 112,941 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On October 1, 2019, the&#13;Company retained a consultant to provide consulting services in support of the Company&amp;#8217;s mission to raise capital, identify&#13;potential mergers, as well as other strategic advice to increase the value of the Company for a monthly fee of $5,000 for each&#13;calendar month commencing October 2019 and continuing through the termination date of September 30, 2024. The consultant received&#13;options to purchase 1,000,000 shares of common stock, vesting in equal increments of 200,000 shares on October 1&lt;sup&gt;st&lt;/sup&gt; of&#13;each year commencing on October 1, 2019 at an exercise price of $2.09 per share. The consultant is to be paid a 2.0% transaction&#13;fee payable on all transactions consummated during the term. The transaction fee is based on the amount of all proceeds and other&#13;consideration paid or received, to be paid or received, or retained by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On October 10, 2019 Generex amended&#13;the acquisition agreement for the purchase of Pantheon effective on August 1, 2019 to provide a performance incentive up to $500,000&#13;of GNBT Stock for exceeding annual EBIDTA targets of Pantheon of $1,000,000, 1,500,000 and $2,000,000 for the years ending July&#13;31, 2020, 2021 and 2022, respectively, plus an additional $50,000 of GENBT Stock for each additional $100,000 of EBDITA achieved&#13;by Pantheon.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;18 - Subsequent Events:&lt;/u&gt;&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has evaluated subsequent events occurring after the balance sheet date through the date the unaudited condensed interim&#13;consolidated financial statements were issued.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 12, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $80,000 of principal and $4,778 of interest into 115,344 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 12, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $50,000 of principal and $3,096 of interest into 128,561 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 14, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $50,000 of principal and $2,712 of interest into 80,110 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 18, 2019&amp;#160;&amp;#160;, the Company&#13;entered into three Securities Purchase Agreements with investors pursuant to which the Company agreed to sell and sold three convertible&#13;notes bearing interest at 10% per annum in the aggregate principal amount of $275,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 21, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $80,000 of principal and $4,493 of interest into 134,865 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 21, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $100,000 of principal and $6,219 of interest into 169,543 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 22, 2019, effective as of&#13;November 15, 2019, the Company entered into a Stock Purchase Agreement for the purchase of 51% of the outstanding capital stock&#13;of GH Care, Inc. DBA ALTuCELL, Inc.(&amp;#8220;ALTuCELL&amp;#8221;&lt;u&gt;)&lt;/u&gt;.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Under the SPA, in exchange for the ALTuCELL&#13;Stock, Generex will issue to ALTuCELL 1,600,000 shares of Generex common stock with a down round provision and price floor of $1.25&#13;per share. The Company will also pay $2.5 million in cash of which $112,000 has already been paid. In addition to stock and cash&#13;at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCell upon ALTuCell&amp;#8217;s attainment of certain&#13;milestones.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 24, 2019&amp;#160;, the Company&#13;amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November&#13;30, 2019, in connection with the purchase of Olaregen capital stock. Effective November 24, 2019, the deadline has been extended&#13;to January 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 25, 2019&amp;#160;, the Company&#13;amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three&#13;payments of $2,039,001, $2,000,000, and $3,000,000 are all payable on or before December 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 25, 2019&amp;#160;, the Company&#13;entered an Equity Purchase Agreement with an investor to purchase up to $40,00,000 of the Company&amp;#8217;s stock at 92% of the market&#13;price for the period of five (5) consecutive trading days immediately subject to a put notice on such date on which the Purchase&#13;Price is calculated in accordance with the terms and conditions of this Agreement and 1,228,501 shares of common stock (&amp;#8220;Commitment&#13;Shares&amp;#8221;) will be issued to an investor upon signing.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 27, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $100,000 of principal and $6,384 of interest into 202,635 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 27, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $125,000 of principal and $7,226 of interest into 251,859 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On November 29, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $50,000 of principal into 79,214 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On December 5, 2019&amp;#160;, the Company&#13;entered an Equity Purchase Agreement with an investor pursuant to which the Company will issue 100,000 shares of common stock to&#13;the investor as a commitment fee and a convertible note in the principal amount of $2,200,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;On December 5, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $70,000 of principal and $4,621 of interest into 180,682 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 5, 2019&amp;#160;, the Company&amp;#8217;s&#13;note holder converted $75,000 of principal and $4,500 of interest into 192,494 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 10, 2019, the Company announced&#13;revisions to previously announced stock dividends and approved by the Board of Directors on December 13, 2019 that the previously&#13;approved 1:1 common stock dividend shall be restructured to provide for a 2 to 5 stock dividend to shareholders of the Company&#13;and for shareholders to also receive an additional 2 to 5 stock dividend of Antigen Express, Inc, d/b/a NuGenerex Immuno-Oncology&#13;commons shares; that the record date for the stock dividend be August 30, 2019; and the new pay date for this 2:5 dividend will&#13;be January 3, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 12, 2019, the Company&amp;#8217;s&#13;note holder converted $75,000 of principal and $4,756 of interest into 181,007&amp;#160;shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On&lt;/font&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&#13;&lt;/font&gt;&lt;font style="font-size: 10pt"&gt;December 12, 2019, the Company&amp;#8217;s note holder converted $50,000 of principal and $ 3095.89&#13;of interest into 128,561&amp;#160;shares of common stock.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <GNBT:ScheduleOfWarrantActivitiesTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the Company&amp;#8217;s warrant activities is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price per Share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Remaining Life (Years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    Intrinsic Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 29%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    &amp;#8211; August 1, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - July 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,399,681&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - July 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,399,681&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;$&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</GNBT:ScheduleOfWarrantActivitiesTableTextBlock>
    <GNBT:ScheduleOfWarrantActivitiesTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the Company&amp;#8217;s warrant activities is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price per Share&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Remaining Life (Years)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    Intrinsic Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,399,681&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.53&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.40&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,500,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;62,857&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.50&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.01&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(57,143&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.50&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    - October 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,405,395&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.52&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.18&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:ScheduleOfWarrantActivitiesTableTextBlock>
    <GNBT:ChangesInValueOfGoodwillTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Changes&#13;in the value of goodwill:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;    of Veneto (revaluation)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,051,768&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;    of Regentys (revaluation)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,834,581&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;    of Olaregen (revaluation)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,411,224&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,297,573&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:ChangesInValueOfGoodwillTableTextBlock>
    <GNBT:ChangesInValueOfGoodwillTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Changes&#13;in the value of goodwill:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of July 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,297,573&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition&#13;    of MediSource and Pantheon&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;603,553&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&#13;    as of October 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,901,126&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:ChangesInValueOfGoodwillTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The following table provides&#13;weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive,&#13;for the years ended July 31, 2019 and 2018, respectively.&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,831,301&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;17,850&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;15,399,681&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;18,230,982&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;17,850&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table provides weighted average number of common stock equivalents not included in diluted income per share, because&#13;the effects are anti-dilutive, for the three months ended October 31, 2019 and 2018, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Three&#13;    Months Ended October 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series&#13;    H Convertible Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,200,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series&#13;    I Convertible Preferred Stock&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,636,000&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible&#13;    debt&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,744,548&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#13;    options&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,871,675&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,747,850&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,405,395&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;28,021,618&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34,583,850&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Common stock equivalents are included in the diluted income per share calculation only when option exercise prices&#13;are lower than the average market price of the common shares for the period presented.&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt"&gt;Weighted average number of common shares outstanding - Basic&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;48,360,127&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;1,068,100&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Potentially dilutive common stock&amp;#160;equivalents&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5,157,374&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,523,028&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Weighted average number of common and equivalent shares outstanding-Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;53,517,501&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,591,129&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common stock equivalents are included in the diluted income per share calculation only when option&#13;exercise prices are lower than the average market price of the common shares for the period presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended October 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt"&gt;Weighted average number of common shares outstanding - Basic&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;53,186,407&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;22,806,777&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Potentially dilutive common stock&amp;#160;equivalents&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;31,892,421&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average number of common and equivalent shares outstanding - Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;53,186,407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;54,699,198&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;Value of Financial Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&#13;value is defined under FASB ASC Topic 820 as the exchange price that would be received for an asset or paid to transfer a liability&#13;(an exit price) in the principal or the most advantageous market for an asset or liability in an orderly transaction between participants&#13;on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize&#13;the use of unobservable inputs. The standard describes a fair value hierarchy based on the levels of inputs, of which the first&#13;two are considered observable and the last unobservable, that may be used to measure fair value. The levels are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    1 - Quoted prices in active markets for identical assets or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets&#13;    or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable&#13;    market data for substantially the full term of the assets or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 98%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    3 - Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets&#13;    or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company&amp;#8217;s financial instruments consist of cash and cash equivalents, trade receivables, other receivables, payables, and&#13;short term and long term debt. The carrying values of cash and cash equivalents, trade receivables, other receivables, and payables&#13;approximate their fair value due to their short maturities. The carrying value of long term debt approximates the&amp;#160;&lt;/font&gt;fair&#13;value of debt&lt;font style="font-size: 10pt"&gt;&amp;#160;of similar terms and remaining maturities available to the company.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;July 31, 2019, the Company did not have any assets measured at fair value on a recurring basis. The following is a listing of&#13;the Company&amp;#8217;s liabilities required to be measured at fair value on a recurring basis and where they are classified within&#13;the fair value hierarchy as of July 31, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Call option&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,168,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The following is a listing&#13;of the Company&amp;#8217;s liabilities required to be measured at fair value on a recurring basis and where they are classified within&#13;the fair value hierarchy as of July 31, 2019 and July 31, 2018:&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2019&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Derivative liability&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,820,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;July 31, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrants to be issued&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;24,962,507&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;10 &amp;#8211; Income Taxes:&lt;/u&gt;&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company has incurred&#13;losses since inception, which have generated net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards. The NOL carryforwards arise&#13;from both United States and Canadian sources. Pre-tax gain or (loss) arising from domestic operations (United States) were ($11,006,793)&#13;and $35,948,698 for the years ended July 31, 2019 and 2018, respectively. Pre-tax (losses) arising from foreign operations (Canada)&#13;were $(326,461) and $(150,394) for the years ended July 31, 2019 and 2018, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As of July 31, 2019,&#13;the Company has NOL carryforwards in Generex Biotechnology Corporation of approximately $196.2 million, which expire in 2020 through&#13;2038, and $13.7 million will not expire. The non-expiring portion is limited to 80% of the current year taxable income of the&#13;respective entity. Generex Pharmaceuticals Inc. has NOL carryforwards of approximately $34.4 million, which expire in 2024 through&#13;2039. Antigen Express, Inc. has NOL carryforwards of approximately $36.2 million which expire in 2020 through 2038. Regentys Corporation&#13;has NOL carryforwards of approximately $6.0 million of which $5.0 million will expire 2033 through 2039. Olaregen Therapeutics,&#13;Inc. has NOL carryforwards of $1.1 million of which $1.1 million will not expire. Veneto has NOL carryforwards of $8.4 million&#13;which will not expire. Some of these loss carryforwards are subject to limitation due to the acquisition of Regentys, Olaregen&#13;and Antigen and may be limited in future years due to certain structural ownership changes which have occurred over the last several&#13;years related to the Company&amp;#8217;s equity and convertible debenture financing transactions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;For the years ended July&#13;31, 2019 and 2018, the Company&amp;#8217;s effective tax rate differs from the federal statutory rate principally due to net operating&#13;losses and other temporary differences for which no benefit was recorded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Deferred income taxes consist of the following:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;64,308,679&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;59,296,530&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Other temporary differences&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,812,190&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(102,273&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,173,419&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,518,572&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Total Deferred Tax Assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;68,294,288&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;61,712,829&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(68,294,288&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(61,712,829&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Deferred Tax Liabilities&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Intangible assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(&amp;#8212;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(&amp;#8212;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Other temporary differences&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Total Deferred Tax Liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Net Deferred Income Taxes&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;reconciliation of the United States Federal Statutory rate to the Company&amp;#8217;s effective tax rate for the years ended July&#13;31, 2019 and 2018 is as follows:&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: justify"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(26.5&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Increase (decrease) in income taxes resulting from:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Change in fair value of purchase consideration&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(40.2&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;28.5&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Expiration of net operating loss carryforward&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9.9&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Other&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2.4&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.9&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Tax rate change&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(88.7&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;48.9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;85.8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;December 22, 2017, the Tax Cuts and Jobs Act (&amp;#8220;The Act&amp;#8221;), was signed into law by President Trump. The Act includes&#13;a number of provisions, including the lowering of the U.S. corporate tax rate from 34 percent to 21 percent, effective January&#13;1, 2018 and the establishment of a territorial-style system for taxing foreign-source income of domestic multinational corporations.&#13;In December 2017, the SEC issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Act (&amp;#8220;SAB118&amp;#8221;),&#13;which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment. The&#13;Company remeasured its deferred tax assets and liabilities as of July 31, 2018, applying the reduced corporate income tax rate&#13;and recorded a provisional decrease to the deferred tax assets of $31,876,520, with a corresponding adjustment to the valuation&#13;allowance. In the fourth quarter of fiscal year ended July 31, 2019, we completed our analysis to determine the effect of the&#13;Tax Act and there were no material adjustments as of July 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of July 31, 2019, the Company had no tax benefits which have not been fully allowed for, and no adjustment to its financial position,&#13;results of operations or cash flows was required. The Company does not expect that unrecognized tax benefits will increase within&#13;the next twelve months. The Company records interest and penalties related to tax matters within other expense on the accompanying&#13;consolidated statement of operations. These amounts are not material to the consolidated financial statements for the years presented.&#13;Generally, tax years 2016 to 2019 remain open to examination by the Internal Revenue Agency or other tax jurisdictions to which&#13;the Company is subject. The Company&amp;#8217;s Canadian tax returns are subject to examination by federal and provincial taxing authorities&#13;in Canada. Generally, tax years 2011 to 2019 remain open to examination by the Canada Revenue Agency or other tax jurisdictions&#13;to which the Company is subject.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;17 &amp;#8211; Income Taxes:&lt;/u&gt;&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has incurred losses since inception, which have generated net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards. The NOL&#13;carryforwards arise from both United States and Canadian sources. Pre-tax gain or (loss) arising from domestic operations (United&#13;States) were $(9,179,902) and $(11,006,793) for the three months ended October 31, 2019 and the year ended July 31, 2019, respectively.&#13;Pre-tax (losses) arising from foreign operations (Canada) were $(10,963) and $(326,461) for the three months ended October 31,&#13;2019 and the year ended July 31, 2019, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of October 31, 2019, the Company has NOL carryforwards in Generex Biotechnology Corporation of approximately $214 million&amp;#160;,&#13;of which $196 million will expire in 2020 through 2038, and $17.7 million will not expire. The non-expiring portion is limited&#13;to 80% of the current year taxable income of the respective entity. Generex Pharmaceuticals Inc. has NOL carryforwards of approximately&#13;$34.3 million, which expire in 2025 through 2040. Antigen Express, Inc. has NOL carryforwards of approximately $36.2 which will&#13;expire in 2020 through 2038. Regentys Corporation has NOL carryforwards of approximately $6.1 million, of which $4.9 million will&#13;expire in 2033 through 2038. Olaregen Therapeutics, Inc. has NOL carryforwards of $1.3 million which will not expire. Veneto has&#13;NOL carryforwards of $8.7 million which will not expire. Some of these loss carryforwards are subject to limitation due to the&#13;acquisition of Regentys, Olaregen and Antigen and may be limited in future years due to certain structural ownership changes which&#13;have occurred over the last several years related to the Company&amp;#8217;s equity and convertible debenture financing transactions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of October 31, 2019, the Company had no tax benefits which have not been fully allowed for, and no adjustment to its financial&#13;position, results of operations or cash flows was required. The Company has deferred tax assets of over $70 million with a full&#13;allowance equally to the to the amount of the deferred tax asset. The Company does not expect that unrecognized tax benefits will&#13;increase within the next twelve months. During the period ended October 31, 2019, the Company acquired certain assets of MediSource&#13;Partners, LLC and Pantheon Medical. The assets are included within Generex Biotechnology Corporation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company records interest and penalties related to tax matters within other expense on the accompanying consolidated statement&#13;of operations. These amounts are not material to the consolidated financial statements for the years presented. Generally, tax&#13;years 2016 to 2019 remain open to examination by the Internal Revenue Agency or other tax jurisdictions to which the Company is&#13;subject. The Company&amp;#8217;s Canadian tax returns are subject to examination by federal and provincial taxing authorities in Canada.&#13;Generally, tax years 2011 to 2019 remain open to examination by the Canada Revenue Agency or other tax jurisdictions to which&#13;the Company is subject.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Deferred income taxes consist of the following:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;64,308,679&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;59,296,530&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Other temporary differences&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,812,190&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(102,273&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,173,419&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,518,572&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Total Deferred Tax Assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;68,294,288&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;61,712,829&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(68,294,288&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(61,712,829&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Deferred Tax Liabilities&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Intangible assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(&amp;#8212;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(&amp;#8212;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Other temporary differences&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Total Deferred Tax Liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Net Deferred Income Taxes&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2018-08-01to2019-07-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;reconciliation of the United States Federal Statutory rate to the Company&amp;#8217;s effective tax rate for the years ended July&#13;31, 2019 and 2018 is as follows:&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;July 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="width: 56%; font-size: 10pt; text-align: justify"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(26.5&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Increase (decrease) in income taxes resulting from:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Change in fair value of purchase consideration&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(40.2&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;28.5&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Expiration of net operating loss carryforward&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9.9&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Other&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2.4&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.9&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify"&gt;Tax rate change&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(88.7&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;48.9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;85.8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">75892</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AmortizationOfLeasedAsset contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">18887</us-gaap:AmortizationOfLeasedAsset>
    <us-gaap:AmortizationOfLeasedAsset contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfLeasedAsset>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">52912</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-18500</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <GNBT:ReductionOfDerivativeLiabilities contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">1911487</GNBT:ReductionOfDerivativeLiabilities>
    <GNBT:ReductionOfDerivativeLiabilities contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:ReductionOfDerivativeLiabilities>
    <GNBT:DiscountOnDerivativeLiabilityUponIssuanceOfDebt contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">1052349</GNBT:DiscountOnDerivativeLiabilityUponIssuanceOfDebt>
    <GNBT:DiscountOnDerivativeLiabilityUponIssuanceOfDebt contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:DiscountOnDerivativeLiabilityUponIssuanceOfDebt>
    <GNBT:IssuanceOfCommonStockForConversionOfDebt contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">1694851</GNBT:IssuanceOfCommonStockForConversionOfDebt>
    <GNBT:IssuanceOfCommonStockForConversionOfDebt contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:IssuanceOfCommonStockForConversionOfDebt>
    <GNBT:RecordingOfRightOfUseAssetAndLiability contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">116440</GNBT:RecordingOfRightOfUseAssetAndLiability>
    <GNBT:RecordingOfRightOfUseAssetAndLiability contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:RecordingOfRightOfUseAssetAndLiability>
    <GNBT:IncreaseCommonStockPayable contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">14500</GNBT:IncreaseCommonStockPayable>
    <GNBT:IncreaseCommonStockPayable contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:IncreaseCommonStockPayable>
    <GNBT:IssuanceOfSharescommonStockPayable contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">921895</GNBT:IssuanceOfSharescommonStockPayable>
    <GNBT:IssuanceOfSharescommonStockPayable contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">0</GNBT:IssuanceOfSharescommonStockPayable>
    <GNBT:NotePayableIssuedForAcquisitionOfBusiness contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">0</GNBT:NotePayableIssuedForAcquisitionOfBusiness>
    <GNBT:NotePayableIssuedForAcquisitionOfBusiness contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">15000000</GNBT:NotePayableIssuedForAcquisitionOfBusiness>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;5 &amp;#8211; Leases&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has various operating lease agreements&#13;with terms up to 2 years, including leases of office space. Some leases include purchase, termination or extension options for&#13;one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company adopted ASC 842 effective August&#13;1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective&#13;date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the&#13;following accounting policies related to this standard update:&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 15pt; text-align: right"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The option to not reassess prior conclusions related to the identification, classification&#13;and accounting for initial direct costs for leases that commenced prior to January 1, 2019.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 15pt; text-align: right"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Short-term lease accounting policy election allowing lessees to not recognize right-of-use&#13;assets and liabilities for leases with a term of 12 months or less; and&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 15pt; text-align: right"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The option to not separate lease and non-lease components for certain equipment lease&#13;asset categories such as freight car, vehicles and work equipment.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 15pt; text-align: right"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The package of practical expedients applied to all of its leases, including (i) not&#13;reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for&#13;any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of&#13;remaining lease payments over the lease term using the Company&amp;#8217;s incremental borrowing rates or implicit rates, when readily&#13;determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s operating leases do not provide an implicit rate that can readily be determined. Therefore, the Company uses a&#13;discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated&#13;in the Company&amp;#8217;s convertible debt.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s weighted-average remaining lease term relating to its operating leases is 1.3 years, with a weighted-average discount&#13;rate of 9.5%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company incurred lease expense for its operating leases of $21,508 for three months ended October 31, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table presents information about the amount and timing of liabilities arising from the Company&amp;#8217;s operating leases&#13;as of October 31, 2019:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity&#13;    of Operating Lease Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 45%; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,801&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,879&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    undiscounted operating lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;104,680&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less:&#13;    Imputed interest&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,740&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Present&#13;    value of operating lease liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;97,940&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table presents information about the amount and timing of liabilities arising from the Company&amp;#8217;s operating leases&#13;as of October 31, 2019:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity&#13;    of Operating Lease Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 45%; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,801&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,879&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    undiscounted operating lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;104,680&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less:&#13;    Imputed interest&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,740&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Present&#13;    value of operating lease liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;97,940&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <GNBT:SummaryOfAllocationOfPreliminaryPurchasePriceTableTextBlock contextRef="From2019-08-01to2019-10-31_custom_MedisourceMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the preliminary purchase price as of the MediSource acquisition:&amp;#9;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&#13;    &lt;br /&gt;Allocation as of &lt;br /&gt;August 1, &lt;br /&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&#13;    and cash equivalents&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,895&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    current assets&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,864&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property&#13;    and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,992&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    payable and accrued liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(31,439&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    Tangible Assets&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,312&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tradename&#13;    / Trademarks&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;47,600&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&#13;    Contracts&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;346,800&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Competes&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;124,600&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    Fair Value of Assets Acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;522,312&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration:&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&#13;    value of common stock&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;479,980&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent&#13;    consideration&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;409,790&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration&#13;    included in consulting agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;104,168&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    Purchase Price&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;993,938&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,626&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:SummaryOfAllocationOfPreliminaryPurchasePriceTableTextBlock>
    <GNBT:SummaryOfAllocationOfPreliminaryPurchasePriceTableTextBlock contextRef="From2019-08-01to2019-10-31_custom_PantheonMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the allocation of the preliminary purchase price as of the Pantheon acquisition:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&#13;    &lt;br /&gt;Allocation as of &lt;br /&gt;August 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash&#13;    and cash equivalents&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35,410&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    receivable&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;133,269&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,336&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;266,071&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Medical&#13;    Equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;67,299&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts&#13;    payable&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(53,242&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued&#13;    liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(15,573&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    Tangible Assets&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;436,570&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tradename&#13;    / Trademarks&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;55,400&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;IP/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,500&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;232,100&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer&#13;    Base&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;274,600&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    assets acquired&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,040,170&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration:&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair&#13;    value of common stock&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;671,972&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent&#13;    consideration&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;354,292&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration&#13;    included in consulting agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;145,833&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,927&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</GNBT:SummaryOfAllocationOfPreliminaryPurchasePriceTableTextBlock>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock contextRef="From2019-08-01to2019-10-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;components of the acquired intangible assets were as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preliminary&#13;    &lt;br /&gt; Fair &lt;br /&gt; Value&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&#13;    Estimated Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tradename&#13;    / Trademarks&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;103,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;IP/Technology&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,500&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&#13;    Contracts&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;346,800&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer&#13;    Base&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;274,600&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: Silver; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-compete&#13;    agreement&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;356,700&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,112,600&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <GNBT:MajorityInterest contextRef="AsOf2017-01-18_custom_HemaDiagnosticSystemsMember" unitRef="Pure" decimals="INF">0.51</GNBT:MajorityInterest>
    <GNBT:WorkingCapitalDeficiency contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">28000000</GNBT:WorkingCapitalDeficiency>
    <GNBT:WorkingCapitalDeficiency contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">32500000</GNBT:WorkingCapitalDeficiency>
    <GNBT:SecuredPromissoryNoteDescription contextRef="From2019-01-06to2019-01-07">On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (&#8220;Regentys&#8221;) and Olaregen Therapeutix Inc. (&#8220;Olaregen&#8221;). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product.</GNBT:SecuredPromissoryNoteDescription>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">7820282</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2019-07-31_custom_DerivativeliabilityMember" unitRef="USD" decimals="0">7820282</us-gaap:DerivativeLiabilitiesCurrent>
    <GNBT:Total contextRef="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</GNBT:Total>
    <GNBT:Total contextRef="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">2168211</GNBT:Total>
    <GNBT:Total contextRef="AsOf2018-07-31_us-gaap_CallOptionMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</GNBT:Total>
    <GNBT:Total contextRef="AsOf2018-07-31_us-gaap_CallOptionMember206716051" unitRef="USD" decimals="0">2168211</GNBT:Total>
    <GNBT:Total contextRef="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</GNBT:Total>
    <GNBT:Total contextRef="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</GNBT:Total>
    <GNBT:Total contextRef="AsOf2019-07-31_custom_DerivativeliabilityMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">7820282</GNBT:Total>
    <GNBT:Total contextRef="AsOf2019-07-31_custom_DerivativeliabilityMember" unitRef="USD" decimals="0">7820282</GNBT:Total>
    <GNBT:Total contextRef="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</GNBT:Total>
    <GNBT:Total contextRef="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">24962507</GNBT:Total>
    <GNBT:Total contextRef="AsOf2018-07-31_custom_WarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</GNBT:Total>
    <GNBT:Total contextRef="AsOf2018-07-31_custom_WarrantsMember" unitRef="USD" decimals="0">24962507</GNBT:Total>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2018-08-01to2019-07-31_us-gaap_ComputerEquipmentMember">3-5 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2018-08-01to2019-07-31_us-gaap_MachineryAndEquipmentMember">3-5 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2018-08-01to2019-07-31_us-gaap_FurnitureAndFixturesMember">3-7 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">784999</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:AssetImpairmentCharges contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">287587</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2018-08-01to2019-07-31_custom_EmpireStatePharmacyMember" unitRef="USD" decimals="0">188069</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2018-08-01to2019-07-31_custom_GrainlandPharmacyAssetsMember" unitRef="USD" decimals="0">99519</us-gaap:AssetImpairmentCharges>
    <us-gaap:InventoryWriteDown contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">645351</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">31876520</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">70000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2017-08-01to2018-07-31" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2019-08-01to2019-10-31" unitRef="Pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2018-08-01to2018-10-31" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:LongtermDebtWeightedAverageInterestRate contextRef="AsOf2018-07-31_custom_HDSMember_custom_HemaDiagnosticSystemsMember" unitRef="Pure" decimals="INF">0.0075</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:LongtermDebtPercentageBearingFixedInterestAmount contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">72612</us-gaap:LongtermDebtPercentageBearingFixedInterestAmount>
    <us-gaap:LongtermDebtPercentageBearingFixedInterestAmount contextRef="AsOf2018-07-31_custom_HDSMember_custom_HemaDiagnosticSystemsMember" unitRef="USD" decimals="0">13239837</us-gaap:LongtermDebtPercentageBearingFixedInterestAmount>
    <us-gaap:LongtermDebtPercentageBearingFixedInterestAmount contextRef="AsOf2019-07-31_custom_RegentysMember" unitRef="USD" decimals="0">19700</us-gaap:LongtermDebtPercentageBearingFixedInterestAmount>
    <us-gaap:LongtermDebtPercentageBearingFixedInterestAmount contextRef="AsOf2019-10-31_custom_RegentysMember" unitRef="USD" decimals="0">19700</us-gaap:LongtermDebtPercentageBearingFixedInterestAmount>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2018-07-31_custom_HDSMember_custom_HemaDiagnosticSystemsMember" unitRef="USD" decimals="0">191869</us-gaap:InterestPayableCurrent>
    <GNBT:AgreementTerms contextRef="From2019-01-01to2019-01-18_custom_BerkmanMember">Pursuant to the January 18, 2017 Acquisition, Mr. Berkman, previous owner of NGDx and debt holder, agreed, under certain conditions to transfer the remaining 49% of the NGDx equity to the Company for a consideration of $1.00. On December 1, 2018, the Company and Mr. Berkman entered into an Agreement, Assignment and Release, pursuant to which Mr. Berkman transferred the remaining NGDx equity interests to the Company, waiving and releasing any conditions to such transfer. NGDx is now a wholly owned subsidiary of the Company. In addition to the assignment of the NGDx interests, Mr. Berkman released these loans in exchange for shares of the Company&#8217;s common stock valued at the aggregate of such amount using the closing price for the common stock on November 30, 2018. The closing price was $18.99, resulting in 32,881 shares issuable to Mr. Berkman. This transaction resulted in Mr. Berkman&#8217;s advances of $624,404 plus the loan and call option which resulted in additional paid in capital of $13,431,705 which was reclassified to the Company&#8217;s stockholders&#8217; equity as an extinguishment of debt for $14,056,109.</GNBT:AgreementTerms>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2019-01-07_custom_RegentysMember302122456" unitRef="USD" decimals="0">16505</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:RepaymentsOfDebt contextRef="From2018-08-01to2019-07-31_custom_RegentysMember302174389" unitRef="USD" decimals="0">3305</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromLoans contextRef="From2018-08-01to2019-07-31_custom_RegentysMember302174389" unitRef="USD" decimals="0">6500</us-gaap:ProceedsFromLoans>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-10-31_custom_PantheonMember" unitRef="USD" decimals="0">52912</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">133269</us-gaap:AccountsReceivableNetCurrent>
    <GNBT:ValueOfDamagesSought contextRef="From2011-12-01to2011-12-31_custom_DamagesForUnpaidInvoicesMember" unitRef="USD" decimals="0">429000</GNBT:ValueOfDamagesSought>
    <us-gaap:GainContingencyUnrecordedAmount contextRef="AsOf2011-12-31_custom_BreachOfContractMember" unitRef="USD" decimals="0">200000</us-gaap:GainContingencyUnrecordedAmount>
    <us-gaap:LossContingencyLawsuitFilingDate contextRef="From2011-12-01to2011-12-31_custom_DamagesForUnpaidInvoicesMember">31-Dec-11</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyNameOfPlaintiff contextRef="From2011-12-01to2011-12-31_custom_DamagesForUnpaidInvoicesMember">Vendor</us-gaap:LossContingencyNameOfPlaintiff>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="From2011-12-01to2012-11-16_custom_DamagesForUnpaidInvoicesMember" unitRef="USD" decimals="0">125000</us-gaap:GainLossRelatedToLitigationSettlement>
    <GNBT:InterestPerAnnumFailureToPaySettlement contextRef="From2011-12-01to2011-12-31_custom_DamagesForUnpaidInvoicesMember" unitRef="Pure" decimals="INF">0.03</GNBT:InterestPerAnnumFailureToPaySettlement>
    <us-gaap:LitigationSettlementInterest contextRef="From2011-12-01to2011-12-31_custom_DamagesForUnpaidInvoicesMember" unitRef="USD" decimals="0">25000</us-gaap:LitigationSettlementInterest>
    <us-gaap:OtherCommitmentsDescription contextRef="From2017-08-01to2017-08-22">The letter from AEXG counsel claimed that Generex&amp;#8217;s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney&amp;#8217;s fees and costs.</us-gaap:OtherCommitmentsDescription>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">112801</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">39879</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">39879</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="From2018-11-29to2018-12-02" unitRef="USD" decimals="0">315695</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <GNBT:LitigationAwardsExercisableShares contextRef="AsOf2018-12-02" unitRef="Shares" decimals="INF">84000</GNBT:LitigationAwardsExercisableShares>
    <GNBT:ExercisePrice contextRef="AsOf2018-12-02" unitRef="USDPShares" decimals="INF">2.50</GNBT:ExercisePrice>
    <GNBT:MemorandumOfUnderstandingDescription contextRef="From2018-11-29to2018-12-02_custom_AlternativeExecutionGroupMember">The petition includes a demand of $3,300,360 as the value of the Warrants. The arbitrator did not award the specific amount of $3.3 million, but only liquidated damages in the amount of $220,000 and the value of 84,000 warrants &#8220;as of today&#8221; (the date of the award) plus attorney&#8217;s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees.</GNBT:MemorandumOfUnderstandingDescription>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">446600</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2018-10-26" unitRef="USD" decimals="0">682000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-07-31_custom_RegentysMember307928251" unitRef="USD" decimals="0">353375</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-08-31" unitRef="USD" decimals="0">1150000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2018-11-25" unitRef="USD" decimals="0">1060000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-01-24" unitRef="USD" decimals="0">530000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-02-28" unitRef="USD" decimals="0">1500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-04-30" unitRef="USD" decimals="0">1060000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-05-31" unitRef="USD" decimals="0">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">2222500</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-10-31_custom_RegentysMember106908249" unitRef="USD" decimals="0">349656</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-08-14_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember" unitRef="USD" decimals="0">1100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-08-29_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember" unitRef="USD" decimals="0">250000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-05_us-gaap_SubsequentEventMember_custom_EquityPurchaseAgreementMember_custom_InvestorsMember" unitRef="USD" decimals="0">2200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-11-18_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember" unitRef="USD" decimals="0">275000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired contextRef="From2019-11-01to2019-11-27_custom_OlaregenMember" unitRef="USD" decimals="0">650000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">232283</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">65613</us-gaap:FairValueAdjustmentOfWarrants>
    <GNBT:LiquidatedDamages contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">220000</GNBT:LiquidatedDamages>
    <GNBT:LiquidatedDamages contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">220000</GNBT:LiquidatedDamages>
    <GNBT:AccruedLiquidatedDamages contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">452283</GNBT:AccruedLiquidatedDamages>
    <GNBT:AccruedLiquidatedDamages contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">285613</GNBT:AccruedLiquidatedDamages>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscounted contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">2752235</us-gaap:MalpracticeLossContingencyAccrualUndiscounted>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscounted contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">2752235</us-gaap:MalpracticeLossContingencyAccrualUndiscounted>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">64801</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">104680</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <GNBT:ImputedInterest contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">-6740</GNBT:ImputedInterest>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">97940</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-10-31">P1Y3M19D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2019-10-31" unitRef="Pure" decimals="INF">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">21508</us-gaap:OperatingLeaseExpense>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">52745</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">639920</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">769463</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-07-31_custom_ComputersAndTechnologicalAssetsMember" unitRef="USD" decimals="0">163168</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-07-31_custom_ComputersAndTechnologicalAssetsMember" unitRef="USD" decimals="0">11365</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-07-31_us-gaap_MachineryAndEquipmentMember" unitRef="USD" decimals="0">386929</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-07-31_us-gaap_MachineryAndEquipmentMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-07-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">73227</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-07-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">19879</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-07-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">16596</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-07-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">21501</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-10-31_custom_ComputersAndTechnologicalAssetsMember" unitRef="USD" decimals="0">163168</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-10-31_us-gaap_MachineryAndEquipmentMember" unitRef="USD" decimals="0">500576</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-10-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">89123</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-10-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">16596</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">21209</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">139927</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">237575</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">170605</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">21782</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">48847</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">25664</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">292681</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="From2018-08-01to2019-07-31_custom_VenetoMember" unitRef="USD" decimals="0">292681</us-gaap:PropertyPlantAndEquipmentDisposals>
    <GNBT:ImpairmentOfLonglivedAssets contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">11208</GNBT:ImpairmentOfLonglivedAssets>
    <GNBT:ImpairmentOfLonglivedAssets contextRef="From2018-08-01to2019-07-31_custom_GrainlandPharmaciesHoldingsMember" unitRef="USD" decimals="0">11208</GNBT:ImpairmentOfLonglivedAssets>
    <GNBT:AcquisitionInHds contextRef="AsOf2017-01-18" unitRef="Pure" decimals="INF">0.51</GNBT:AcquisitionInHds>
    <GNBT:SharesOfCommonStockObligatedToIssue contextRef="AsOf2017-01-18" unitRef="Shares" decimals="INF">4830000</GNBT:SharesOfCommonStockObligatedToIssue>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="AsOf2019-07-31_us-gaap_SeriesHPreferredStockMember" unitRef="Shares" decimals="INF">25200000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="AsOf2018-12-01_custom_BhSanfordMember" unitRef="Shares" decimals="INF">25200000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="AsOf2018-11-30_custom_SalvoMember" unitRef="Shares" decimals="INF">3354645</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="AsOf2018-11-30_custom_MoscatoMember" unitRef="Shares" decimals="INF">3276000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="AsOf2019-09-13_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">592683</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SharesIssued contextRef="AsOf2019-10-31" unitRef="Shares" decimals="INF">286377</us-gaap:SharesIssued>
    <GNBT:CommonStockPayableShares contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">1238517</GNBT:CommonStockPayableShares>
    <GNBT:CommonStockPayableShares contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">296793</GNBT:CommonStockPayableShares>
    <GNBT:CommonStockPayableAmount contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">1123188</GNBT:CommonStockPayableAmount>
    <GNBT:CommonStockPayableAmount contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">215793</GNBT:CommonStockPayableAmount>
    <GNBT:LoiTerms contextRef="From2019-01-01to2019-01-07_custom_RegentysMember">Pursuant to the Company&#8217;s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of October 31, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.</GNBT:LoiTerms>
    <GNBT:LoiTerms contextRef="From2019-01-01to2019-01-07_custom_OlaregenMember">Pursuant to the Company&#8217;s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock. In May 2019, the Company issued 4,000,000 shares of common stock and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. On August 16, 2019, the Company entered into a Share Exchange Agreement to purchase an additional 900,000 shares of common stock in Olaregen from other shareholders of Olaregen in exchange for 1,905,912 shares of Generex common stock and 476,478 shares of Antigen common stock. In September 2019, the Company converted all of the Series A Preferred Stock of Olaregen into common stock of Olaregen.</GNBT:LoiTerms>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-05-01to2019-05-31_custom_StockPurchaseAgreementMember_custom_OlaregenMember" unitRef="Shares" decimals="INF">4000000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-08-01to2019-08-31_custom_MedisourceMember" unitRef="Shares" decimals="INF">400000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-08-01to2019-08-31_custom_PantheonMember" unitRef="Shares" decimals="INF">560000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-07-30to2019-08-02_custom_PantheonMember" unitRef="Shares" decimals="INF">560000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-07-30to2019-08-02_us-gaap_SubsequentEventMember_custom_MediSourcePartnersMember" unitRef="Shares" decimals="INF">400000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">960000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <GNBT:NotesPayableForAcquisition contextRef="From2019-05-01to2019-05-31_custom_StockPurchaseAgreementMember_custom_OlaregenMember" unitRef="USD" decimals="0">2000000</GNBT:NotesPayableForAcquisition>
    <GNBT:NumberOfPreferredStock contextRef="From2019-05-01to2019-05-31_custom_StockPurchaseAgreementMember_custom_OlaregenMember" unitRef="Shares" decimals="INF">592682</GNBT:NumberOfPreferredStock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">1164190</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-07-01to2019-07-31" unitRef="Shares" decimals="INF">1920376</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-07-01to2019-07-31_custom_NotePayableMember" unitRef="Shares" decimals="INF">1065826</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-08-01to2019-08-19_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">46110</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-08-01to2019-08-12_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">30666</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-08-01to2019-08-08_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">384000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-08-01to2019-08-21_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">94373</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-09-02to2019-09-10_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">75737</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-09-02to2019-09-17_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">95130</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-09-02to2019-09-18_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">112941</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-11-02to2019-11-12_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">115344</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-11-02to2019-11-14_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">80110</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-11-02to2019-11-21_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">134865</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-11-03to2019-11-21_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">169543</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-11-02to2019-11-27_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">202635</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-11-03to2019-11-27_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">251859</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-11-02to2019-11-29_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">79214</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-12-02to2019-12-05_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">180682</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-12-03to2019-12-05_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">192494</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-11-03to2019-11-12_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">128561</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-12-02to2019-12-12_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">181007</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-12-03to2019-12-12_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">128561</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1953257</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">18406684</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">1736900</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-07-01to2019-07-31" unitRef="USD" decimals="0">4350571</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_custom_PrincipalMember" unitRef="USD" decimals="0">615000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-07-01to2019-07-31_custom_NotePayableMember_custom_PrincipalMember" unitRef="USD" decimals="0">1425000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-07-01to2019-07-31_custom_NotePayableMember_custom_AccruedInterestMember" unitRef="USD" decimals="0">76976</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-10-31_custom_NotePayableMember_custom_PrincipalMember" unitRef="USD" decimals="0">350000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-03to2019-10-31_custom_PrincipalMember" unitRef="USD" decimals="0">110000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-10-31_custom_PrincipalMember" unitRef="USD" decimals="0">615000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-08-19_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">60000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-08-19_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">3450</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-08-12_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">45000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-08-12_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">2500</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-08-08_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">649851</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-08-21_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-08-01to2019-08-21_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">5699</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-09-02to2019-09-10_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-09-02to2019-09-10_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">6361</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-09-02to2019-09-17_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">130000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-09-02to2019-09-17_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">8522</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-09-02to2019-09-18_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">150000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-09-02to2019-09-18_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">9699</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-12_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">80000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-12_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">4778</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-14_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">50000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-14_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">2712</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-21_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">80000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-21_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">4493</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-03to2019-11-21_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-03to2019-11-21_us-gaap_SubsequentEventMember_custom_AccruedInterestMember" unitRef="USD" decimals="0">6219</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-27_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-27_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">6384</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-03to2019-11-27_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">125000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-03to2019-11-27_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">7226</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-02to2019-11-29_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">50000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-02to2019-12-05_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">70000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-02to2019-12-05_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">4621</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-03to2019-12-05_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">75000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-03to2019-12-05_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">4500</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-03to2019-11-12_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">50000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-11-03to2019-11-12_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">3096</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-02to2019-12-12_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">75000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-02to2019-12-12_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">4756</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-03to2019-12-12_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">50000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-03to2019-12-12_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">3096</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1953</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">18404731</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">18406684</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:StockIssuedForConversionOfNotePayableShares contextRef="From2019-05-01to2019-07-31" unitRef="Shares" decimals="INF">30000</GNBT:StockIssuedForConversionOfNotePayableShares>
    <GNBT:StockIssuedForConversionOfNotePayableValue contextRef="From2019-05-01to2019-07-31" unitRef="USD" decimals="0">53000</GNBT:StockIssuedForConversionOfNotePayableValue>
    <GNBT:FairValue contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">69000</GNBT:FairValue>
    <us-gaap:BusinessAcquisitionSharePrice contextRef="AsOf2019-08-31_custom_MedisourceMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice contextRef="AsOf2019-08-31_custom_PantheonMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:BusinessAcquisitionSharePrice>
    <GNBT:CancellationOfCommonStock contextRef="From2019-09-02to2019-09-12" unitRef="Shares" decimals="INF">20375900</GNBT:CancellationOfCommonStock>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-10-31_custom_OlaregenMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <GNBT:NoncontrollingInterest contextRef="AsOf2019-10-31_custom_OlaregenMember" unitRef="Shares" decimals="INF">1461075</GNBT:NoncontrollingInterest>
    <GNBT:PercentageOfNoncontrollingInterest contextRef="AsOf2019-10-31_custom_OlaregenMember" unitRef="Pure" decimals="INF">0.2343</GNBT:PercentageOfNoncontrollingInterest>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">77782</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">74444</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">12075</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">285226</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">652819</us-gaap:InventoryFinishedGoods>
    <GNBT:PurchasePriceOfNote contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">400000</GNBT:PurchasePriceOfNote>
    <GNBT:PurchasePriceOfNote contextRef="AsOf2018-10-26" unitRef="USD" decimals="0">550000</GNBT:PurchasePriceOfNote>
    <GNBT:PurchasePriceOfNote contextRef="AsOf2019-08-31" unitRef="USD" decimals="0">1000000</GNBT:PurchasePriceOfNote>
    <GNBT:PurchasePriceOfNote contextRef="AsOf2018-11-25" unitRef="USD" decimals="0">1000000</GNBT:PurchasePriceOfNote>
    <GNBT:PurchasePriceOfNote contextRef="AsOf2019-01-24" unitRef="USD" decimals="0">505000</GNBT:PurchasePriceOfNote>
    <GNBT:PurchasePriceOfNote contextRef="AsOf2019-02-28" unitRef="USD" decimals="0">1425000</GNBT:PurchasePriceOfNote>
    <GNBT:PurchasePriceOfNote contextRef="AsOf2019-04-30" unitRef="USD" decimals="0">1000000</GNBT:PurchasePriceOfNote>
    <GNBT:PurchasePriceOfNote contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">1976745</GNBT:PurchasePriceOfNote>
    <GNBT:InvestorFee contextRef="AsOf2018-10-26" unitRef="USD" decimals="0">15000</GNBT:InvestorFee>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">46600</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2018-10-26" unitRef="USD" decimals="0">147000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2019-08-31" unitRef="USD" decimals="0">150000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2018-11-25" unitRef="USD" decimals="0">60000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2019-01-24" unitRef="USD" decimals="0">25000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2019-02-28" unitRef="USD" decimals="0">75000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2019-04-30" unitRef="USD" decimals="0">60000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2019-05-31" unitRef="USD" decimals="0">25000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">245755</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2018-10-26" unitRef="Pure" decimals="INF">0.275</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2017-12-28" unitRef="Pure" decimals="INF">0.03</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-07-01to2019-07-31" unitRef="Pure" decimals="INF">0.09</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-05-01to2019-05-31" unitRef="Pure" decimals="INF">0.07</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-01-01to2019-01-24" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-02-01to2019-02-28" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-04-01to2019-04-30" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-08-01to2019-09-30_srt_MinimumMember" unitRef="Pure" decimals="INF">0.09</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-08-01to2019-09-30_srt_MaximumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-08-01to2019-08-31" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-08-01to2019-08-14_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-08-01to2019-08-29_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember" unitRef="Pure" decimals="INF">0.09</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-11-02to2019-11-18_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2018-10-01to2018-10-26">2019-10-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2018-11-01to2018-11-25">2019-11-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-05-01to2019-05-31">2019-08-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2017-12-01to2017-12-28_custom_GrainlandPharmacyHoldingsMember">2018-06-28</us-gaap:DebtInstrumentMaturityDate>
    <GNBT:CommonStockIssuedInSatisfactionNotes contextRef="From2019-05-01to2019-05-31" unitRef="Shares" decimals="INF">400000</GNBT:CommonStockIssuedInSatisfactionNotes>
    <GNBT:NumberOfWarrantsSold contextRef="AsOf2019-01-24" unitRef="Shares" decimals="INF">30285</GNBT:NumberOfWarrantsSold>
    <GNBT:NumberOfWarrantsSold contextRef="AsOf2019-02-28" unitRef="Shares" decimals="INF">102143</GNBT:NumberOfWarrantsSold>
    <GNBT:NumberOfWarrantsSold contextRef="AsOf2019-04-30" unitRef="Shares" decimals="INF">176968</GNBT:NumberOfWarrantsSold>
    <GNBT:NumberOfWarrantsSold contextRef="AsOf2019-05-31" unitRef="Shares" decimals="INF">84126</GNBT:NumberOfWarrantsSold>
    <GNBT:NumberOfWarrantsSold contextRef="AsOf2019-08-14_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember" unitRef="Shares" decimals="INF">62857</GNBT:NumberOfWarrantsSold>
    <GNBT:PaymentOfPromissoryNote contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">320000</GNBT:PaymentOfPromissoryNote>
    <GNBT:PaymentOfPromissoryNote contextRef="From2018-08-01to2019-07-31_custom_RegentysMember" unitRef="USD" decimals="0">51625</GNBT:PaymentOfPromissoryNote>
    <GNBT:PaymentOfPromissoryNote contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">320000</GNBT:PaymentOfPromissoryNote>
    <GNBT:PaymentOfPromissoryNote contextRef="From2019-05-01to2019-05-22_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">4800000</GNBT:PaymentOfPromissoryNote>
    <GNBT:PaymentOfPromissoryNote contextRef="From2019-05-21to2019-05-22_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">4361500</GNBT:PaymentOfPromissoryNote>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2018-08-01to2019-07-31_custom_RegentysMember" unitRef="USD" decimals="0">24940</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2019-08-01to2019-10-31_custom_RegentysMember" unitRef="USD" decimals="0">39191</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">3008849</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">2065835</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">1938994</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">1473842</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-07-31_custom_RegentysMember307928251" unitRef="USD" decimals="0">3719</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-10-31_custom_RegentysMember106908249" unitRef="USD" decimals="0">3719</us-gaap:DebtInstrumentUnamortizedDiscount>
    <GNBT:NumberOfCommonStockConverted contextRef="From2018-08-01to2019-07-31_custom_RegentysMember" unitRef="Shares" decimals="INF">187500</GNBT:NumberOfCommonStockConverted>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">1040173</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">889782</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">889782</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-30320</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">859462</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">1040173</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-397513</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">642660</us-gaap:DeferredTaxLiabilities>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">950000</us-gaap:NotesPayableCurrent>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="From2019-08-01to2019-10-31_custom_NotePayableMember" unitRef="USD" decimals="0">900000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">59296530</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">64308679</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">-102273</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">1812190</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:IntangibleAssetsCurrent contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">2518572</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">2173419</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">61712829</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">68294288</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">61712829</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">68294288</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-08-01to2018-07-31" unitRef="Pure" decimals="INF">0.2650</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <GNBT:ChangeInFairValueOfPurchaseConsideration contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">-0.4020</GNBT:ChangeInFairValueOfPurchaseConsideration>
    <GNBT:ChangeInFairValueOfPurchaseConsideration contextRef="From2017-08-01to2018-07-31" unitRef="Pure" decimals="INF">0.2850</GNBT:ChangeInFairValueOfPurchaseConsideration>
    <GNBT:ExpirationOfNetOperatingLossCarryforward contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">0.0990</GNBT:ExpirationOfNetOperatingLossCarryforward>
    <GNBT:ExpirationOfNetOperatingLossCarryforward contextRef="From2017-08-01to2018-07-31" unitRef="Pure" decimals="INF">0.0000</GNBT:ExpirationOfNetOperatingLossCarryforward>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">0.0240</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2017-08-01to2018-07-31" unitRef="Pure" decimals="INF">0.0090</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="From2017-08-01to2018-07-31" unitRef="Pure" decimals="INF">-0.8870</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">0.4890</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2017-08-01to2018-07-31" unitRef="Pure" decimals="INF">0.8580</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-08-01to2018-07-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <GNBT:PretaxGainOrLossArisingFromDomesticOperations contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-11006793</GNBT:PretaxGainOrLossArisingFromDomesticOperations>
    <GNBT:PretaxGainOrLossArisingFromDomesticOperations contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">35948698</GNBT:PretaxGainOrLossArisingFromDomesticOperations>
    <GNBT:PretaxGainOrLossArisingFromDomesticOperations contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-9179902</GNBT:PretaxGainOrLossArisingFromDomesticOperations>
    <GNBT:PretaxGainOrLossArisingFromDomesticOperations contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-11006793</GNBT:PretaxGainOrLossArisingFromDomesticOperations>
    <GNBT:PretaxLossesArisingFromForeignOperations contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-326461</GNBT:PretaxLossesArisingFromForeignOperations>
    <GNBT:PretaxLossesArisingFromForeignOperations contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-150394</GNBT:PretaxLossesArisingFromForeignOperations>
    <GNBT:PretaxLossesArisingFromForeignOperations contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-10963</GNBT:PretaxLossesArisingFromForeignOperations>
    <GNBT:PretaxLossesArisingFromForeignOperations contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-326461</GNBT:PretaxLossesArisingFromForeignOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">196200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-07-31_custom_RegentysMember" unitRef="USD" decimals="0">6000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-10-31_custom_RegentysMember" unitRef="USD" decimals="0">6100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-07-31_custom_GenerexPharmaceuticalsMember" unitRef="USD" decimals="0">34400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-07-31_custom_AntigenExpressMember" unitRef="USD" decimals="0">36200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-07-31_custom_OlaregenMember" unitRef="USD" decimals="0">1100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-10-31_custom_GenerexPharmaceuticalsMember" unitRef="USD" decimals="0">214000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-10-31_custom_AntigenExpressMember" unitRef="USD" decimals="0">36200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-10-31_custom_OlaregenMember142468271" unitRef="USD" decimals="0">1300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:WeightedAverageBasicSharesOutstandingProForma contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">48360127</us-gaap:WeightedAverageBasicSharesOutstandingProForma>
    <us-gaap:WeightedAverageBasicSharesOutstandingProForma contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">1068100</us-gaap:WeightedAverageBasicSharesOutstandingProForma>
    <us-gaap:WeightedAverageBasicSharesOutstandingProForma contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">53186407</us-gaap:WeightedAverageBasicSharesOutstandingProForma>
    <us-gaap:WeightedAverageBasicSharesOutstandingProForma contextRef="From2018-08-01to2018-10-31" unitRef="Shares" decimals="INF">22806777</us-gaap:WeightedAverageBasicSharesOutstandingProForma>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">5157374</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">1523028</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="From2019-08-01to2019-10-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="From2018-08-01to2018-10-31" unitRef="Shares" decimals="INF">31892421</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">53517501</us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">2591129</us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">53186407</us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted contextRef="From2018-08-01to2018-10-31" unitRef="Shares" decimals="INF">54699198</us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">18230982</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">17850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">28021618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2018-10-31" unitRef="Shares" decimals="INF">34583850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-08-01to2019-10-31_custom_SeriesHConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-08-01to2019-10-31_custom_SeriesIConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-08-01to2019-10-31_custom_ConvertibleDebtsMember" unitRef="Shares" decimals="INF">3744548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-08-01to2019-10-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">8871675</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-08-01to2019-10-31_custom_WarrantsMember" unitRef="Shares" decimals="INF">15405395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2018-10-31_custom_SeriesHConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">25200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2018-10-31_custom_SeriesIConvertiblePreferredStockMember" unitRef="Shares" decimals="INF">6636000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2018-10-31_custom_ConvertibleDebtsMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2018-10-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">2747850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2018-10-31_custom_WarrantsMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2019-07-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">2831301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-08-01to2019-07-31_custom_WarrantsMember" unitRef="Shares" decimals="INF">15399681</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-08-01to2018-07-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">17850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-08-01to2018-07-31_custom_WarrantsMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">3239031</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">10153701</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">11276301</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-10-31_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="USD" decimals="0">8761427</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-10-31_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">1566700</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-10-31_us-gaap_SoftwareDevelopmentMember" unitRef="USD" decimals="0">172500</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-10-31_custom_VendorAgreementsAndOtherIntangibleMember" unitRef="USD" decimals="0">775674</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-07-31_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="USD" decimals="0">8761427</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-07-31_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">1210000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-07-31_us-gaap_SoftwareDevelopmentMember" unitRef="USD" decimals="0">131000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-07-31_custom_VendorAgreementsAndOtherIntangibleMember" unitRef="USD" decimals="0">51274</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-07-31_us-gaap_OtherIntangibleAssetsMember" unitRef="USD" decimals="0">51274</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2018-07-31_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="USD" decimals="0">2911377</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2018-07-31_us-gaap_NoncompeteAgreementsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2018-07-31_us-gaap_SoftwareDevelopmentMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2018-07-31_us-gaap_OtherIntangibleAssetsMember" unitRef="USD" decimals="0">327654</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">-27994</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">-319432</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">-473859</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">97553</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">434117</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">570708</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">434118</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">616744</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">164895</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">246324</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">30787</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">94511</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">11138</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">68491</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">7898</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">444658</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">1082952</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">2041435</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2017-12-28" unitRef="USD" decimals="0">276380</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-01-31_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-01-31_custom_FinalAllocationMember" unitRef="USD" decimals="0">276380</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">35603</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">7110000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">7145603</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">35603</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">811000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">846603</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">255835</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">2571</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">154426</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">646</us-gaap:AmortizationOfIntangibleAssets>
    <GNBT:StockPriceAtClosing contextRef="From2016-08-01to2017-01-18_custom_AtClosingMember" unitRef="USDPShares" decimals="INF">0.23</GNBT:StockPriceAtClosing>
    <GNBT:StockPriceAtClosing contextRef="From2016-08-01to2017-01-18_custom_AfterMember" unitRef="USDPShares" decimals="INF">0.23</GNBT:StockPriceAtClosing>
    <GNBT:StockPriceAtClosing contextRef="From2016-08-01to2017-01-18_custom_PostReverseStockSplitMember" unitRef="USDPShares" decimals="INF">0.23</GNBT:StockPriceAtClosing>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="From2016-08-01to2017-01-18_custom_AtClosingMember" unitRef="USD" decimals="0">253721</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="From2016-08-01to2017-01-18_custom_AfterMember" unitRef="USD" decimals="0">95</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="From2016-08-01to2017-01-18_custom_PostReverseStockSplitMember" unitRef="USD" decimals="0">1097100</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="From2016-08-01to2017-01-18_custom_NetPurchasePriceMember" unitRef="USD" decimals="0">1350916</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-01_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-07-31_us-gaap_WarrantMember948760875" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2019-07-31_srt_MinimumMember" unitRef="USDPShares" decimals="INF">0.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2019-07-31_srt_MaximumMember" unitRef="USDPShares" decimals="INF">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2019-10-31_srt_MinimumMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2019-10-31_srt_MaximumMember" unitRef="USDPShares" decimals="INF">2.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2019-08-01to2019-10-31">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2018-11-29to2018-12-01_us-gaap_WarrantMember">P3Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2017-08-01to2018-07-31_us-gaap_WarrantMember">P3Y5M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2018-08-01to2019-07-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2018-08-01to2019-07-31_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-11-29to2018-12-01_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.0301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-08-01to2018-07-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.0277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-11-29to2018-12-01_us-gaap_CallOptionMember" unitRef="Pure" decimals="INF">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-08-01to2018-07-31_us-gaap_CallOptionMember" unitRef="Pure" decimals="INF">0.0244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-08-01to2019-07-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.0203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-08-01to2019-07-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.0315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-08-01to2019-10-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.0151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-08-01to2019-10-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-08-01to2019-10-31" unitRef="Pure" decimals="INF">1.534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-11-29to2018-12-01_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">1.3861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-08-01to2018-07-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">1.4397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-11-29to2018-12-01_us-gaap_CallOptionMember" unitRef="Pure" decimals="INF">1.6443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-08-01to2018-07-31_us-gaap_CallOptionMember" unitRef="Pure" decimals="INF">1.2995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-08-01to2019-07-31_srt_MinimumMember" unitRef="Pure" decimals="INF">1.352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-08-01to2019-07-31_srt_MaximumMember" unitRef="Pure" decimals="INF">2.222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-08-01to2019-07-31" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-08-01to2019-10-31" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-11-29to2018-12-01_us-gaap_WarrantMember" unitRef="Pure" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-08-01to2018-07-31_us-gaap_WarrantMember" unitRef="Pure" xsi:nil="true" />
    <us-gaap:SharePrice contextRef="AsOf2018-12-01_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.9</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-07-31_us-gaap_WarrantMember948760875" unitRef="USDPShares" decimals="INF">0.1</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-12-01_us-gaap_CallOptionMember" unitRef="USDPShares" decimals="INF">0.9043</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-07-31_us-gaap_CallOptionMember" unitRef="USDPShares" decimals="INF">0.0976</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-07-31_srt_MinimumMember" unitRef="USDPShares" decimals="INF">0.11</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-07-31_srt_MaximumMember" unitRef="USDPShares" decimals="INF">1.85</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-10-31_srt_MinimumMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-10-31_srt_MaximumMember" unitRef="USDPShares" decimals="INF">2.09</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2018-11-29to2018-12-01_us-gaap_CallOptionMember">P1Y1M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2017-08-01to2018-07-31_us-gaap_CallOptionMember">P1Y5M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <GNBT:PropertyAndEquipmentAcquisition contextRef="AsOf2017-12-28" unitRef="USD" decimals="0">19879</GNBT:PropertyAndEquipmentAcquisition>
    <GNBT:PropertyAndEquipmentAcquisition contextRef="AsOf2019-01-31_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</GNBT:PropertyAndEquipmentAcquisition>
    <GNBT:PropertyAndEquipmentAcquisition contextRef="AsOf2019-01-31_custom_FinalAllocationMember" unitRef="USD" decimals="0">19879</GNBT:PropertyAndEquipmentAcquisition>
    <GNBT:ComputerSoftwareAcquisition contextRef="AsOf2017-12-28" unitRef="USD" decimals="0">5980</GNBT:ComputerSoftwareAcquisition>
    <GNBT:ComputerSoftwareAcquisition contextRef="AsOf2019-01-31_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</GNBT:ComputerSoftwareAcquisition>
    <GNBT:ComputerSoftwareAcquisition contextRef="AsOf2019-01-31_custom_FinalAllocationMember" unitRef="USD" decimals="0">5980</GNBT:ComputerSoftwareAcquisition>
    <GNBT:LeaseholdImprovementsAcquisition contextRef="AsOf2017-12-28" unitRef="USD" decimals="0">17761</GNBT:LeaseholdImprovementsAcquisition>
    <GNBT:LeaseholdImprovementsAcquisition contextRef="AsOf2019-01-31_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</GNBT:LeaseholdImprovementsAcquisition>
    <GNBT:LeaseholdImprovementsAcquisition contextRef="AsOf2019-01-31_custom_FinalAllocationMember" unitRef="USD" decimals="0">17761</GNBT:LeaseholdImprovementsAcquisition>
    <us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized contextRef="AsOf2017-12-28" unitRef="USD" decimals="0">320000</us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized contextRef="AsOf2019-01-31_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized contextRef="AsOf2019-01-31_custom_FinalAllocationMember" unitRef="USD" decimals="0">320000</us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="AsOf2017-12-28" unitRef="USD" decimals="0">320000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="AsOf2019-01-31_custom_FinalAllocationMember" unitRef="USD" decimals="0">320000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">95804</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">95804</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">95804</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">95804</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">3336</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">20488</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">20488</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivables contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">1014316</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherReceivables contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">1014316</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">1014316</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherReceivables contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">1014316</us-gaap:OtherReceivables>
    <us-gaap:NotesReceivableNet contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">1387763</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesReceivableNet contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">1387763</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">1387763</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesReceivableNet contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">1387763</us-gaap:NotesReceivableNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">8625905</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">7110000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">15735905</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">8181465</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">811000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">8992465</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">2509887</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">3403948</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">5913835</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">2065448</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">3403948</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">5469396</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">6116018</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">3706052</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">9822070</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">6116017</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">-2592948</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">3523069</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">522312</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">1040170</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">1259447</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-751613</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">907833</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">3844925</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-1383485</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">2461440</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="AsOf2018-10-03_custom_VenetoFirstClosingMember" unitRef="USD" decimals="0">15000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="AsOf2018-11-02_custom_VenetoSecondClosingMember" unitRef="USD" decimals="0">20000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="AsOf2019-07-31_custom_TotalMember107864546" unitRef="USD" decimals="0">35000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="AsOf2019-07-31_custom_VenetoFirstClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="AsOf2019-07-31_custom_VenetoSecondClosingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="AsOf2019-07-31_custom_Total1Member" unitRef="USD" decimals="0">18574838</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">993938</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <GNBT:NetTangibleAssets contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">3312</GNBT:NetTangibleAssets>
    <GNBT:NetTangibleAssets contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">436570</GNBT:NetTangibleAssets>
    <GNBT:TradenameTrademarks contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">47600</GNBT:TradenameTrademarks>
    <GNBT:TradenameTrademarks contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">55400</GNBT:TradenameTrademarks>
    <GNBT:BusinessContracts contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">346800</GNBT:BusinessContracts>
    <GNBT:Noncompetes contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">124600</GNBT:Noncompetes>
    <GNBT:FairValueOfCommonStock contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">479980</GNBT:FairValueOfCommonStock>
    <GNBT:FairValueOfCommonStock contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">671972</GNBT:FairValueOfCommonStock>
    <GNBT:ContingentConsideration contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">409790</GNBT:ContingentConsideration>
    <GNBT:ContingentConsideration contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">354292</GNBT:ContingentConsideration>
    <GNBT:ConsiderationIncludedInConsultingAgreement contextRef="AsOf2019-08-02_custom_MedisourceMember" unitRef="USD" decimals="0">104168</GNBT:ConsiderationIncludedInConsultingAgreement>
    <GNBT:ConsiderationIncludedInConsultingAgreement contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">145833</GNBT:ConsiderationIncludedInConsultingAgreement>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">53242</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">216670</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">216670</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">15573</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">216694</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">216694</us-gaap:AccruedLiabilitiesCurrent>
    <GNBT:IpTechnology contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">41500</GNBT:IpTechnology>
    <GNBT:NoncompeteAgreement contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">232100</GNBT:NoncompeteAgreement>
    <GNBT:NoncompeteAgreement contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">790000</GNBT:NoncompeteAgreement>
    <GNBT:NoncompeteAgreement contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-260000</GNBT:NoncompeteAgreement>
    <GNBT:NoncompeteAgreement contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">530000</GNBT:NoncompeteAgreement>
    <GNBT:CustomerBase contextRef="AsOf2019-08-02_custom_PantheonMember" unitRef="USD" decimals="0">274600</GNBT:CustomerBase>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-10-03_custom_PreliminaryFairValueMember_us-gaap_SoftwareDevelopmentMember" unitRef="USD" decimals="0">131000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-10-03_custom_PreliminaryFairValueMember_custom_ReferralBaseMember" unitRef="USD" decimals="0">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-10-03_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">680000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-10-03_custom_PreliminaryFairValueMember" unitRef="USD" decimals="0">811000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-07-31_custom_PreliminaryFairValueMember_us-gaap_SoftwareDevelopmentMember" unitRef="USD" decimals="0">397000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-07-31_custom_PreliminaryFairValueMember_custom_ReferralBaseMember" unitRef="USD" decimals="0">10000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-07-31_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">1870000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-07-31_custom_PreliminaryFairValueMember" unitRef="USD" decimals="0">2277000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-08-02_custom_PreliminaryFairValueMember_custom_TradenameTrademarksMember" unitRef="USD" decimals="0">103000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-08-02_custom_PreliminaryFairValueMember_custom_IpTechnologyMember" unitRef="USD" decimals="0">41500</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-08-02_custom_PreliminaryFairValueMember_custom_BusinessContractsMember" unitRef="USD" decimals="0">346800</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-08-02_custom_PreliminaryFairValueMember_custom_CustomerBaseMember" unitRef="USD" decimals="0">274600</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-08-02_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">356700</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2019-08-02_custom_PreliminaryFairValueMember" unitRef="USD" decimals="0">1112600</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2018-11-27_custom_OlaregenMember_us-gaap_SoftwareDevelopmentMember" unitRef="USD" decimals="0">3980000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2018-11-27_custom_OlaregenMember_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">790000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="AsOf2018-11-27_custom_RegentysMember_custom_OlaregenMember" unitRef="USD" decimals="0">4770000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-10-02to2019-10-03_custom_PreliminaryFairValueMember_us-gaap_SoftwareDevelopmentMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-10-02to2019-10-03_custom_PreliminaryFairValueMember_custom_ReferralBaseMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-10-02to2019-10-03_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2018-08-01to2019-07-31_custom_PreliminaryFairValueMember_us-gaap_SoftwareDevelopmentMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2018-08-01to2019-07-31_custom_PreliminaryFairValueMember_custom_ReferralBaseMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2018-08-01to2019-07-31_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_custom_TradenameTrademarksMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_custom_IpTechnologyMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_custom_BusinessContractsMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_custom_CustomerBaseMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-07-29to2019-08-02_custom_PreliminaryFairValueMember_us-gaap_NoncompeteAgreementsMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-11-01to2019-11-27_custom_OlaregenMember_us-gaap_NoncompeteAgreementsMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">16506</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">399999</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">416505</us-gaap:DueFromRelatedPartiesCurrent>
    <GNBT:InprocessResearchDevelopment contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">3510680</GNBT:InprocessResearchDevelopment>
    <GNBT:InprocessResearchDevelopment contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-119630</GNBT:InprocessResearchDevelopment>
    <GNBT:InprocessResearchDevelopment contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">3391050</GNBT:InprocessResearchDevelopment>
    <GNBT:InprocessResearchDevelopment contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">3980000</GNBT:InprocessResearchDevelopment>
    <GNBT:InprocessResearchDevelopment contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-1521000</GNBT:InprocessResearchDevelopment>
    <GNBT:InprocessResearchDevelopment contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">2459000</GNBT:InprocessResearchDevelopment>
    <GNBT:NoteReceivableFromGenerexs contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">14345205</GNBT:NoteReceivableFromGenerexs>
    <GNBT:NoteReceivableFromGenerexs contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-2791</GNBT:NoteReceivableFromGenerexs>
    <GNBT:NoteReceivableFromGenerexs contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">14345414</GNBT:NoteReceivableFromGenerexs>
    <GNBT:NoteReceivableFromGenerexs contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">11472663</GNBT:NoteReceivableFromGenerexs>
    <GNBT:NoteReceivableFromGenerexs contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</GNBT:NoteReceivableFromGenerexs>
    <GNBT:NoteReceivableFromGenerexs contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">11472663</GNBT:NoteReceivableFromGenerexs>
    <GNBT:CashPaidPriorToTimeOfClosings contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">0</GNBT:CashPaidPriorToTimeOfClosings>
    <GNBT:CashPaidPriorToTimeOfClosings contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">400000</GNBT:CashPaidPriorToTimeOfClosings>
    <GNBT:CashPaidPriorToTimeOfClosings contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">400000</GNBT:CashPaidPriorToTimeOfClosings>
    <GNBT:CashPaidPriorToTimeOfClosings contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">0</GNBT:CashPaidPriorToTimeOfClosings>
    <GNBT:CashPaidPriorToTimeOfClosings contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">400000</GNBT:CashPaidPriorToTimeOfClosings>
    <GNBT:CashPaidPriorToTimeOfClosings contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">400000</GNBT:CashPaidPriorToTimeOfClosings>
    <GNBT:CashPaidPriorToTimeOfClosing contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">400000</GNBT:CashPaidPriorToTimeOfClosing>
    <GNBT:CashPaidPriorToTimeOfClosing contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</GNBT:CashPaidPriorToTimeOfClosing>
    <GNBT:CashPaidPriorToTimeOfClosing contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">400000</GNBT:CashPaidPriorToTimeOfClosing>
    <GNBT:CashPaidPriorToTimeOfClosing contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">400000</GNBT:CashPaidPriorToTimeOfClosing>
    <GNBT:CashPaidPriorToTimeOfClosing contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</GNBT:CashPaidPriorToTimeOfClosing>
    <GNBT:CashPaidPriorToTimeOfClosing contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">400000</GNBT:CashPaidPriorToTimeOfClosing>
    <GNBT:NoteReceivableFromGenerex contextRef="AsOf2019-01-07" unitRef="USD" decimals="0">14345205</GNBT:NoteReceivableFromGenerex>
    <GNBT:NoteReceivableFromGenerex contextRef="AsOf2019-01-07_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">-2791</GNBT:NoteReceivableFromGenerex>
    <GNBT:NoteReceivableFromGenerex contextRef="AsOf2019-01-07_custom_RevisedAllocationMember" unitRef="USD" decimals="0">14342414</GNBT:NoteReceivableFromGenerex>
    <GNBT:NoteReceivableFromGenerex contextRef="AsOf2018-11-27_custom_PreliminaryAllocationsMember" unitRef="USD" decimals="0">11472663</GNBT:NoteReceivableFromGenerex>
    <GNBT:NoteReceivableFromGenerex contextRef="AsOf2018-11-27_custom_AllocationAdjustmentsMember" unitRef="USD" decimals="0">0</GNBT:NoteReceivableFromGenerex>
    <GNBT:NoteReceivableFromGenerex contextRef="AsOf2018-11-27_custom_RevisedAllocationMember" unitRef="USD" decimals="0">11472664</GNBT:NoteReceivableFromGenerex>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">11217169</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">57137821</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">721661</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">2141000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <GNBT:BusinessAcquisitionsProFormaCostOfRevenues contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">4143586</GNBT:BusinessAcquisitionsProFormaCostOfRevenues>
    <GNBT:BusinessAcquisitionsProFormaCostOfRevenues contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">19236850</GNBT:BusinessAcquisitionsProFormaCostOfRevenues>
    <GNBT:BusinessAcquisitionsProFormaCostOfRevenues contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">133618</GNBT:BusinessAcquisitionsProFormaCostOfRevenues>
    <GNBT:BusinessAcquisitionsProFormaCostOfRevenues contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">987409</GNBT:BusinessAcquisitionsProFormaCostOfRevenues>
    <GNBT:BusinessAcquisitionsProFormaGrossProfit contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">7073583</GNBT:BusinessAcquisitionsProFormaGrossProfit>
    <GNBT:BusinessAcquisitionsProFormaGrossProfit contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">37900971</GNBT:BusinessAcquisitionsProFormaGrossProfit>
    <GNBT:BusinessAcquisitionsProFormaGrossProfit contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">588043</GNBT:BusinessAcquisitionsProFormaGrossProfit>
    <GNBT:BusinessAcquisitionsProFormaGrossProfit contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">1153591</GNBT:BusinessAcquisitionsProFormaGrossProfit>
    <GNBT:BusinessAcquisitionsProFormaOperatingExpenses contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">13338328</GNBT:BusinessAcquisitionsProFormaOperatingExpenses>
    <GNBT:BusinessAcquisitionsProFormaOperatingExpenses contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">45146085</GNBT:BusinessAcquisitionsProFormaOperatingExpenses>
    <GNBT:BusinessAcquisitionsProFormaOperatingExpenses contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">5136754</GNBT:BusinessAcquisitionsProFormaOperatingExpenses>
    <GNBT:BusinessAcquisitionsProFormaOperatingExpenses contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">2629854</GNBT:BusinessAcquisitionsProFormaOperatingExpenses>
    <GNBT:BusinessAcquisitionsProFormaOperatingLoss contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-6264744</GNBT:BusinessAcquisitionsProFormaOperatingLoss>
    <GNBT:BusinessAcquisitionsProFormaOperatingLoss contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-7245114</GNBT:BusinessAcquisitionsProFormaOperatingLoss>
    <GNBT:BusinessAcquisitionsProFormaOperatingLoss contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-4548711</GNBT:BusinessAcquisitionsProFormaOperatingLoss>
    <GNBT:BusinessAcquisitionsProFormaOperatingLoss contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">-1476262</GNBT:BusinessAcquisitionsProFormaOperatingLoss>
    <GNBT:BusinessAcquisitionsProFormaOtherIncomeExpense contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">1469732</GNBT:BusinessAcquisitionsProFormaOtherIncomeExpense>
    <GNBT:BusinessAcquisitionsProFormaOtherIncomeExpense contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">523226</GNBT:BusinessAcquisitionsProFormaOtherIncomeExpense>
    <GNBT:BusinessAcquisitionsProFormaOtherIncomeExpense contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-4763836</GNBT:BusinessAcquisitionsProFormaOtherIncomeExpense>
    <GNBT:BusinessAcquisitionsProFormaOtherIncomeExpense contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">19389944</GNBT:BusinessAcquisitionsProFormaOtherIncomeExpense>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-4795012</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-6721888</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-9312547</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">17913682</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <GNBT:NetLossAttributableToNoncontrollingInterests contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-1606316</GNBT:NetLossAttributableToNoncontrollingInterests>
    <GNBT:NetLossAttributableToNoncontrollingInterests contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-230222</GNBT:NetLossAttributableToNoncontrollingInterests>
    <GNBT:NetLossAvailableToCommonStockholders contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-3188696</GNBT:NetLossAvailableToCommonStockholders>
    <GNBT:NetLossAvailableToCommonStockholders contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-6491666</GNBT:NetLossAvailableToCommonStockholders>
    <GNBT:BusinessAcquisitionsProFormaComprehensiveNetLoss contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-3188696</GNBT:BusinessAcquisitionsProFormaComprehensiveNetLoss>
    <GNBT:BusinessAcquisitionsProFormaComprehensiveNetLoss contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">-6491666</GNBT:BusinessAcquisitionsProFormaComprehensiveNetLoss>
    <GNBT:BusinessAcquisitionsProFormaComprehensiveNetLoss contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-9312547</GNBT:BusinessAcquisitionsProFormaComprehensiveNetLoss>
    <GNBT:BusinessAcquisitionsProFormaComprehensiveNetLoss contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">17913682</GNBT:BusinessAcquisitionsProFormaComprehensiveNetLoss>
    <GNBT:BasicAndDilutedNetLossPerCommonShare contextRef="From2018-08-01to2019-07-31" unitRef="USDPShares" decimals="INF">-0.05</GNBT:BasicAndDilutedNetLossPerCommonShare>
    <GNBT:BasicAndDilutedNetLossPerCommonShare contextRef="From2017-08-01to2018-07-31" unitRef="USDPShares" decimals="INF">-0.29</GNBT:BasicAndDilutedNetLossPerCommonShare>
    <us-gaap:NoncashOrPartNoncashAcquisitionInterestAcquired1 contextRef="From2018-11-01to2018-11-28_custom_RegentysMember" unitRef="Pure" decimals="INF">0.51</us-gaap:NoncashOrPartNoncashAcquisitionInterestAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionInterestAcquired1 contextRef="From2016-08-01to2017-01-18" unitRef="Pure" decimals="INF">0.51</us-gaap:NoncashOrPartNoncashAcquisitionInterestAcquired1>
    <GNBT:AcquisitionOfOutstandingLimitedLiabilityCompanyUnits contextRef="AsOf2017-01-18" unitRef="Shares" decimals="INF">4950</GNBT:AcquisitionOfOutstandingLimitedLiabilityCompanyUnits>
    <GNBT:ValueOfSharesExchangedForOutstandingLimitedLiabilityUnits contextRef="AsOf2017-01-18" unitRef="USD" decimals="0">253721</GNBT:ValueOfSharesExchangedForOutstandingLimitedLiabilityUnits>
    <us-gaap:CommonUnitIssued contextRef="AsOf2017-01-18" unitRef="Shares" decimals="INF">300</us-gaap:CommonUnitIssued>
    <GNBT:CallOption contextRef="From2016-08-01to2017-01-18" unitRef="USD" decimals="0">13431706</GNBT:CallOption>
    <GNBT:ChangesInFairValueOfContingentPurchaseConsiderations contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">15147591</GNBT:ChangesInFairValueOfContingentPurchaseConsiderations>
    <us-gaap:TemporaryEquitySharesIssued contextRef="AsOf2017-01-18" unitRef="Shares" decimals="INF">15000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-07-31" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2019-07-31" unitRef="USDPShares" decimals="INF">2.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-07-31" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2019-10-31" unitRef="USDPShares" decimals="INF">2.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-01-18" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-01_custom_BerkmanMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="From2016-08-01to2017-01-18" unitRef="USD" decimals="0">1350916</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationAsset contextRef="AsOf2017-01-18" unitRef="USD" decimals="0">2911377</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <GNBT:AggregatePurchasePrice contextRef="From2016-08-01to2017-01-18" unitRef="USD" decimals="0">1</GNBT:AggregatePurchasePrice>
    <GNBT:SharesExercisable contextRef="AsOf2018-12-01_custom_BerkmanMember" unitRef="Shares" decimals="INF">15000000</GNBT:SharesExercisable>
    <us-gaap:DebtInstrumentFairValue contextRef="AsOf2017-12-28" unitRef="USD" decimals="0">320000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:GoodwillImpairmentLoss contextRef="From2017-12-01to2017-12-28_custom_GrainlandPharmacyHoldingsMember" unitRef="USD" decimals="0">99519</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="From2017-12-01to2017-12-28_custom_EmpireStatePharmacyHoldingsMember" unitRef="USD" decimals="0">188068</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription contextRef="From2018-11-01to2018-11-02">On November 1, 2018 we consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto&amp;#8217;s management services organization business and two additional ancillary services. The aggregate price for the First Closing Assets and the Second Closing Assets was $30,000,000. The Company issued a promissory note in the principal amount of $35,000,000 (the &amp;#8220;New Note&amp;#8221;) consisting of the $30,000,000 purchase price and a $5,000,000 original issue discount, as the sole consideration payable on the Second Closing Date. In addition, we agreed to assume approximately $3.8 million in outstanding institutional debt of Veneto subsidiaries, but will have use of Veneto cash which would otherwise have been applied to paying down the debt.</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription contextRef="From2018-10-01to2018-10-03_custom_VenetoMember">The aggregate purchase price for the Assets is $35,000,000 including the Promissory Note. At the Second Closing, the Company will pay the principal of the Promissory Note plus interest to Veneto, (i) $9,000,000 will be paid by the Company into a trust or other fiduciary account acceptable to Veneto to be used exclusively for satisfaction of certain contingent liabilities of Veneto and subsidiaries of Veneto not being acquired by the Company, (ii) $3,000,000 will be paid by the Company into an escrow account to secure potential obligations of Veneto in respect of the Second Closing date working capital and under the indemnification provisions of the Agreement and (iii) the balance will be payable directly to Veneto in cash.</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription contextRef="From2018-11-01to2018-11-27_custom_OlaregenMember">The Company acquired 3,282,632 newly issued shares of the Olaregen common stock representing 51% percent of the issued and outstanding capital stock of Olaregen (&#8220;Olaregen Shares&#8221;).</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription contextRef="From2018-11-01to2018-11-28_custom_RegentysMember">Pursuant to a Stock Purchase Agreement between the Company and Regentys (the &#8220;Purchase Agreement&#8221;) the Company acquired 12,048,161 newly issued shares of the Regentys common stock representing 51% percent of the issued and outstanding capital stock of Regentys (&#8220;Regentys Shares&#8221;).  In addition to $400,000 paid to Regentys upon signing of the LOI, the purchase price for the Regentys Shares will consist of the following cash payments, with the proceeds intended to be used for specific purposes, as noted:  &#8226;   $3,450,000 to initiate pre-clinical activities on or before January 15, 2019. As of the date this report was filed, the Company has paid $650,000 and the remaining balance of $2,800,000 is payable on or before November 30, 2019 per extension in amended agreement.   &#8226;   $2,000,000 to initiate patient recruitment activities on or before May 1, 2019. As of the date this report was filed, the Company has not yet paid this installment and the full balance of $2,000,000 is payable on or before November 30, 2019 per extension in amended agreement.   &#8226;   $3,000,000 to initiate a first-in-human pilot study on or before September 1, 2019.   &#8226;   $5,000,000 to initiate a human pivotal study on or before February 1, 2020.   &#8226;   $1,150,000 to submit a 510(k) de novo submission to the FDA on or about February 1, 2021.  The Company issued its Promissory Note in the amount of $14,600,000 (the &#8220;Note&#8217;) representing its obligation to pay the above amounts. The Note is secured by a pledge of the Regentys shares pursuant to a Pledge and Security Agreement. In the event that Generex does not make any of the first three payments listed above, at Regentys&#8217; option either:  &#8226;   Generex will forfeit all of the Regentys shares issued with no refund of amounts paid; or   &#8226;   Generex will issue shares of its common stock to Regentys equivalent to 110% of the value of the missing payment, which shares will be registered for resale.</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription contextRef="From2019-07-29to2019-08-02">Under the APAs:       &#8226; Generex will issue 400,000 shares of common stock in exchange for the Pantheon assets, and 560,000 shares of common stock in exchange for the MediSource assets.       &#8226; Generex and NDS will pay up to $700,000 in cash to Pantheon as an earn out payment. No payment will be made unless the business conducted by NDS using the former Pantheon assets has EBITDA in the twelve months following closing in excess of $500,000. If the Pantheon business&#8217;s EBITDA meets or exceeds $1,000,000, the entire $700,000 will be paid. If the Pantheon business&#8217;s EBITDA exceeds $500,000 but is less than $1,000,000, a pro rata portion of the $700,000 earn-out will be paid.       &#8226; Generex and NDS will pay up to $500,000 in cash to MediSource as an earn out payment. No payment will be made unless the business conducted by NDS using the former MediSource assets has EBITDA in the twelve months following closing in excess of $130,000. If the MediSource business&#8217;s EBITDA meets or exceeds $500,000, the entire $500,000 will be paid. If the MediSource business&#8217;s EBITDA exceeds $130,000 but is less than $500,000, a pro rata portion of the $500,000 earn-out will be paid.</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription>
    <GNBT:LoiDescription contextRef="From2018-11-01to2018-11-27_custom_OlaregenMember">On November 27, 2018, Generex and Olaregen entered into a binding letter of intent (&#8220;LOI&#8221;) contemplating the Company&#8217;s acquisition of 51% of the outstanding capital stock of Olaregen for a total consideration of twelve million dollars ($12,000,000).  As of January 7, 2019, the Company completed a definitive Stock Purchase Agreement (&#8220;Purchase Agreement&#8221;) and related documents effecting the transactions contemplated by the LOI.</GNBT:LoiDescription>
    <GNBT:LoiDescription contextRef="From2018-11-01to2018-11-28_custom_RegentysMember">On November 28, 2018, Generex and Regentys entered into a binding letter of intent (&#8220;LOI&#8221;) contemplating the Company&#8217;s acquisition of 51% of the outstanding capital stock of Regentys for a total consideration of $15,000,000. On January 7, 2019 the Company completed a definitive Stock Purchase Agreement and related documents effecting the transactions contemplated by the LOI.</GNBT:LoiDescription>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">206548</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">1052349</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">7820282</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2017-07-31" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">8797354</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-07-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">4156196</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-10-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">2171983</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-07-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">325250</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-10-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">252715</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-07-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">3338836</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-10-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">6372656</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2018-07-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2018-07-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2018-07-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2017-07-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2017-07-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2017-07-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">11956043</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">1052349</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">1021996</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">30353</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">5178241</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">353464</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">6424338</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <GNBT:ChangeDueToExerciseRedemptions contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-2010312</GNBT:ChangeDueToExerciseRedemptions>
    <GNBT:ChangeDueToExerciseRedemptions contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-1911484</GNBT:ChangeDueToExerciseRedemptions>
    <GNBT:ChangeDueToExerciseRedemptions contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">-1875052</GNBT:ChangeDueToExerciseRedemptions>
    <GNBT:ChangeDueToExerciseRedemptions contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">-36432</GNBT:ChangeDueToExerciseRedemptions>
    <GNBT:ChangeDueToExerciseRedemptions contextRef="From2019-08-01to2019-10-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">0</GNBT:ChangeDueToExerciseRedemptions>
    <GNBT:ChangeDueToExerciseRedemptions contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityConvertibleNotesMember" unitRef="USD" decimals="0">-2010312</GNBT:ChangeDueToExerciseRedemptions>
    <GNBT:ChangeDueToExerciseRedemptions contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">0</GNBT:ChangeDueToExerciseRedemptions>
    <GNBT:ChangeDueToExerciseRedemptions contextRef="From2018-08-01to2019-07-31_custom_DerivativeLiabilityDownsideProtectionMember" unitRef="USD" decimals="0">0</GNBT:ChangeDueToExerciseRedemptions>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-07-31" unitRef="Shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2019-07-31" unitRef="Shares" decimals="INF">15399681</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2017-07-31" unitRef="Shares" decimals="INF">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2019-10-31" unitRef="Shares" decimals="INF">15405395</us-gaap:ClassOfWarrantOrRightOutstanding>
    <GNBT:NumberOfWarrantsIssued contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">15399681</GNBT:NumberOfWarrantsIssued>
    <GNBT:NumberOfWarrantsIssued contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">0</GNBT:NumberOfWarrantsIssued>
    <GNBT:NumberOfWarrantsIssued contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">62857</GNBT:NumberOfWarrantsIssued>
    <GNBT:NumberOfWarrantsIssued contextRef="From2019-08-01to2019-10-31_custom_InvestorsMember" unitRef="Shares" decimals="INF">62857</GNBT:NumberOfWarrantsIssued>
    <GNBT:NumberOfWarrantsIssued contextRef="From2019-08-01to2019-10-31_custom_AEXGMember" unitRef="Shares" decimals="INF">84000</GNBT:NumberOfWarrantsIssued>
    <GNBT:NumberOfWarrantsIssued contextRef="From2018-08-01to2019-07-31_custom_InvestorsMember" unitRef="Shares" decimals="INF">399681</GNBT:NumberOfWarrantsIssued>
    <GNBT:NumberOfWarrantsIssued contextRef="From2018-08-01to2019-07-31_custom_FormershareholderMember" unitRef="Shares" decimals="INF">15000000</GNBT:NumberOfWarrantsIssued>
    <GNBT:NumberOfWarrantsForfeited contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">-57143</GNBT:NumberOfWarrantsForfeited>
    <GNBT:WeightedAverageExercisePricePerShareIssued contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">2.53</GNBT:WeightedAverageExercisePricePerShareIssued>
    <GNBT:WeightedAverageExercisePricePerShareIssued contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">0.00</GNBT:WeightedAverageExercisePricePerShareIssued>
    <GNBT:WeightedAverageExercisePricePerShareIssued contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">3.50</GNBT:WeightedAverageExercisePricePerShareIssued>
    <GNBT:WeightedAverageExercisePricePerShareForfeited contextRef="From2019-08-01to2019-10-31" unitRef="USDPShares" decimals="INF">3.50</GNBT:WeightedAverageExercisePricePerShareForfeited>
    <GNBT:WeightedAverageRemainingLifeOfWarrantsOutstandingAtBeginningYears contextRef="From2019-08-01to2019-10-31">P4M24D</GNBT:WeightedAverageRemainingLifeOfWarrantsOutstandingAtBeginningYears>
    <GNBT:WeightedAverageRemainingLifeOfWarrantsIssued contextRef="From2018-08-01to2019-07-31">P1Y22D</GNBT:WeightedAverageRemainingLifeOfWarrantsIssued>
    <GNBT:WeightedAverageRemainingLifeOfWarrantsIssued contextRef="From2019-08-01to2019-10-31">P5Y4D</GNBT:WeightedAverageRemainingLifeOfWarrantsIssued>
    <GNBT:WeightedAverageRemainingLifeOfWarrantsOutstanding contextRef="From2018-08-01to2019-07-31">P4M24D</GNBT:WeightedAverageRemainingLifeOfWarrantsOutstanding>
    <GNBT:WeightedAverageRemainingLifeOfWarrantsOutstanding contextRef="From2019-08-01to2019-10-31">P2M5D</GNBT:WeightedAverageRemainingLifeOfWarrantsOutstanding>
    <GNBT:AggregateIntrinsicValueWarrantsOutstanding contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">0</GNBT:AggregateIntrinsicValueWarrantsOutstanding>
    <GNBT:AggregateIntrinsicValueWarrantsOutstanding contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">4500000</GNBT:AggregateIntrinsicValueWarrantsOutstanding>
    <GNBT:AggregateIntrinsicValueWarrantsOutstanding contextRef="AsOf2017-07-31" unitRef="USD" decimals="0">0</GNBT:AggregateIntrinsicValueWarrantsOutstanding>
    <GNBT:AggregateIntrinsicValueWarrantsOutstanding contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">0</GNBT:AggregateIntrinsicValueWarrantsOutstanding>
    <GNBT:AggregateIntrinsicValueWarrantsIssued contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">4500000</GNBT:AggregateIntrinsicValueWarrantsIssued>
    <GNBT:AggregateIntrinsicValueWarrantsIssued contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">0</GNBT:AggregateIntrinsicValueWarrantsIssued>
    <GNBT:AggregateIntrinsicValueWarrantsIssued contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">0</GNBT:AggregateIntrinsicValueWarrantsIssued>
    <GNBT:AggregateIntrinsicValueWarrantsForfeited contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">0</GNBT:AggregateIntrinsicValueWarrantsForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">57143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-07-31" unitRef="Shares" decimals="INF">232221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-07-31" unitRef="Shares" decimals="INF">7988675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-07-31" unitRef="Shares" decimals="INF">379998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-10-31" unitRef="Shares" decimals="INF">8861675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">9976125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">1003000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">2219671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">147777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2018-08-01to2019-07-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2017-08-01to2018-07-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-07-31" unitRef="USDPShares" decimals="INF">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-07-31" unitRef="USDPShares" decimals="INF">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-07-31" unitRef="USDPShares" decimals="INF">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-10-31" unitRef="USDPShares" decimals="INF">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-08-01to2019-07-31" unitRef="USDPShares" decimals="INF">0.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-08-01to2018-07-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-08-01to2019-10-31" unitRef="USDPShares" decimals="INF">2.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <GNBT:WeightedAverageExercisePricePerShareForfeitedOrExpired contextRef="From2018-08-01to2019-07-31" unitRef="USDPShares" decimals="INF">-0.43</GNBT:WeightedAverageExercisePricePerShareForfeitedOrExpired>
    <GNBT:WeightedAverageExercisePricePerShareForfeitedOrExpired contextRef="From2017-08-01to2018-07-31" unitRef="USDPShares" decimals="INF">-0.05</GNBT:WeightedAverageExercisePricePerShareForfeitedOrExpired>
    <GNBT:WeightedAverageExercisePricePerShareForfeitedOrExpired contextRef="From2019-08-01to2019-10-31" unitRef="USDPShares" decimals="INF">1.11</GNBT:WeightedAverageExercisePricePerShareForfeitedOrExpired>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2018-08-01to2019-07-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-08-01to2018-07-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2019-08-01to2019-10-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-08-01to2019-07-31">P7Y2M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-08-01to2018-07-31">P2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-08-01to2019-10-31">P6Y8M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-08-01to2017-07-31">P1Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <GNBT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1 contextRef="From2018-08-01to2019-07-31">P7Y7M2D</GNBT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1>
    <GNBT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1 contextRef="From2019-08-01to2019-10-31">P4Y11M1D</GNBT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1>
    <GNBT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrExpiredWeightedAverageRemainingContractualTerm1 contextRef="From2018-08-01to2019-07-31">P8Y2M5D</GNBT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrExpiredWeightedAverageRemainingContractualTerm1>
    <GNBT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrExpiredWeightedAverageRemainingContractualTerm1 contextRef="From2019-08-01to2019-10-31">P7Y7M24D</GNBT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrExpiredWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-07-31" unitRef="USD" decimals="0">10719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-07-31" unitRef="USD" decimals="0">15961391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2017-07-31" unitRef="USD" decimals="0">69843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-10-31" unitRef="USD" decimals="0">5859392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <GNBT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantntrinsicValue contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">20821821</GNBT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantntrinsicValue>
    <GNBT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantntrinsicValue contextRef="From2019-08-01to2019-10-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2019-10-31_custom_StockOptionPlan2006Member" unitRef="Shares" decimals="INF">2835000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2019-10-31_custom_StockOptionPlan2017Member" unitRef="Shares" decimals="INF">240000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2019-10-31_custom_StockOptionPlan2019Member" unitRef="Shares" decimals="INF">1200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2019-07-31_custom_StockOptionPlan2006Member" unitRef="Shares" decimals="INF">2835000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2019-07-31_custom_StockOptionPlan2017Member" unitRef="Shares" decimals="INF">240000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2019-07-31_custom_StockOptionPlan2019Member" unitRef="Shares" decimals="INF">1200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2019-08-01to2019-10-31_custom_StockOptionPlan2006Member" unitRef="Shares" decimals="INF">2823450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2019-08-01to2019-10-31_custom_StockOptionPlan2017Member" unitRef="Shares" decimals="INF">231149875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2018-08-01to2019-07-31_custom_StockOptionPlan2006Member" unitRef="Shares" decimals="INF">2823450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2018-08-01to2019-07-31_custom_StockOptionPlan2017Member" unitRef="Shares" decimals="INF">232022875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2018-08-01to2019-07-31_custom_StockOptionPlan2019Member" unitRef="Shares" decimals="INF">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <GNBT:MarketValue contextRef="AsOf2019-07-31" unitRef="USDPShares" decimals="INF">2.80</GNBT:MarketValue>
    <GNBT:MarketValue contextRef="AsOf2019-10-31" unitRef="USDPShares" decimals="INF">1.53</GNBT:MarketValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2019-08-01to2019-10-31_custom_StockOptionPlan2006Member" unitRef="Shares" decimals="INF">3540675</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2018-08-01to2019-07-31_custom_StockOptionPlan2006Member" unitRef="Shares" decimals="INF">3369842</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2019-10-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">4256191</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2019-07-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">3263569</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2019-08-01to2019-10-31_us-gaap_StockOptionMember">P2Y8M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2018-08-01to2019-07-31_us-gaap_StockOptionMember">P2Y5M27D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="From2019-08-01to2019-08-19_us-gaap_SubsequentEventMember_custom_PrincipalMember" unitRef="USD" decimals="0">100149</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="From2019-08-01to2019-08-19_us-gaap_SubsequentEventMember_custom_InterestMember" unitRef="USD" decimals="0">37411</us-gaap:RepaymentsOfLongTermDebt>
    <GNBT:FinancialAdvisoryServicesDescription contextRef="From2019-08-01to2019-08-12_us-gaap_SubsequentEventMember">Company retained a consultant to provide financial advisory services in connection with and support of the various financing options and other services for the Company to raise up to Seven Million Dollars ($7,000,000) in debt capital for the Company payable upon funding equal to five (5%) of the principal amount funded by investors introduced by the Consultant.</GNBT:FinancialAdvisoryServicesDescription>
    <GNBT:FinancingFacilityDescription contextRef="From2019-08-01to2019-08-13_us-gaap_SubsequentEventMember_custom_PublicSecuredFinancingFacilityAgreementMember_custom_InvestorsMember">Company entered into a Public Secured Financing Facility Agreement with an investor pursuant to which the Company will receive a $5,000,000 financing facility bearing 13.50% interest per annum. The Company may receive subsequent financing in addition to the initial amount of $5,000,000 but shall not exceed a total of $7,000,000. The financing facility matures on August 13, 2021.</GNBT:FinancingFacilityDescription>
    <GNBT:NoteDescription contextRef="From2019-08-01to2019-08-15_us-gaap_SubsequentEventMember_custom_InvestorsMember">Company entered an agreement to pay an investor $900,000 for the prepayment of $666,667 owed under the note. Pursuant to the agreement, the Company converted $350,000 owed under the note into 230,351 shares of the Company&#8217;s common stock based upon a conversion price of $1.51942 per share.</GNBT:NoteDescription>
    <GNBT:NumberOfSharesIncreased contextRef="From2019-08-01to2019-08-16_us-gaap_SubsequentEventMember_custom_ShareExchangeAgreementMember" unitRef="Shares" decimals="INF">900000</GNBT:NumberOfSharesIncreased>
    <GNBT:LetterOfIntentDescription contextRef="From2019-09-02to2019-09-06_custom_ALTuCELLMember_us-gaap_SubsequentEventMember">Generex signed a binding Letter of Intent with ALTuCELL, Inc (&#8220;ALTuCELL&#8221;), a clinical-stage development company with a broad intellectual property portfolio focused on cell encapsulation technology for the treatment of diabetes, autoimmune diseases, and inflammatory conditions to purchase 51% of ALTuCELL&#8217;s equity in exchange for $2,000,000 in cash, $8,000,000 in the Company&#8217;s common stock price at $2.50/share, and commitment to fund $5,000,000 towards ALTuCELL&#8217;s development costs pursuant to a mutually agreed upon clinical development plan based upon a valuation of ALTuCELL equal to $29,500,000 On September 20, 2019, Generex paid ALTuCELL a preliminary payment of $50,000 to bind the agreement.</GNBT:LetterOfIntentDescription>
    <GNBT:NumberOfSharesCancelled contextRef="From2019-09-02to2019-09-12_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">20375900</GNBT:NumberOfSharesCancelled>
    <GNBT:ConsultingServicesDescription contextRef="From2019-08-28to2019-09-01_us-gaap_SubsequentEventMember">Company retained a consultant to provide consulting services directly or through affiliated entities, certain management, administrative, marketing and/or clinical services to various ancillary healthcare for providers for a fee of $2,000,000; $250,000 payable in shares of common stock; and $1,750,000 payable in 18 equal installments of $97,222.22 per month payable in cash as is available from the operations of newly acquired subsidiaries Pantheon and MediSource, or shares of common stock issued monthly.</GNBT:ConsultingServicesDescription>
    <GNBT:ConsultingServicesDescription contextRef="From2019-09-29to2019-10-01_us-gaap_SubsequentEventMember">Company retained a consultant to provide consulting services in support of the Company&#8217;s mission to raise capital, identify potential mergers, as well as other strategic advice to increase the value of the Company for a monthly fee of $5,000 for each calendar month commencing October 2019 and continuing through the termination date of September 30, 2024. The consultant received options to purchase 1,000,000 shares of common stock, vesting in equal increments of 200,000 shares on October 1st of each year commencing on October 1, 2019 at an exercise price of $2.09 per share. The consultant is to be paid a 2.0% transaction fee payable on all transactions consummated during the term. The transaction fee is based on the amount of all proceeds and other consideration paid or received, to be paid or received, or retained by the Company.</GNBT:ConsultingServicesDescription>
    <GNBT:PerformanceIncentiveDecription contextRef="From2019-10-02to2019-10-10_us-gaap_SubsequentEventMember">On October 10, 2019 Generex amended the acquisition agreement for the purchase of Pantheon effective on August 1, 2019 to provide a performance incentive up to $500,000 of GNBT Stock for exceeding annual EBIDTA targets of Pantheon of $1,000,000, 1,500,000 and $2,000,000 for the years ending July 31, 2020, 2021 and 2022, respectively, plus an additional $50,000 of GENBT Stock for each additional $100,000 of EBDITA achieved by Pantheon.</GNBT:PerformanceIncentiveDecription>
    <GNBT:CommonStockDescription contextRef="From2019-11-02to2019-11-22_us-gaap_SubsequentEventMember_custom_ALTuCELLMember">ALTuCELL Stock, Generex will issue to ALTuCELL 1,600,000 shares of Generex common stock with a down round provision and price floor of $1.25 per share. The Company will also pay $2.5 million in cash of which $112,000 has already been paid. In addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCell upon ALTuCell&#8217;s attainment of certain milestones.</GNBT:CommonStockDescription>
    <GNBT:CommonStockDescription contextRef="From2019-11-02to2019-11-25_us-gaap_SubsequentEventMember_custom_InvestorsMember">Company entered an Equity Purchase Agreement with an investor to purchase up to $40,00,000 of the Company&#8217;s stock at 92% of the market price for the period of five (5) consecutive trading days immediately subject to a put notice on such date on which the Purchase Price is calculated in accordance with the terms and conditions of this Agreement and 1,228,501 shares of common stock (&#8220;Commitment Shares&#8221;) upon signing were issued to an investor.</GNBT:CommonStockDescription>
    <GNBT:StockPurchaseAgreementDescription contextRef="From2019-11-02to2019-11-24_us-gaap_SubsequentEventMember_custom_OlaregenMember">Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock. Effective November 24, 2019, the deadline has been extended to January 31, 2020.</GNBT:StockPurchaseAgreementDescription>
    <GNBT:StockPurchaseAgreementDescription contextRef="From2019-11-02to2019-11-25_us-gaap_SubsequentEventMember_custom_RegentysMember">Company amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three payments of $2,039,001, $2,000,000, and $3,000,000 are all payable on or before December 30, 2019.</GNBT:StockPurchaseAgreementDescription>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-07-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">79590</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-07-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">79590</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-07-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">22430121</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-07-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">22430121</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-07-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-07-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">62290940</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-10-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">79590</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-10-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">28427049</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-10-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-10-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">44336023</us-gaap:SharesOutstanding>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">227245</GNBT:InvestmentInSubsidiaryByNoncontrollingInterests>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">327593</GNBT:InvestmentInSubsidiaryByNoncontrollingInterests>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">91027</GNBT:InvestmentInSubsidiaryByNoncontrollingInterests>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2017-08-01to2018-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2017-08-01to2018-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2017-08-01to2018-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2017-08-01to2018-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2017-08-01to2018-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2017-08-01to2018-07-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2017-08-01to2018-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">327593</GNBT:InvestmentInSubsidiaryByNoncontrollingInterests>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">227245</GNBT:InvestmentInSubsidiaryByNoncontrollingInterests>
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2018-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2018-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2018-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2018-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2018-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2018-10-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:InvestmentInSubsidiaryByNoncontrollingInterests contextRef="From2018-08-01to2018-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">91027</GNBT:InvestmentInSubsidiaryByNoncontrollingInterests>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-1206</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31" unitRef="USD" decimals="0">15272</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">-294</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">1626</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">15272</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">15272</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2017-08-01to2018-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-1206</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">-1206</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">1626</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">1626</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2018-08-01to2018-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-294</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">-294</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">-3</GNBT:ConversionOfPreferredSeriesH>
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">25200</GNBT:ConversionOfPreferredSeriesH>
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-25197</GNBT:ConversionOfPreferredSeriesH>
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesH contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesHInShares contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-63000</GNBT:ConversionOfPreferredSeriesHInShares>
    <GNBT:ConversionOfPreferredSeriesHInShares contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">25200000</GNBT:ConversionOfPreferredSeriesHInShares>
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">-1</GNBT:ConversionOfPreferredSeriesI>
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6639</GNBT:ConversionOfPreferredSeriesI>
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-6638</GNBT:ConversionOfPreferredSeriesI>
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesI contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfPreferredSeriesIInShares contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-16590</GNBT:ConversionOfPreferredSeriesIInShares>
    <GNBT:ConversionOfPreferredSeriesIInShares contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6639045</GNBT:ConversionOfPreferredSeriesIInShares>
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-1385730</GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest>
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-6951015</GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest>
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">-6951015</GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest>
    <GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">5565285</GNBT:ExerciseOfCallOptionToAcquireNoncontrollingInterest>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">921895</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6068</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" decimals="0">-1967657</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1961589</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5997</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31_custom_CommonStockPayableMember" unitRef="USD" decimals="0">-1917334</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1911337</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2018-08-01to2018-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">297</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">921598</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">921895</GNBT:IssuanceOfCommonStockPayable>
    <GNBT:IssuanceOfCommonStockPayable contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayableShares contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayableShares contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6068517</GNBT:IssuanceOfCommonStockPayableShares>
    <GNBT:IssuanceOfCommonStockPayableShares contextRef="From2018-08-01to2018-10-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayableShares contextRef="From2018-08-01to2018-10-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5996928</GNBT:IssuanceOfCommonStockPayableShares>
    <GNBT:IssuanceOfCommonStockPayableShares contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <GNBT:IssuanceOfCommonStockPayableShares contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">296793</GNBT:IssuanceOfCommonStockPayableShares>
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">15176629</GNBT:ConversionOfDebtToEquity>
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">1736837</GNBT:ConversionOfDebtToEquity>
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">15176629</GNBT:ConversionOfDebtToEquity>
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">15176629</GNBT:ConversionOfDebtToEquity>
    <GNBT:ConversionOfDebtToEquity contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1164</GNBT:ConversionOfDebtToEquity>
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1735673</GNBT:ConversionOfDebtToEquity>
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">1736837</GNBT:ConversionOfDebtToEquity>
    <GNBT:ConversionOfDebtToEquity contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">3006203</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31" unitRef="USD" decimals="0">103194</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3006203</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">3006203</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">103194</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">103194</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-08-01to2018-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31" unitRef="USD" xsi:nil="true" />
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1070456</GNBT:AntigenDividend>
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">-1070456</GNBT:AntigenDividend>
    <GNBT:AntigenDividend contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">1070456</GNBT:AntigenDividend>
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">9873553</GNBT:AcquisitionOfNciOfRegentys>
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfRegentys contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">9873553</GNBT:AcquisitionOfNciOfRegentys>
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">11999559</GNBT:AcquisitionOfNciOfOlaregen>
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfNciOfOlaregen contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">11999559</GNBT:AcquisitionOfNciOfOlaregen>
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-2000000</GNBT:AcquisitionOfOlaregenSeriesPreferredStock>
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2520000</GNBT:AcquisitionOfOlaregenSeriesPreferredStock>
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">2520000</GNBT:AcquisitionOfOlaregenSeriesPreferredStock>
    <GNBT:AcquisitionOfOlaregenSeriesPreferredStock contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-4520000</GNBT:AcquisitionOfOlaregenSeriesPreferredStock>
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">-201294</GNBT:ReclassificationOfEquityToLiability>
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" decimals="0">-201294</GNBT:ReclassificationOfEquityToLiability>
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">-201294</GNBT:ReclassificationOfEquityToLiability>
    <GNBT:ReclassificationOfEquityToLiability contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31" unitRef="USD" decimals="0">1570174</GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes>
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1570174</GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes>
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31_custom_SubTotalMember" unitRef="USD" decimals="0">1570174</GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes>
    <GNBT:ExtinguishmentOfDerivativeLiabilityAssociatedWithConvertibleNotes contextRef="From2018-08-01to2019-07-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">787458</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">787458</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">787458</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquityInShares contextRef="From2019-08-01to2019-10-31" unitRef="Shares" decimals="INF">1164190</GNBT:ConversionOfDebtToEquityInShares>
    <GNBT:ConversionOfDebtToEquityInShares contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <GNBT:ConversionOfDebtToEquityInShares contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1164190</GNBT:ConversionOfDebtToEquityInShares>
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">1911487</GNBT:ReductionOfDerivativeLiability>
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1911487</GNBT:ReductionOfDerivativeLiability>
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">1911487</GNBT:ReductionOfDerivativeLiability>
    <GNBT:ReductionOfDerivativeLiability contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31" unitRef="USD" xsi:nil="true" />
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">-20376</GNBT:CancellationOfShares>
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">20376</GNBT:CancellationOfShares>
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" xsi:nil="true" />
    <GNBT:CancellationOfShares contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <GNBT:CancellationOfSharesInShares contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <GNBT:CancellationOfSharesInShares contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">-20375900</GNBT:CancellationOfSharesInShares>
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31" unitRef="USD" xsi:nil="true" />
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1987390</GNBT:PurchaseOfSharesInSubsidiary>
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">1987390</GNBT:PurchaseOfSharesInSubsidiary>
    <GNBT:PurchaseOfSharesInSubsidiary contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-1987390</GNBT:PurchaseOfSharesInSubsidiary>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">1151952</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">960</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31_custom_CommonStockPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1150992</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31_custom_SubTotalMember" unitRef="USD" decimals="0">1151952</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-08-01to2019-10-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2019-08-01to2019-10-31" unitRef="USD" decimals="0">603553</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2018-08-01to2019-07-31_us-gaap_GoodwillMember_custom_VenetoMember310484733" unitRef="USD" decimals="0">15051768</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2018-08-01to2019-07-31_us-gaap_GoodwillMember_custom_RegentysMember310494499" unitRef="USD" decimals="0">13834581</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2018-08-01to2019-07-31_us-gaap_GoodwillMember_custom_OlaregenMember310502783" unitRef="USD" decimals="0">9411224</us-gaap:FinitelivedIntangibleAssetsAcquired1>
</xbrli:xbrl>


